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INTRODUCTION AND GENERAL OUTLINE
1. MELANOCYTIC NEOPLASMS 
1.1 Background
Melanocytic neoplasms originate from melanin-producing cells, which are derived from 
the neural crest early during embryogenesis. [1] Precursors of melanocytes, so-called 
melanoblasts, migrate during embryonic development mainly via the dorsolateral route 
and travel to the skin in the first trimester of gestation. [2-4] The melanoblasts first reach 
the dermis and subsequently the epidermis that starts to become populated around week 
7 in the human embryo. [3, 5] Smaller numbers of melanoblasts also travel to mucosal 
surfaces of e.g. the aerodigestive and urogenital tract, to the inner ear, the uvea, and the 
leptomeninges, i.e. the soft membranes covering the central nervous system (CNS). [6] 
(Figure 1) Primary melanocytic neoplasms can therefore arise in cutaneous as well as 
in extra-cutaneous localizations, although the latter is much less frequent. The primary 
function of melanin pigment is protection against the adverse effects of sunlight, but 
its function in UV-protected locations is less clear. [6] In the inner ear, melanocytes are 
involved in maintaining endocochlear potential that is essential for hearing. [6, 7] The 
function of leptomeningeal melanocytes is not well determined.
Melanocytes give rise to both benign (melanocytic nevi, melanocytomas) as well as 
malignant melanocytic neoplasms (melanoma). Cutaneous melanoma (CM) is the most 
common malignant melanocytic tumor (~95%), while mucosal melanoma (MucM), uveal 
melanoma (UM) and primary melanoma of the CNS account for approximately 1.3%, 3% 
and 1% of all melanomas cases. [8-11]
1.2 Oncogenic mutations in different melanoma subtypes
Relatively recently, it was established that melanoma is a heterogeneous disease with 
distinct oncogenic mutations in different subgroups of melanoma. [12-14] (Figure 2) 
Activating mutations in the BRAF gene, encoding a member of the RAF family of serine/
threonine kinases, are frequent in CMs, especially in those occurring in intermittently sun-
exposed skin (approximately 50%). [15] Activating BRAF mutations lead to constitutive 
activation of the mitogen-activated protein kinase (MAPK) pathway, by transduction of 
signals from the cell surface to the nucleus through phosphorylation of a cascade of 
kinases that results in cell proliferation. [16, 17] Approximately 70-75% of BRAF mutations 
involve the c.1799T>A (p.(Val600Glu)) alias BRAFV600E hotspot mutation, which is a target 
for treatment with selective BRAF inhibitors in metastatic melanoma patients carrying this 
mutation. [18-24] 
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Activating mutations in NRAS, one of the three major isoforms of the RAS family of GTPase proteins 
and an upstream signaling component in the MAPK pathway, are present in approximately 
20% of CMs and MucMs, respectively. [25-30] NRAS mutations are hotspot mutations 
occurring in codon 12, 13 or 61, and are mutually exclusive with BRAFV600 mutations. 
[31-33] Activating NRAS mutations cause aberrant signaling in several downstream 
cascades including the MAPK and the PI3K/AKT/mTOR pathways that are implicated in 
cell proliferation and survival. [34] In contrast to BRAF, small molecules that selectively 
inhibit mutant NRAS are not available. [35] One strategy for therapeutically interfering with 
mutant NRAS is the use of inhibitors that target downstream activated cascades such as 
the MAPK pathway and the PI3K/AKT/mTOR pathway. [36] Melanoma cell lines harboring 
NRAS mutations were shown to be sensitive to inhibition of MEK, and a recent clinical 
Figure 1 Melanoblasts, the precursors of melanocytes, are derived from the neural crest early 
during embryogenesis and undergo migration to reach their destination in cutaneous and 
extra-cutaneous localizations, the latter including mucosal surfaces, uveal tract, inner ear, and 
leptomeninges (arrows). The highest concentration of melanocytes is found in the epidermis of 
the skin. At the centre, a cross section of a human embryo is depicted showing neural crest (NC) 
cells that detach from the tips of the neural folds just before or shortly after they fuse to give rise 
to the neural tube (NT) (in embryonic week 4) [1]. These multipotent NC cells, represented by 
black dots, yield melanoblasts, which become spatially and temporally segregated from other 
NC-derived cell types.
13
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phase 2 trial with MEK162, a potent MEK inhibitor, has revealed activity in patients with 
NRAS-mutant melanoma. [37-40] As NRAS activates multiple downstream pathways, 
combination of inhibitors such as MEK and PI3K/mTOR effectors might be more effective, 
and clinical trials with such combinatorial approaches are currently underway. [36, 41, 42] 
In contrast to melanoma in (intermittently) sun-exposed skin, BRAF mutations are rare in 
melanomas of the non-hair-bearing skin (acral melanomas (AMs), approximately 15%), in 
MucMs (10%), and are virtually absent in UMs. [15, 43-45] Instead, MucMs and AMs relatively 
frequently harbor activating mutations and/or increased copy numbers of the gene 
encoding the receptor tyrosine kinase KIT (approximately 40%, and 20%, respectively). 
[46, 47] KIT activation results in activation of several downstream pathways including 
the MAPK en PI3/AKT/mTOR pathways. [48] Several case reports and Phase II trials have 
reported objective responses to KIT-inhibitors such as imatinib and sorafenib in advanced 
KIT-mutated melanomas. [49-54] 
UMs are often driven by oncogenic mutations in the G alpha protein encoding subunits 
genes GNAQ and GNA11 (~ 50% and 30%, respectively). [55-57] To date, there are no direct 
inhibitors of mutant GNAQ or GNA11 and current focus is on inhibition of downstream 
components including MEK and PKC. [56, 58-62] Inactivating mutations in the tumor 
suppressor BAP1 are frequent in metastatic UMs and might be an interesting therapeutic 
target as well. [63-65] (Figure 2)
1.3 Primary leptomeningeal melanocytic neoplasms 
1.3.1 Background
Primary leptomeningeal melanocytic neoplasms (LMNs) are rare and represent a spectrum 
of tumors arising from melanocytes located in the leptomeninges that cover the brain 
and the spinal cord. [11] In the normal situation, the highest concentration of melanocytes 
in the leptomeninges can be found at the ventrolateral surfaces of the medulla oblongata 
and around the upper part of the spinal cord. [69, 70] Macroscopically, these melanocytes 
may cause a greyish hue of the leptomeninges, especially in persons with heavily 
pigmented skin. [71] Microscopically, these melanocytes are generally slender, elongated, 
darkly pigmented, and present as individual cells in intimate association with pia and 
arachnoid membranes. [71] (Figure 3) The function of leptomeningeal melanocytes is 
not well determined, it has been suggested that these cells capture toxic cations and free 
radical species from the blood circulation. [72] 
1.3.2 Classification of primary leptomeningeal melanocytic neoplasms
Proliferation of leptomeningeal melanocytes may give rise to circumscribed or diffuse 
neoplasms, and can either be benign or malignant, the latter arising de novo or by 
14
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Figure 2  Main intracellular pathways implicated in the oncogenesis of melanoma 
Mutations in the receptor tyrosine kinase KIT are frequent in MucMs (20%), result in activation of 
the MAPK and PI3/AKT/mTOR pathways, and can be treated with KIT-inhibitors including imatinib 
mesylate. [46, 49, 50] Signaling components of the MAPK pathway include the membrane-
bound GTPase (N)RAS, and the cytosolic protein kinases (B)RAF, MEK and ERK. BRAF mutations 
(~50% of CMs) are a therapeutic target for selective BRAF inhibitors (BRAF-i). [18, 22] Mutations 
in NRAS (~20% of CMs) signal to MEK/ERK through CRAF, one of the three isoforms of RAF, but 
also to other pathways including the PI3/AKT/mTOR pathway. [41, 66] MEK inhibitors (MEK-i) 
have shown clinical activity in NRAS-mutant melanoma [37] and combinatorial approaches of 
inhibitors of MEK and PI3K/mTOR are currently under investigation. [36, 41] Mutations in GNAQ 
or GNA11 are frequent in UMs. [55-57] Signaling pathways downstream of GNAQ/GNA11 include 
activation of PKC through the release of DAG by β-PLC, which can activate the MAPK pathway by 
phosphorylation of RAF. [56, 62, 67, 68] Current focus for GNAQ/GNA11-mutated melanoma is on 
inhibition of downstream components including MEK. [60, 61] In addition, PKC inhibitors (PKC-i) 
were shown to have antitumor activity against GNAQ-mutated UM cell lines via inhibition of the 
PKC/ERK 1/2 pathway. [58, 59, 62] Metastatic UMs frequently harbor inactivating mutations in 
BAP1. BAP1 has multiple functions including regulation of cell cycle and epigenetic modulation. 
[63-65]
For abbreviations see list of abbreviations at the beginning of this thesis.
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transformation from a non-malignant precursor. [11] Benign as well as malignant LMNs 
can be associated with cutaneous melanocytic neoplasms including blue nevi and 
nevi of Ota (or oculocutaneous melanosis if the eye is involved) and with giant and/
or multiple congenital melanocytic nevi (CMN) of the skin, the latter in the context of 
neurocutaneous melanosis (NCM) (see paragraph 1.3.4). [73-77] According to WHO criteria 
(2007), circumscribed LMNs include melanocytoma (benign) and melanoma (malignant). 
Melanocytosis and melanomatosis are the diffuse benign and malignant counterparts, 
characterized by diffuse spread of tumor cells in the leptomeninges. [11] (Table 1)
1.3.3 Circumscribed primary leptomeningeal melanocytic neoplasms
Melanocytoma is a slow growing neoplasm with a peak incidence in the 5th decade 
and a predilection for the cervical and thoracic spinal region, the posterior cranial fossa 
and Meckle’s cave. [11] (Table 2) Melanocytomas frequently recur, especially in case of 
Figure 3  A, B. Melanocytes are normally present in the leptomeninges, especially around the upper 
part of the cervical spinal cord, and may cause a greyish hue (arrow in panel B). C. Microscopically, 
these leptomeningeal melanocytes are slender, elongated, and darkly pigmented cells (arrow).
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incomplete resection (up to 50% recurrence one year after surgery), and are considered 
by some as a low-grade malignant neoplasm. [80] Indeed, aggressive behavior with 
leptomeningeal seeding or rarely malignant transformation has been reported. [80-86] 
Melanocytomas should be completely excised, and adjuvant radiation therapy is advised, 
especially in case of incomplete excision. [80-82] Histologically, they consist of variably 
pigmented, well-differentiated melanocytes with uniform nuclei and low mitotic activity 
(≤ 1/10 HPFs). [87] In case of atypical histological features such as CNS invasion and / or 
increased mitotic activity (2-5/10 HPFs), they are classified as melanocytic neoplasms of 
intermediate-grade malignancy. The biological behavior of these neoplasms is variable. 
[11, 87]
Melanocytoma should be histologically differentiated from melanotic schwannoma, a rare 
variant of schwannoma demonstrating both schwannian and melanocytic differentiation. 
[96] Although melanotic schwannoma may occur anywhere in the peripheral nervous 
system, it is most frequently found in the gastrointestinal tract (esophagus and 
stomach) and the paraspinal sympathetic chain. [96-99] Correct diagnosis of melanotic 
schwannoma is important to select those patients who need further clinical evaluation for 
possible association with Carney complex. [97] This is a rare multiple neoplasia syndrome, 
characterized by multiple types of skin tumors and pigmented lesions (including 
cutaneous myxoma, mucocutaneous lentigines and (epithelioid) blue nevi), endocrine 
neoplasms, cardiac myxomas, and (psammomatous) melanotic schwannomas. [100, 
101] Early diagnosis of these specific Carney complex-related manifestions is important 
as Carney complex represents a potentially life-threatening disease, mainly as a result of 
Table 1  WHO 2007 classification of primary leptomeningeal melanocytic neoplasms
WHO 2007
Primary leptomeningeal melanocytic neoplasms
CIRCUMSCRIBED
Melanocytoma Benign/low-grade Mostly in adults  
(de novo)Intermediate-grade 
melanocytic tumor 
Intermediate-grade
Melanoma Frankly malignant
DIFFUSE
Melanocytosis Cytologically benign Mostly in children  
(often congenital, and  
in the context of NCM)
Melanomatosis* Malignant
NCM: neurocutaneous melanosis.
* Melanomatosis may also become manifest in adults, mostly in the 4th decade. [78, 79]
17
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cardiac myxomas that are responsible for over 50% of disease-specific mortality in Carney 
complex. [101] Approximately 70% of cases are familial and inherited in an autosomal 
dominant manner. [101] Inactivating mutations in the regulatory subunit type 1 alpha 
gene of protein kinase A (PKA) (PRKAR1A) located at 17q22-24 have been observed in 80% 
of familial cases compared to approximately 40% of sporadic Carney complex patients. 
[102] Histologically, melanocytoma and melanotic schwannoma may be very similar and 
the use of immunohistochemistry is of little value in this differential diagnosis as both 
neoplasms show positivity for S100 and melanocytic markers. As will be demonstrated in 
the current thesis, molecular testing of relevant genes can aid in the differential diagnosis 
between (primary) LMN and melanotic schwannoma. 
Circumscribed primary melanoma of the leptomeninges accounts for approximately 1% 
of all melanoma cases and occurs along the neuroaxis, with a peak incidence in the 5th 
decade. [11, 78] (Table 2) It must be distinguished from a melanoma metastasis, which is 
much more frequent, as CM has a high propensity to metastasize to the CNS. [103] This 
distinction is important, as the prognosis of a primary CNS melanoma is substantially 
better, with long-term survival reported in cases of localized disease and total resection. 
[74, 88-90, 104] In case of a CNS metastasis of skin melanoma, patients carry a dismal 
prognosis with a life expectancy < 1 year.  [105] As primary leptomeningeal melanoma 
is histologically similar to melanomas arising in other sites, the differential diagnosis 
between a primary leptomeningeal melanoma and melanoma metastasis in the CNS can 
be difficult, especially in the absence of apparent melanoma localizations elsewhere in 
the body. [106] Therefore, before concluding that a CNS melanoma is a primary tumor, a 
thorough clinical examination should be performed to rule out a primary melanoma of 
the skin (including acral surfaces and nail beds), the mucosal surfaces (genitals, sinonasal 
cavity, gastrointestinal tract), and the uveal tract. As will be revealed in this thesis, molecular 
testing of relevant genes can also be very helpful for elucidating the origin of melanoma 
in/around the CNS. 
1.3.4 Diffuse primary leptomeningeal melanocytic neoplasms
Diffuse LMNs encompass a benign category called melanocytosis and a malignant 
counterpart known as melanomatosis. [11] (Table 2)
Melanocytosis consists of a proliferation of histological benign appearing melanocytes 
in the leptomeninges, without CNS invasion, and can macroscopically be visible as black 
discoloration of the leptomeninges. [11] Most patients develop neurological symptoms 
due to increased intracranial pressure (mainly hydrocephalus caused by overgrowth 
of melanocytes), mass lesion, or compression of the spinal cord. Even in the absence 
of malignant progression, melanocytosis carries a poor prognosis once neurological 
symptoms develop. [77, 92] 
18
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Melanocytosis mostly occurs in children in the context of neurocutaneous melanosis 
(NCM), a rare congenital neurocutaneous syndrome characterized by the presence of 
large and/or multiple congenital melanocytic nevi (CMN) in association with a primary 
LMN. [77] (Table 2) Since the first description of Rokitansky in 1861, approximately 100 
cases of NCM have been reported in the literature. [78, 107] The diagnostic criteria for 
NCM, originally proposed by Fox [108] and revised by Kadonaga and Frieden [77], are: 
1.  Large (currently or estimated to become equal to or larger than 20 cm in diameter 
in adults, or 6-9 cm in infants) or multiple (≥3) congenital skin nevi associated with 
leptomeningeal melanocytosis or leptomeningeal melanoma; 
2.  No evidence of cutaneous melanoma, except in patients in whom the examined 
areas of the meningeal lesions are histologically benign; and 
3.  No evidence of leptomeningeal melanoma, except in patients in whom the examined 
areas of the cutaneous lesions are histologically benign.
Table 2   Main clinicopathological features of primary leptomeningeal  
melanocytic neoplasms
Incidence Sex, age Localization Behavior / prognosis Treatment
Circum-
scribed 
LMNs
Melanocytoma 1/107/yr [11] F>M (1.5:1) 
Median 45-50 yrs [11]
Spinal region 
(cervical, thoracic)**;                         
posterior fossa; Meckel’s  
cave [11]
Frequent local recurrence, esp. in case of 
incomplete resection [80] ***; malignant 
transformation rare [85, 86]
Complete resection if possible. Radiation therapy in case 
of incomplete resection or recurrence [80]
Melanoma 0.5/107/yr [11] M>F  [78] 
Median 43 years [11]
Along the neuroaxis, slight 
predilection for spinal cord and 
posterior fossa [11]
Distant metastases rare [85]; better 
prognosis in case of complete resection 
compared to CNS melanoma metastasis  
[88-90] 
Complete resection if possible, postoperative radiotherapy 
is recommended [88];  usefulness of chemotherapy is not 
established [78] 
Diffuse 
LMNs
Melanocytosis Very rare* Children, mostly 
in context of NCM 
[11], rarely without 
cutaneous melanocytic 
lesions [91, 92]
Supra- and/or infratentorial/
spinal leptomeninges; most 
frequent in/near cerebellum, 
pons, medulla and temporal 
lobes [11]
Poor prognosis, once symptomatic [77] Usefulness of chemotherapy and radiotherapy is not 
established. Chemotherapy might show some benefit [93]
Melanomatosis Very rare* Bimodal distribution: 
children, mostly in 
context of NCM [11] 
or adults, 4th decade 
[78, 79]
Supra- and/or infratentorial/
spinal leptomeninges, and/or 
superficial brain parenchyma 
[11] 
Dismal prognosis [94] Not established. Chemotherapy and radiotherapy 
was reported to have benefit in a NCM patient with 
melanomatosis [95]
Abbreviations: LMNs: leptomeningeal melanocytic neoplasms; NCM: neurocutaneous melanosis. 
* Population-based incidence is not available [11]; 
** Mostly in the extramedullary, intradural compartment of the spinal canal;
*** The biological behavior of intermediate-grade melanocytomas is variable.
19
1
INTRODUCTION AND GENERAL OUTLINE
Alternatively, these criteria permit either a cutaneous melanoma or a leptomeningeal 
melanoma, but not both, in order to exclude the possibility of a melanoma metastasis 
from the skin to the CNS, or vice versa.
NCM is thought to represent an error in morphogenesis of melanocytes early during 
embryogenesis. [77] Over 90% of large CMN in NCM involve the occipital area, the upper 
back or trunk and/or buttocks (posterior axial location) and patients often have satellite nevi. 
[71, 77] Importantly, NCM patients are at increased risk not only for developing cutaneous 
melanoma (life-time risk estimated to be 2.5 to 5%) [109] but especially leptomeningeal 
melanoma, with up to 64% of patients affected in a review of symptomatic NCM patients. 
[110] NCM carries a substantial morbidity and mortality, even in the absence of malignant 
transformation of the LMN. [77, 110] 
Also, not all patients with melanocytosis have associated CMN, and this is speculated 
to be a ‘forme fruste’ of NCM. [91, 92] Vice versa, not all patients with large CMN have 
Table 2   Main clinicopathological features of primary leptomeningeal  
melanocytic neoplasms
Incidence Sex, age Localization Behavior / prognosis Treatment
Circum-
scribed 
LMNs
Melanocytoma 1/107/yr [11] F>M (1.5:1) 
Median 45-50 yrs [11]
Spinal region 
(cervical, thoracic)**;                         
posterior fossa; Meckel’s  
cave [11]
Frequent local recurrence, esp. in case of 
incomplete resection [80] ***; malignant 
transformation rare [85, 86]
Complete resection if possible. Radiation therapy in case 
of incomplete resection or recurrence [80]
Melanoma 0.5/107/yr [11] M>F  [78] 
Median 43 years [11]
Along the neuroaxis, slight 
predilection for spinal cord and 
posterior fossa [11]
Distant metastases rare [85]; better 
prognosis in case of complete resection 
compared to CNS melanoma metastasis  
[88-90] 
Complete resection if possible, postoperative radiotherapy 
is recommended [88];  usefulness of chemotherapy is not 
established [78] 
Diffuse 
LMNs
Melanocytosis Very rare* Children, mostly 
in context of NCM 
[11], rarely without 
cutaneous melanocytic 
lesions [91, 92]
Supra- and/or infratentorial/
spinal leptomeninges; most 
frequent in/near cerebellum, 
pons, medulla and temporal 
lobes [11]
Poor prognosis, once symptomatic [77] Usefulness of chemotherapy and radiotherapy is not 
established. Chemotherapy might show some benefit [93]
Melanomatosis Very rare* Bimodal distribution: 
children, mostly in 
context of NCM [11] 
or adults, 4th decade 
[78, 79]
Supra- and/or infratentorial/
spinal leptomeninges, and/or 
superficial brain parenchyma 
[11] 
Dismal prognosis [94] Not established. Chemotherapy and radiotherapy 
was reported to have benefit in a NCM patient with 
melanomatosis [95]
Abbreviations: LMNs: leptomeningeal melanocytic neoplasms; NCM: neurocutaneous melanosis. 
* Population-based incidence is not available [11]; 
** Mostly in the extramedullary, intradural compartment of the spinal canal;
*** The biological behavior of intermediate-grade melanocytomas is variable.
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leptomeningeal melanocytic involvement. Also, a number of patients with large CMN 
but without neurological symptoms may still have asymptomatic NCM, as MR imaging 
studies have demonstrated leptomeningeal melanosis in a substantial proportion of 
these asymptomatic children (up to 30% in one study; especially if large CMN are located in 
the posterior axis). [111, 112] 
Diffuse spread of primary melanoma cells along the leptomeninges, often with invasion 
of the brain parenchyma, is known as melanomatosis. [11] (Table 2) This disease has a 
bimodal age distribution and may become manifest in children, with or without a 
context of NCM, as well as in adults, mostly in the 4th decade. [78, 79] Melanomatosis is an 
extremely aggressive disease and carries a high mortality. [94] 
In this thesis, we focus on the genetic alterations in both adult and pediatric LMN cases. 
Of note, adult patients can still have a congenital background of their disease, and it is not 
clear if all LMNs arising in children are truly congenital in origin. 
1.4  Molecular alterations in primary leptomeningeal 
melanocytic neoplasms
Until recently (and in sharp contrast with melanocytic lesions of especially the skin and 
uvea), little was known about the genetic alterations in LMNs. It is increasingly clear that 
melanoma subtypes harbor distinct oncogenic mutations that drive melanomagenesis 
and that identification of such oncogenic mutations is not only important for correct 
diagnosis and estimation of prognosis, but also for selecting patients that might benefit 
from targeted therapies. So far, systematic investigation of the oncogenic events in LMNs 
has been severely hampered by the very low incidence of these neoplasms.
1.5 General outline of the thesis
This thesis describes the presence of oncogenic mutations in LMNs in both the adult and 
pediatric age group. We demonstrate that the detection of these mutations can be used 
as a diagnostic tool in the differential diagnosis with other melanocytic and melanotic 
neoplasms. Also, these findings provide new insight in the pathogenesis of these neoplasms 
and reveal potential targets for molecular therapy in the future.
In the previous part of the current chapter, an introduction was given on melanoma subtypes 
and their driving oncogenic mutations, in addition to an overview of the spectrum of 
LMNs with emphasis on their classification, main clinicopathological characteristics, and 
what is known about their genetic underpinnings. 
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Chapter 2 describes the presence of oncogenic mutations in codon 209 of GNAQ in 
primary LMNs in adult patients, in addition to very rare or absent oncogenic mutations in 
the genes BRAF, NRAS and HRAS involved in the MAPK signaling pathway. Also, implications 
for pathogenesis and differential diagnosis are discussed.   
In chapter 3 the presence of oncogenic mutations in codon 209 of GNA11 is described 
in primary LMNs in adult patients, and genetic similarities with UMs and blue nevi are 
discussed. Additional genetic similarities with UMs are hypothesized: copy number 
variations frequently present in UMs are tested by MLPA and OncoScan analysis in LMNs. 
Furthermore, the value of mutational analysis in the differential diagnosis with a cutaneous 
melanoma metastasis is demonstrated.
In chapter 4 a transgenic mouse model is used to study the effect of expression of 
oncogenic NRASG12D in melanocytes early during embryogenesis. Similarities between 
the disease observed in the mice and that observed in two pediatric cases of primary 
leptomeningeal melanoma harboring oncogenic NRAS mutations are discussed. 
Implications for the pathogenesis of primary leptomeningeal melanoma in children are 
illustrated, and a potential therapeutic strategy with MEK inhibitors is investigated.
An illustrative case report of neurocutaneous melanosis (NCM) is presented in chapter 
5. This part describes a 13-year-old child that died of NRAS-mutated leptomeningeal 
melanocytosis, which was treated with MEK 162, a MEK inhibitor. This case provides further 
evidence that oncogenic NRAS is involved in the pathogenesis of NCM and LMNs in 
children, and the biological effect of treatment with the MEK162 inhibitor in this neoplasm 
was investigated.
Chapter 6 describes how the use of GNAQ mutational analysis can aid in the (sometimes 
difficult) differential diagnosis between primary LMNs and melanotic schwannomas. This 
distinction is important as adequate clinical follow-up is different for these patients, e.g. 
because patients with melanotic schwannoma may need further clinical work-up for 
Carney complex.
In chapter 7, we demonstrate how the combined mutational analysis of the NRAS and the 
CDKN2A gene can aid in the (both clinically and histologically often difficult) differential 
diagnosis between primary UM and cutaneous melanoma metastatic to the eye.
Finally, a summarizing discussion and future perspectives are presented in chapter 8.
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CHAPTER 2
Abstract
Primary melanocytic neoplasms of the central nervous system (CNS) are uncommon 
neoplasms derived from melanocytes that normally can be found in the leptomeninges. 
They cover a spectrum of malignancy grades ranging from low-grade melanocytomas to 
lesions of intermediate malignancy and overtly malignant melanomas.
Characteristic genetic alterations in this group of neoplasms have not yet been identified. 
Using direct sequencing, we investigated 19 primary melanocytic lesions of the CNS (12 
melanocytomas, 3 intermediate-grade melanocytomas, and 4 melanomas) for hotspot 
oncogenic mutations commonly found in melanocytic tumors of the skin (BRAF, NRAS, 
and HRAS  gene) and uvea (GNAQ gene).
Somatic mutations in the GNAQ gene at codon 209, resulting in constitutive activation of 
GNAQ, were detected in 7/19 (37%) tumors, including 6/12 melanocytomas, 0/3 inter-
mediate-grade melanocytomas, and 1/4 melanomas. These GNAQ-mutated tumors were 
predominantly located around the spinal cord (6/7). One melanoma carried a BRAF point 
mutation that is frequently found in cutaneous melanomas (c.1799 T>A (p.(V600E))), raising 
the question whether this is a metastatic rather than a primary tumor. No HRAS or NRAS 
mutations were detected.
We conclude that somatic mutations in the GNAQ gene at codon 209 are a frequent event 
in primary melanocytic neoplasms of the CNS. This finding provides new insight in the 
pathogenesis of these lesions and suggests that GNAQ-dependent mitogen-activated 
kinase signaling is a promising therapeutic target in these tumors. The prognostic and 
predictive value of GNAQ mutations in primary melanocytic lesions of the CNS needs to 
be determined in future studies. 
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ACTIVATING MUTATIONS OF THE GNAQ GENE: A FREQUENT EVENT IN LMNs
Introduction
Primary melanocytic neoplasms of the central nervous system (CNS) are uncommon 
neoplasms occurring in diffuse or localized form. [5,8] Diffuse lesions such as melanocytosis 
and melanomatosis generally occur in the setting of dermatologic syndromes (neurocutaneous 
melanosis, nevus of Ota). [1,16,18] Localized lesions present as leptomeningeal masses and 
consist of a spectrum ranging from ‘well differentiated’ melanocytomas to lesions of 
intermediate malignancy and overtly malignant melanomas. [6] They are derived from 
scattered melanocytes that are normally present in the leptomeninges, especially at the 
base of the brain, in the posterior fossa and around the upper cervical spinal cord.
Melanocytomas are solitary, low-grade tumors that do not invade surrounding structures. 
[5] They are usually characterized by a benign clinical course, but local recurrence can 
occur. [14,25] Intermediate-grade lesions show histological features suggestive of 
aggressive behavior, such as invasion of the CNS, but lack the overt cytological atypia of 
melanomas. [6] The biological behavior of intermediate-grade melanocytomas is unclear. 
[5] Primary melanomas of the CNS occur throughout the neuroaxis with a predilection 
for the spinal cord and posterior fossa. They are cytologically similar to melanomas arising 
in other sites and may metastasize to remote organs. Diffuse spreading of a primary 
meningeal melanoma through the subarachnoid space is referred to as meningeal 
melanomatosis. [5,27]
Discrimination between primary and metastatic melanocytic lesions of the CNS is 
important, because patients with metastatic disease carry a worse prognosis, with a life 
expectancy of less than 1 year in most studies. [7,23] In addition, in some cases of primary 
melanomas of the CNS, long-term survival and even ‘cures’ have been documented after 
complete surgical excision. [6,29] However, especially in cases where the melanocytic 
tumor presents as a solitary mass in the leptomeninges and the patient is not known to 
have a melanocytic tumor of the skin, this differential diagnosis can be very difficult, both 
at the clinical and histological levels.
While the molecular genetics of cutaneous melanomas (CMs) has been investigated in 
numerous studies, the genetic alterations underlying primary CNS melanocytic lesions 
have not yet been addressed. [5] In  melanocytic lesions of the skin -benign nevi as well as 
melanomas- oncogenic mutations in signaling components of the MAP kinase pathway 
are frequent. [11,22] These mutations mostly involve exon 15 of the BRAF gene and exon 3 
(codon 61) of the proto-oncogene NRAS. Mutations in HRAS are less frequent. [13,20] 
Recently, in uveal melanomas (UMs) and in some intradermal melanocytic lesions, such as 
blue nevi and nevi of Ota, somatic activating mutations of the GNAQ gene (or ‘G alpha q 
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gene’) at codon 209 have been reported. [17,32] The GNAQ gene maps on chromosome 
9q21, and encodes a heterotrimeric GTP-binding protein α-subunit that couples G protein 
coupled receptor signalling to the MAP kinase pathway. [24] GNAQ codon 209 mutations 
form an alternative route to MAP kinase activation. [32]
In the present study, we investigated the mutation status of the GNAQ, BRAF, NRAS and 
HRAS genes in a group of 19 primary melanocytic lesions of the CNS and found that 
somatic mutations in the GNAQ gene at codon 209 are relatively frequently present in 
these tumors. While the exact diagnostic, prognostic and predictive value of GNAQ 
mutations in primary melanocytic lesions of the CNS is not yet clear, it is to be expected 
that a better knowledge of the genetic background of these lesions may not only facilitate 
adequate diagnosis, but also identification of (novel) therapeutic targets, and thereby 
ultimately may have predictive value as well.
Materials and methods
Patients and histopathology
For this retrospective study, formalin-fixed and paraffin-embedded (FFPE) tissues of 19 
primary melanocytic lesions of the CNS were retrieved from archives of various 
Departments of Pathology in The Netherlands and Germany. Cases from the Netherlands 
diagnosed between 1991 and 2009 were obtained through the Dutch nationwide 
histopathology and cytopathology data network and archive (PALGA). [9] The study was 
performed in accordance with the ethical standards for this type of investigation in The 
Netherlands. Histology was revised by two pathologists (HK, BK). The diagnosis of 
‘melanocytoma’, ‘intermediate-grade melanocytoma’ or ‘melanoma’ was based on histo-
morphological criteria, as described by Brat et al. [5,6], and immunohistochemical stains 
(S100 positivity and at least one additional melanocytic marker (HMB45 or MelanA) 
positive in combination with lack of EMA staining). Scoring of histology included nuclear 
pleomorphism (mild, moderate or severe), mitotic activity, necrosis, melanin pigmentation, 
and CNS invasion. 
DNA extraction
About three manually dissected sections of 10-mm FFPE tissue with an estimated tumor 
cell percentage of at least 60% were used for DNA extraction. After deparaffinization and 
rehydration, the tissues sections were incubated in proteinase K, followed by subsequent 
affinity-purification of the DNA (QIAGEN GmbH, Germany). DNA sample concentration 
was assessed spectrophotometrically (260/280 nm using a NanoDrop spectrophotometer, 
Peqlab Biotechnologies, Erlangen, Germany). DNA quality of the samples was tested using 
the BIOMED-2 gene control PCR, in which gene segments of house-keeping genes are 
amplified, yielding different fragment sizes (100, 200, 300 and 400 bp) depending on the 
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extent of fragmentation of the DNA. [31] All extracted DNA samples allowed amplification 
of at least the 200 bp amplicon of the BIOMED-2 gene control PCR.
Mutation analyses
Direct sequence analysis of the GNAQ, BRAF, NRAS and HRAS genes was performed on 19 
primary melanocytic lesions of the CNS. Exon 5 of GNAQ, harboring codon 209 which is 
essential for GTP hydrolysis, was sequenced. [19] Furthermore, we performed sequence 
analysis of exon 15 of BRAF and exon 3 of NRAS and HRAS since these are well known 
hotspot regions for oncogenic mutations in melanocytic lesions of the skin. [2,13,20] 
Primer sequences used are listed in Table 1. All primers, except for GNAQ, contained a 
M13 forward or reverse consensus sequence for sequencing the different exons. PCR 
amplification of exon 5 of GNAQ was performed in a total volume of 25 µL, containing 50 ng 
DNA, PCR-buffer IV (Integro),  37 mM MgCl2, 250 µM of each deoxynucleotide triphospate, 
37.5 µg bovine serum albumin (Sigma), 10 pmol of each primer and 0.05 units of 
thermostable DNA polymerase (Sigma).  DNA amplification was performed in a PTC 200 
Thermal Cycler (MJ Research). The PCR was started with 5 min at 92°C and followed with 
35 cycles of denaturation 45 s at 94°C, annealing at 62°C for 45 s and extension at 72°C for 
45 s, followed by a final extension at 72°C for 20 min and cooling down for 5 min at 20°C. 
PCR amplification of exon 15 of BRAF and exon 3 of NRAS and HRAS was performed in a 
total volume of 20 µL. The PCR mix contained 50 ng DNA, buffer IV (Integro), 3 mM MgCl2, 
200 µM of each deoxynucleotide triphospate, 30 µg bovine serum albumin (Sigma), 10 
pmol of each primer and 0.25 units of thermostable DNA polymerase (Sigma). DNA 
amplification was performed in a PTC 200 Thermal Cycler (MJ Research). The PCR was 
started with 5 min at 94°C and followed with 30 cycles of denaturation 45 s at 94°C, 
Table 1  Primers used for mutation analyses
Gene Exon Forward (Fw) 
Reverse (Rv)
Primer sequence 5’- 3’
GNAQ 5 Fw TTCCCTAAGTTTGTAAGTAGTGC
Rv ATCCATTTTCTTCTCTCTGACC
BRAF 15 Fw CCTTTACTTACTACACCTCAG
Rv AAAAATAGCCTCAATTCTTAC
NRAS 3 Fw GATTCTTACAGAAAACAAGTGG
Rv TAATGCTCCTAGTACCTGTACAG
HRAS 3 Fw CTGCAGGATTCCTACCGGA
Rv ACTTGGTGTTTGTTGATGGCA
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annealing at 60°C for 45 s and extension at 72°C for 45 s, with a final extension at 72°C for 
5 min. All PCR products were purified with MinElute plates (Qiagen). One µl of the PCR 
product was used for the sequence reaction on a ABI PRISM 3700 DNA analyzer (Applied 
Biosystems). Both strands were sequenced using the M13 primers. For all mutations detected, 
normal tissue was tested to exclude germ-line mutations (archival FFPE skin tissue).
Results
Patient and histopathological characteristics
Our study group consisted of 12 melanocytomas, 3 intermediate-grade melanocytomas 
and 4 primary melanomas of the CNS. Table 2 summarizes the respective patient and 
Table 2   Patient and histopathological characteristics
Patient Sex Age Diagnosisa Locationb Cell typec Nuclear 
pleomorphismd
Mitosese Necrosisf CNS invasion Pigmentationg Available  
follow- up
1 F 50 IM Th11-12 S ++ 2 - Yes + na
2 F 27 MC Right cerebello-pontine angle E + 0 - nah No na
3 M 41 MC C0-C3 E +(+) 0 + na +++ na
4 na na MM LMb E ++ >15 - na  No na
5 na na MC LM Mx +(+) 1 + na + R
6 F 68 IM Cerebellar tentorium E + 5 - Focal + na
7 M 27 MC Cerebellar tentorium Mx + 1 - No ++ na
8 F 44 MC Pineal region S + 1 - No + na
9 M 55 MC C3-6 Mx + 0 - na ++ R
10 F 59 MM S2 Mx +++ 8 ++ Yes + na
11 na na MC C5-6 E + 0 - na +++ R
12 M 41 MC Th6 S + 0 + No +++ R
13 F 45 MC L3-4 Mx +(+) 0 - na +++ R
14 na na MC Th11 S + 1 - na + na
15 M 49 MM Frontal lobe left E ++ 7 +++ na No na
16 na na MC Cerebellar S + 0 - No ++ na
17 na na IM LM E + 2 - Yes +++ na
18 na na MC Na S + 0 - na +++ na
19 M 7 MM Temporal lobe right E +++ >10 - Yes + Cong. nevusi
F female; M male; na not analyzed/data not available; R recurred, a Diagnosis: MC melanocytoma; MM melanoma;  
IM intermediate-grade melanocytoma, b Location: LM leptomeningeal (more specific information about 
location could not be retrieved), c Cell type:  S spindle; E epithelioid; Mx mixed, d Scoring of nuclear pleomorphism:  
+ mild; ++ moderate; +++ severe, e Number of mitotic figures per 10 HPF, f Scoring of necrosis: + focal; 
++ moderate; +++ extensive, g Scoring of pigmentation: + mild; ++ moderate; +++ severe, h na no CNS tissue 
present in slide for analysis,  i Patient known with a giant congenital melanocytic nevus
35
2
ACTIVATING MUTATIONS OF THE GNAQ GENE: A FREQUENT EVENT IN LMNs
histopathological characteristics. In each patient, no primary melanoma localizations 
elsewhere in the body were known to be present. 
Histology revealed melanocytomas as being often heavily pigmented lesions consisting 
of spindle and/or epithelioid cells arranged in fascicles, sheets and/or compact nests 
(Figure 1 a,b). Nucleoli were mostly inconspicuous. Mitotic activity was low (0-1 per 10 
HPFs). In some cases focal necrosis was present. Nuclear pleomorphism was mostly mild. 
As summarized in Table 2, the melanocytomas often recurred. Three tumors were 
classified as intermediate-grade melanocytomas based on increased mitotic activity (2-5 
per 10 HPFs) and CNS invasion (patient 1, 6 and 17) (Figure 1 b,c). In the melanomas, 
nuclear pleomorphism was prominent, together with conspicuous nucleoli, higher 
Table 2   Patient and histopathological characteristics
Patient Sex Age Diagnosisa Locationb Cell typec Nuclear 
pleomorphismd
Mitosese Necrosisf CNS invasion Pigmentationg Available  
follow- up
1 F 50 IM Th11-12 S ++ 2 - Yes + na
2 F 27 MC Right cerebello-pontine angle E + 0 - nah No na
3 M 41 MC C0-C3 E +(+) 0 + na +++ na
4 na na MM LMb E ++ >15 - na  No na
5 na na MC LM Mx +(+) 1 + na + R
6 F 68 IM Cerebellar tentorium E + 5 - Focal + na
7 M 27 MC Cerebellar tentorium Mx + 1 - No ++ na
8 F 44 MC Pineal region S + 1 - No + na
9 M 55 MC C3-6 Mx + 0 - na ++ R
10 F 59 MM S2 Mx +++ 8 ++ Yes + na
11 na na MC C5-6 E + 0 - na +++ R
12 M 41 MC Th6 S + 0 + No +++ R
13 F 45 MC L3-4 Mx +(+) 0 - na +++ R
14 na na MC Th11 S + 1 - na + na
15 M 49 MM Frontal lobe left E ++ 7 +++ na No na
16 na na MC Cerebellar S + 0 - No ++ na
17 na na IM LM E + 2 - Yes +++ na
18 na na MC Na S + 0 - na +++ na
19 M 7 MM Temporal lobe right E +++ >10 - Yes + Cong. nevusi
F female; M male; na not analyzed/data not available; R recurred, a Diagnosis: MC melanocytoma; MM melanoma;  
IM intermediate-grade melanocytoma, b Location: LM leptomeningeal (more specific information about 
location could not be retrieved), c Cell type:  S spindle; E epithelioid; Mx mixed, d Scoring of nuclear pleomorphism:  
+ mild; ++ moderate; +++ severe, e Number of mitotic figures per 10 HPF, f Scoring of necrosis: + focal; 
++ moderate; +++ extensive, g Scoring of pigmentation: + mild; ++ moderate; +++ severe, h na no CNS tissue 
present in slide for analysis,  i Patient known with a giant congenital melanocytic nevus
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mitotic activity (> 7 per 10 HPFs) and often extensive necrosis (Figure 1 d). All lesions were 
positive for S100, HMB-45 and/or MelanA, and lacked staining for EMA, the latter to exclude 
meningioma.
Mutation analyses
In this group of 19 primary melanocytic neoplasms of the CNS, we detected 7 mutations 
in the GNAQ gene (37%) (Table 3). 
All mutations were present in codon 209 (p.(Gln209Pro) and p.(Gln209Leu)) and were 
somatic mutations (Figure 2). Of these 7 GNAQ-mutant lesions, 6 were melanocytomas 
(50%) and one was a melanoma (1/4, 25%). The intermediate-grade melanocytomas (n=3) 
contained no mutations in the GNAQ gene.                                
Figure 1 Heavily pigmented melanocytoma adjacent to the thoracic spinal cord (patient 
12) consisting of spindle cells arranged in fascicles (a) (magnification 400x). Epithelioid cell 
morphology in an intermediate-grade melanocytoma (patient 17) showing increased mitotic 
activity (2/10 HPFs) (b) (arrow) (magnification 200x). Intermediate-grade melanocytoma 
showing invasion in the thoracic spinal cord (c) (patient 1); note the Rosenthal fiber (arrow) in 
the surrounding neuropil (magnification 200x). Strong nuclear pleomorphism and high mitotic 
activity (arrows) in a melanoma in the sacral region (d) (patient 10) (magnification 200x).
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Of the GNAQ-mutated melanocytomas, five were located in the leptomeninges of the 
spinal cord and one attached to the tentorium cerebelli. All but one GNAQ-mutated 
melanocytomas were strongly pigmented. The one melanoma containing a GNAQ 
mutation was located in the spinal cord (sacral) and was mildly pigmented.
Mutation analysis of the BRAF gene revealed one BRAF mutation (c.1799T>A (p.(V600E))), in 
a melanoma. No HRAS or NRAS mutations were detected in any of the samples.                     
Table 3  Mutation analysis of the GNAQ, BRAF, NRAS and HRAS genes
Patient Diagnosis GNAQ BRAF NRAS HRAS
1 IM wt wt na na
2 MC wt wt wt na
3 MC c.626 A>C (p.(Gln209Pro)) wt wt wt
4 MM wt wt wt wt
5 MC wt wt wt wt
6 IM wt wt wt wt
7 MC c.626 A>C (p.(Gln209Pro)) wt wt wt
8 MC wt wt wt wt
9 MC c.626 A>C (p.(Gln209Pro)) wt na wt
10 MM c.626 A>T (p.(Gln209Leu)) wt wt na
11 MC wt wt wt wt
12 MC c.626 A>T (p.(Gln209Leu)) wt na na
13 MC c.626 A>T (p.(Gln209Leu)) wt wt na
14 MC c.626 A>T (p.(Gln209Leu)) wt wt wt
15 MM wt c.1799 T>A 
(p.(V600E))
na wt
16 MC wt wt wt wt
17 IM wt wt na na
18 MC wt wt wt wt
19 MM wt wt wt wt
MC melanocytoma; MM melanoma; IM intermediate-grade melanocytoma; na mutation status could not 
reliably be evaluated due to suboptimal DNA quality, the DNA being derived from formaline fixed and paraffin- 
embedded tissues
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Discussion
Primary melanocytic tumors of the CNS consist of a spectrum of rare neoplasms derived 
from scattered melanocytes located in the leptomeninges. These melanocytes are 
derived from the neural crest during early embryonic development and are most 
frequently encountered in the recesses of the sulci at the base of the brain and around the 
brain stem and upper part of the cervical spinal cord. [12] Up to now, the genetic alterations 
associated with these neoplasms are unknown. 
There is increasing evidence that melanocytic neoplasms in general are a heterogeneous 
group of tumors with different molecular changes in melanocytic lesions from different 
body sites. Most melanocytic nevi and CMs show oncogenic mutations in signaling 
components of the MAP kinase pathway, in particular BRAF and NRAS [11,22], although in 
UMs, Spitz nevi and blue nevi these mutations are infrequent. [26] Very recently, mutations 
in the GNAQ gene at codon 209 were described as an alternative route to MAP kinase 
activation in a particular subgroup of melanocytic neoplasms, namely UMs and specific 
intradermal melanocytic lesions such as blue nevi and nevi of Ota. [17,32]
We analyzed a group of 19 primary melanocytic lesions of the CNS for hotspot oncogenic 
mutations as described in melanocytic tumors of the skin (exon 15 of  BRAF gene, exon 3 
of NRAS, and exon 3 of HRAS) and uvea (exon 5 of GNAQ). In 7 out of these 19 CNS 
melanocytic tumors, a somatic GNAQ mutation was present at codon 209 (37%). This gene 
is located on chromosome 9q21 and encodes GTP-binding proteins, a family of 
heterotrimeric proteins that couple cell surface receptors to intracellular signaling 
pathways, such as the MAP kinase pathway. Codon 209 encodes the catalytic domain of 
Figure 2 Sequence tracings for GNAQ surrounding codon 209. Wild type (CAA) (a), CAA > 
CTA (b) and CAA > CCA (c). *‘W’ is the nucleotide code for A/T according to the Kyoto Encyclopedia 
of Genes and Genomes (http://www.genome.jp/kegg/catalog/codes1.html).
a b c
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GNAQ. Mutations in this catalytic domain prevent hydrolysis of GTP and turns GNAQ into 
its active, GTP-bound state. In UMs, identical somatic mutations of GNAQ at codon 209 
have been described. [21,32] GNAQ is important in melanocyte homeostasis and survival 
of melanocytes early in neural crest development. [28]
The presence of GNAQ mutations in primary melanocytic neoplasms of the CNS as well as 
in UMs and intradermal melanocytic proliferations such as nevi of Ota and blue nevi [17,32] 
is interesting as these lesions share some other features. First of all, these melanocytic 
tumors are non-epithelium related neoplasms. GNAQ mutations might thus preferentially 
occur in melanocytes already present in extra-epithelial structures such as dermis and 
leptomeninges. Secondly, they often share strong melanin pigmentation. Thirdly, in this 
context, the nevus of Ota is interesting because this is a ‘dermal melanocytosis’, mostly 
congenital, involving the skin innervated by the first and the second branch of the 
trigeminal nerve. The nevus of Ota is often associated with ‘ocular melanocytosis’, 
involving the sclera, conjunctiva and uveal tract. The involvement of different anatomical 
structures in the nevus of Ota might indicate that the GNAQ gene product plays a role in 
migration of melanocytes early during embryonic development. Histology of this nevus 
of Ota ranges from scattered dendritic melanocytes to a morphology strongly resembling 
blue nevi. [4] These nevi of Ota  are not only associated with the development of UM but 
are also associated with the presence of CNS melanocytoma. [25] Thus, it appears that 
GNAQ mutations are preferentially present in a group of non-epithelium related 
melanocytic lesions, sharing histological features and occurring in an anatomical 
distribution indicating a possible role of GNAQ in migration of melanocytes early during 
embryonic development. Interestingly, tumorigenicity studies in nude mice with injection 
of GNAQQ209L-transfected melanocytes resulted in heavily pigmented melanocytic tumors 
at the injection site. [32] Furthermore, dominant dark skin (Dsk) mutations that are found 
in mutant mice with increased dermal melanin, are mutations of the mouse GNAQ gene, 
and the hyperpigmentation in these mutant mice is due to an increase of intradermal, but 
not epidermal melanocytes. It is important to note here, however, that these Dsk mutations 
are different from the oncogenic human GNAQ mutation at codon position 209. [33] Other 
studies in mice have shown that activating mutations in GNAQ or Galpha11, another gene 
encoding G-protein subunits, result in an aberrant accumulation of melanin-producing 
melanocytes in the dermal layer of the skin. [15]
The finding that GNAQ-mutated melanocytic lesions (UMs, blue nevi [10,26,34] and our 
series of melanocytic lesions of the CNS) only infrequently carry BRAF and NRAS mutations 
might be helpful for differential diagnostic purposes. For instance, in our series, one 
melanoma contained a GNAQ mutation, which, in the differential diagnosis with a 
metastasis of a primary CM -often harboring BRAF or NRAS mutations- might favor a 
primary location in the CNS. So, the presence of GNAQ mutations and lack of BRAF or NRAS 
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mutations in melanocytic neoplasms of the CNS seems to strongly indicate a primary CNS 
tumor, a diagnosis that has obvious prognostic implications.
Vice versa, as BRAF point mutations are a frequent event in CMs [30], the one melanoma in 
our series with a BRAF point mutation (case 15; c.1799T>A (p.(V600E))) might be a metastasis 
rather than a primary tumor. The fact that in this patient the tumor was located in the 
frontal lobe (rather than in the posterior fossa or around the spinal cord) might support 
this notion. However, according to the available data a melanocytic tumor outside the 
CNS was absent in this patient.                          
                                                                        
In our study, GNAQ mutations were preferentially present in the melanocytomas, while the 
intermediate melanocytomas and melanomas were only infrequently mutated. This 
might suggest that the presence of a GNAQ mutation favors a benign or low-grade course. 
On the other hand, activating GNAQ mutations are also reported in UMs and, in addition, 
are shown to have no effect on disease-free survival in these neoplasms. [3]                      
                                                                                                            
In conclusion, mutations in the GNAQ gene are a frequent event in primary melanocytic 
neoplasms of the CNS. This finding provides important new insight in the pathogenesis of 
melanocytic CNS lesions and suggest that GNAQ-dependent mitogen-activated kinase 
signaling is a promising therapeutic target in these tumors. 
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Abstract  
Limited data is available on the genetic features of primary leptomeningeal melanocytic 
neoplasms. Similarities with uveal melanoma were recently suggested as both entities 
harbor oncogenic mutations in the GNAQ and GNA11 genes. Whether primary 
leptomeningeal melanocytic neoplasms share additional genetic alterations with uveal 
melanoma including copy number variations frequently present in uveal melanoma is 
unknown.
Twenty primary leptomeningeal melanocytic neoplasms ranging from benign and inter-
mediate-grade melanocytomas to melanomas were tested by direct sequencing for 
hotspot mutations in the genes GNA11, GNAQ, BRAF, NRAS and HRAS. Furthermore, the 
lesions were tested for copy number variations of chromosomes frequently present in 
uveal melanoma (1p, 3, 6 and 8q) by multiplex ligation-dependent probe amplification 
(MLPA). Genome-wide analyses of two leptomeningeal melanocytic neoplasms were 
performed using the OncoScan SNP-array.
GNAQQ209 mutations were present in eleven leptomeningeal melanocytic neoplasms, 
while only two of 20 cases carried a GNA11Q209 mutation. No BRAF, HRAS or NRAS hotspot 
mutations were detected. Monosomy 3 and gain of 8q were present in one leptomeningeal 
melanoma, and one intermediate-grade melanocytoma harbored a gain of chromosome 
6. The melanocytomas did not show any further gross chromosomal variations with 
MLPA.
Our data underscore that primary leptomeningeal melanocytic neoplasms, like uveal 
melanoma but in contrast to cutaneous melanoma, often harbor oncogenic mutations in 
GNAQ and GNA11 but lack mutations in BRAF, NRAS and HRAS. This finding may help in the 
difficult differential diagnosis between a primary leptomeningeal melanocytic neoplasm 
and a metastasis from a cutaneous melanoma to the central nervous system. Copy 
number variations in some aggressive leptomeningeal melanocytic neoplasms resemble 
those present in uveal melanoma but their significance is unclear.  
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Introduction
Primary leptomeningeal melanocytic neoplasms (LMNs) comprise a spectrum of neoplasms 
ranging from benign melanocytoma to melanoma. [1] Melanocytomas (MCs) are slow- 
growing neoplasms generally characterized by a benign clinical course, although local 
recurrence and malignant transformation can occur. [2-5] Intermediate-grade melano -
cytomas (IMCs) show histological features that are suggestive of more aggressive behavior, 
and their clinical behavior is unpredictable. [1, 6] Primary leptomeningeal melanomas 
(LMMs) are histological similar to melanomas arising in other sites but rarely metastasize to 
remote organs. [7, 8]
Systematic study of LMNs is hampered by their very low incidence, and the genetic events 
underlying the oncogenesis of these tumors are largely unknown. Several recent studies, 
including our previous study, reported the presence of activating GNAQQ209 mutations in 
a substantial proportion of LMNs (37%). [9-11] Identical GNAQQ209 mutations are present in 
uveal melanomas (UMs) and blue nevi, but they are very rare in cutaneous melanomas 
(CMs). [12-15] The GNAQ gene encodes the α-subunit of G-proteins (Gαq) that are associated 
with G protein coupled receptors on the cell surface. [16] Substitution of the critical 
glutamine (Q at codon 209) or arginine (R at codon 183) of Gαq leads to decreased GTPase 
activity, preventing hydrolysis of GTP and locking GNAQ in its active, GTP-bound state. This 
results eventually in constitutive activation of the MAPK pathway. [12, 14, 16-18] Activating 
mutations in R183 of GNAQ are very rare in UMs and blue nevi, and little is known about its 
incidence in LMNs. [19]
Activating mutations in GNA11, a homologue of GNAQ located on chromosome 19p13, are 
present in UMs and blue nevi, and were more recently demonstrated in some cases of 
LMNs as well. [10, 14, 19, 20]
The gross chromosomal alterations present in LMNs are yet to be investigated. In UMs, 
monosomy 3 is a frequent event and strongly associated with metastatic disease (50%). 
[21, 22] Other frequent chromosomal aberrations in UMs include gain of chromosome 8q 
that is also associated with metastasis, and loss of chromosome 6p, that is associated with 
good prognosis. [21] Based on the presence of GNAQ and GNA11 mutations in both LMNs 
and UMs, we hypothesized that some LMNs might also share gross chromosomal 
alterations.   
In this study, we investigated a series of twenty LMNs for mutations in Q209 and R183 of 
both GNA11 and GNAQ, as well as for other well-known “hotspot” mutations in BRAF, NRAS 
and HRAS. Additionally, lesions were tested for copy number variations of chromosomes 
frequently present in UMs (1p, 3, 6, 8q) using MLPA and two LMN cases were selected for 
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in depth investigation of copy number alterations across the genome using the OncoScan 
SNP-array). Genetic changes were correlated with clinicopathological characteristics and 
patient follow-up.
Materials and Methods 
Patients and histopathology
For this retrospective study, we collected formalin-fixed, paraffin-embedded tissues of 
20 LMNs, including 14 cases from our previously published series. [9] The diagnosis of 
‘melanocytoma’ (MC) (n=11), ‘intermediate-grade melanocytoma’ (IMC) (n=5) or 
‘leptomeningeal melanoma’ (LMM) (n=4) was based on the criteria previously described. 
[1, 6, 9] None of these patients had clinical evidence of primary melanoma outside the 
central nervous system (CNS).
DNA extraction and mutational analysis
DNA extraction and assessment of DNA quality by the BIOMED-2 control gene PCR were 
performed as previously described. [9] All but seven DNA samples allowed amplification 
of the 200bp amplicon, minimally. [23] The remaining cases (n=7) allowed amplification of 
the 100bp-amplicon only, and still could be evaluated by mutational analysis (Table 1).
Twenty LMNs were investigated for “hotspot” mutations in: GNAQ and GNA11 (Q209 in 
exon 5, and R183 of exon 4); BRAFV600 mutations; G12, G13, G15 mutations in exon 2 and Q61 
mutations in exon 3 of the NRAS gene; and HRASQ61 mutations in exon 3. Primer sequences 
are listed in Supplementary Table 1. PCR conditions as well as assessment on the ABI 
PRISM 3730 DNA analyzer were standardized and described previously. [9] PCR for direct 
sequence analysis of exon 4 of GNAQ and GNA11 were performed using the Amplitaq Gold 
360 Master Mix (Applied Biosystems) with standardized cycling conditions and duplicate 
PCRs were submitted for Sanger sequencing on an ABI PRISM 3730 DNA analyzer (Life 
Technologies, Foster City, USA).
Determination of copy number variations
1. MLPA procedure 
We used the MLPA P027-B1 assay prepared by MRC-Holland (Amsterdam, the Netherlands) 
containing probes on chromosomes 1p, 3, 6, and 8q (as the MLPA assay contains only one 
probe for chromosome arm 8p we did not include 8p analysis in our study)
A further twelve probes were used as reference probes (details available at; http://www.
mlpa.com). Immortalized cell lines of healthy controls were used as baseline control 
samples. MLPA was performed according to the manufacturer’s instructions, and as 
previously described. [21] Samples were analyzed on an ABI 3730 DNA analyzer using the 
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Genescan software (Life Technologies, Foster City, USA). Details on data analysis can be 
found in the Supplementary data.                 
2. OncoScan analysis
One LMM and one IMC (Table 1), selected due to the presence of copy number variations 
(CNVs) detected by MLPA, were further investigated for CNVs across the whole genome by 
OncoScan analysis (molecular inversion probe technology), as described by Wang et al. 
[24] This array consists of ~335,000 probes of which the majority (~283,000) are SNP based. 
DNA was processed by the Affymetrix Research Services Laboratory (ARSL, Santa Clara, 
California, USA). The normalized OncoScan data (2Log(test/reference)-ratios and B-allele 
frequency plots) were analyzed with the Nexus copy number software version 5.1 
(Biodiscovery, Inc, El Segundo, California, USA) for copy number calling.
Statistical analysis
Fisher’s exact test was used to test whether significant associations were present between 
mutational status and cell type; location of the lesion (spinal versus intracranial); dis-
ease-related death; and clinical behavior of the lesion (stable versus progressive lesions, 
the latter including local recurrence, leptomeningeal seeding and/or distant metastasis). 
Statistical analyses were performed using SPSS 16.0 for Windows (IBM Statistics 20, IBM 
Corporation, Armonk, New York, United States).
Results
Patient and histopathological characteristics
Our study group consisted of 11 MCs, five IMCs and four LMMs (Table 1). Most lesions 
were located around the spinal cord (13/20). MC recurred in four patients and aggressive 
behavior with leptomeningeal seeding or locoregional disease progression was present in 
three MC patients (#3, #5, #7). One IMC recurred with leptomeningeal seeding (patient 
#14), while two IMCs had stable disease (patients #12 and #13). Follow-up data was available 
for three LMM patients and all had succumbed to their disease. One LMM patient 
presented with a melanoma in the sacral region and developed distant metastases in the 
bone and lungs two years after initial diagnosis (patient #18). The late manifestation of 
other melanoma locations in this patient is supportive of the sacral lesion being the 
primary tumor. The other two LMM patients demonstrated subsequent leptomeningeal 
seeding but did not develop distant metastases (patients #19 and #20).  
Mutational analysis 
A summary of the mutational analyses is provided in Table 1. Briefly, mutations in codon 
209 of GNAQ in were detected in 11 neoplasms (55%), while in two other LMNs a mutation 
in codon 209 of GNA11 was observed (10%). In this series, GNA11Q209 and GNAQQ209 
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Table 1   Patient characteristics, histopathology and results of mutational analysis and  
copy number changes detected by MLPA
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
1 * F 27 MC right CPA E no Local recurrence.                        
No distant metastases.  
wt wt wt wt - - - - - -
2 *, # M 41 MC C0-C3 E 3+ Local recurrence. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - -
3 *, #, + M 27 MC cerebellar 
tentorium
Mx 2+ LM seeding.                                  
Stable since.                               
Alive.            
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
4 * M 55  MC C3-6 Mx 2+ Local recurrence.                     
Stable since.                             
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - - 
5 *, #, + na na MC C5-6 E 3+ Tumor spread in                      
neck and vertebra.                   
Deceased.
wt wt wt wt na na na na na na
6 *, #, + M 41 MC Th6 S 3+ Local recurrence. na na c.626A>T 
(p.(Gln209Leu))
na na na na na na na
7 *, #, + F 45 MC L3-4 Mx 3+ LM seeding.                              
No distant metastases.  
Alive.                  
wt wt c.626A>T 
(p.(Gln209Leu))
wt na na na na na na
8 * na na MC Th11 S 1+ na wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
9 *, + na na MC cerebellar S 2+ na wt wt wt wt na na na na na na
10 *, #, + na na MC na S 3+ na wt wt wt wt na na na na na na
11 na na MC EM, ID E 3+ No recurrence.                            
Stable.                                          
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
12 na na IMC IM Mx 3+ No recurrence.                          
Stable.                                        
Alive.
wt wt wt wt - - - - na na
13 na na IMC cauda S 2+ No recurrence.                           
Stable.                                        
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
14 & M na IMC IM E 1+ Local recurrence.                 
LM seeding.                                    
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - gain& gain& na
15 *, + na na IMC LM E 3+ na na na wt na na na na na na na
16 * F 68 IMC cerebellar 
tentorium
E 1+ Deceased                                   
(not disease related)
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - - - -
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Table 1   Patient characteristics, histopathology and results of mutational analysis and  
copy number changes detected by MLPA
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
1 * F 27 MC right CPA E no Local recurrence.                        
No distant metastases.  
wt wt wt wt - - - - - -
2 *, # M 41 MC C0-C3 E 3+ Local recurrence. 
Stable since. 
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - -
3 *, #, + M 27 MC cerebellar 
tentorium
Mx 2+ LM seeding.                                  
Stable since.                               
Alive.            
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
4 * M 55  MC C3-6 Mx 2+ Local recurrence.                     
Stable since.                             
Alive.
wt wt c.626A>C 
(p.(Gln209Pro))
wt - - - - - - 
5 *, #, + na na MC C5-6 E 3+ Tumor spread in                      
neck and vertebra.                   
Deceased.
wt wt wt wt na na na na na na
6 *, #, + M 41 MC Th6 S 3+ Local recurrence. na na c.626A>T 
(p.(Gln209Leu))
na na na na na na na
7 *, #, + F 45 MC L3-4 Mx 3+ LM seeding.                              
No distant metastases.  
Alive.                  
wt wt c.626A>T 
(p.(Gln209Leu))
wt na na na na na na
8 * na na MC Th11 S 1+ na wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
9 *, + na na MC cerebellar S 2+ na wt wt wt wt na na na na na na
10 *, #, + na na MC na S 3+ na wt wt wt wt na na na na na na
11 na na MC EM, ID E 3+ No recurrence.                            
Stable.                                          
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
12 na na IMC IM Mx 3+ No recurrence.                          
Stable.                                        
Alive.
wt wt wt wt - - - - na na
13 na na IMC cauda S 2+ No recurrence.                           
Stable.                                        
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - - - -
14 & M na IMC IM E 1+ Local recurrence.                 
LM seeding.                                    
Alive.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - - - gain& gain& na
15 *, + na na IMC LM E 3+ na na na wt na na na na na na na
16 * F 68 IMC cerebellar 
tentorium
E 1+ Deceased                                   
(not disease related)
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - - - -
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mutations were mutually exclusive. Both GNA11Q209 mutations resulted in substitution of 
glutamine at position 209 by leucine c.626A>T (p.(Gln209Leu)) (Figure 1a), and were 
present in an IMC and LMM (patients #16 and #19) (Figure 1b,c). GNAQQ209 mutations 
were present in seven of 11 MCs (64%), two of five IMCs (40%) and two of four LMMs (50%). 
These GNAQQ209 mutations resulted in substitution of glutamine to leucine in 64% (7/11) 
and to proline in 36% of cases (4/11). 
In all samples, “hotspot” mutations in exon 4 of GNAQ and GNA11, and BRAF, HRAS or NRAS 
were absent. 
There was no significant association between GNAQ/GNA11 mutational status and cell 
type, location of the lesion, disease-related death, or clinical behavior (Fisher’s exact, 
P>0.05).      
Copy number variations 
MLPA results for eleven cases were of sufficient quality for further analysis (Table 1). Five 
MC cases did not harbor gross CNVs for the chromosome regions investigated (Figure 2a, 
patients #1, #2, #4, #8 and #11). 
Table 1   Continued
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
17 *, # na na LMM LM E no na wt na wt wt - na na na na -
18 *, & F 59 LMM S2 Mx 1+ Distant metastases             
(bone, lungs).                         
Deceased.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - loss& loss& - - gain&
19 F 32 LMM Th10-11 Mx 1+ LM seeding.                                            
No extradural                              
disease.                                  
Deceased.
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - gain loss -
20 M 55 LMM L1-L2 Mx 1+ LM seeding.                                                
No distant metastases.    
Deceased.                             
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
F female, M male, MC melanocytoma, IMC intermediate-grade melanocytoma, LMM  leptomeningeal melanoma, 
CPA cerebello-pontine angle, EM extramedullary, ID intradural, LM leptomeningeal, S spindle, E epithelioid, Mx 
mixed; * cases of which results of mutation analysis were in part described previously [9]; - no copy number 
changes with MLPA; na not available (sex, age, location, follow-up) or not assessable (MLPA and/or mutation 
analysis); # cases with 100bp- amplicon in the BIOMED-2 gene control PCR (n=7). The remaining cases (n=13) 
allowed amplification of the 200bp-amplicon, minimally; & copy number alterations of two cases confirmed by 
use of OncoScan analysis (Affymetrix); cases not assessable in the mutational analysis (data not further shown): 
case 6 for GNA11 and NRAS, case 7 for HRAS, case 10 and 18 for NRAS ex 2, case 15 for GNA11, NRAS and HRAS, case 17 for 
GNA11 exon 4; nine cases not assessable with MLPA (na), possibly due to the combination of low quality DNA (100bp-
amplicon in the BIOMED-2 gene control PCR, marked with #) and/or heavily pigmentation, marked with +
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Three of four IMCs did not show chromosomal CNVs (patient #12, #13 and #16; patient #12 
and #13 had stable disease and patient #16 died of non-disease related illness. Of note, 
patient #12 could only be evaluated for 1p, 3p, 3q and 6p. One IMC showed gain of 
chromosome 6 confirmed by OncoScan analysis (Figure 3a, Supplementary Figure 1, 
patient #14). This was a GNAQ-mutated IMC showing local recurrence and leptomeningeal 
seeding at follow-up. With the OncoScan analysis, no other gross chromosomal CNVs 
were detected in this sample. Of the two LMMs that were evaluated using MLPA, one 
GNA11-mutated LMM showed gain of 6p, and loss of 6q (Figure 2b, patient #19). The 
patient with this LMM suffered from leptomeningeal seeding at presentation but had no 
extradural melanoma dissemination. The second case was a GNAQ-mutated LMM that 
demonstrated monosomy 3 and gain of 8q, confirmed by OncoScan analysis (patient #18) 
(Figure 3b). In addition, the OncoScan data revealed the following CNVs for this LMM: loss 
of chromosome 1p, loss of chromosome 2p, loss of chromosome 8p, loss of chromosomes 
10, 11 and 18, and gains of chromosomes 4p, 17 and 22 (Figure 3b, Supplementary 
Figure 2). 
Table 1   Continued
Patient Sex Age Diagnosis Location Cell 
type 
Pigmentation Follow-up GNA11 
ex 5
GNA11 
ex 4
GNAQ 
ex 5
GNAQ 
ex 4
Chrom 
1p
Chrom 
3p
Chrom 
3q
Chrom 
6p
Chrom 
6q
Chrom 
8q
17 *, # na na LMM LM E no na wt na wt wt - na na na na -
18 *, & F 59 LMM S2 Mx 1+ Distant metastases             
(bone, lungs).                         
Deceased.
wt wt c.626A>T 
(p.(Gln209Leu))
wt - loss& loss& - - gain&
19 F 32 LMM Th10-11 Mx 1+ LM seeding.                                            
No extradural                              
disease.                                  
Deceased.
c.626A>T 
(p.(Gln209Leu))
wt wt wt - - - gain loss -
20 M 55 LMM L1-L2 Mx 1+ LM seeding.                                                
No distant metastases.    
Deceased.                             
wt wt c.626A>C 
(p.(Gln209Pro))
wt na na na na na na
F female, M male, MC melanocytoma, IMC intermediate-grade melanocytoma, LMM  leptomeningeal melanoma, 
CPA cerebello-pontine angle, EM extramedullary, ID intradural, LM leptomeningeal, S spindle, E epithelioid, Mx 
mixed; * cases of which results of mutation analysis were in part described previously [9]; - no copy number 
changes with MLPA; na not available (sex, age, location, follow-up) or not assessable (MLPA and/or mutation 
analysis); # cases with 100bp- amplicon in the BIOMED-2 gene control PCR (n=7). The remaining cases (n=13) 
allowed amplification of the 200bp-amplicon, minimally; & copy number alterations of two cases confirmed by 
use of OncoScan analysis (Affymetrix); cases not assessable in the mutational analysis (data not further shown): 
case 6 for GNA11 and NRAS, case 7 for HRAS, case 10 and 18 for NRAS ex 2, case 15 for GNA11, NRAS and HRAS, case 17 for 
GNA11 exon 4; nine cases not assessable with MLPA (na), possibly due to the combination of low quality DNA (100bp-
amplicon in the BIOMED-2 gene control PCR, marked with #) and/or heavily pigmentation, marked with +
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Figure 1 a. Forward sequence tracing for GNA11 surrounding codon 209 of exon 5, showing 
the mutation c.626 A>T (p.(Gln209Leu)) for patient #16 (IMC). b. GNA11-mutated IMC in the 
cerebellar tentorium (magnification 400x) showing an epithelioid cell type and increased mitotic 
activity (arrow) (patient #16). c. GNA11-mutated melanoma in a 32-year-old female (magnification 
200x) located at the spinal region Th10-11 (patient #19), showing a mixed cell type, nuclear 
pleomorphism and mitotic activity (arrow).
a
b c
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Discussion 
We previously demonstrated the presence of oncogenic mutations in Q209 of GNAQ in a 
series of LMNs (37%). [9] In the present study, we broadened our sequencing analysis and 
tested a series of 20 LMNs for the presence of  “hotspot” mutations in Q209 and R183 of 
GNA11 and GNAQ, as these “hotspots” were recently shown to be mutated in cases of 
LMNs. [10, 19, 20]
We identified two cases of LMNs harboring a GNA11Q209 mutation (c.626A>T  (p.
(Gln209Leu)) (10%). This result is similar to the study of Gessi et al. who detected a GNA11Q209 
mutation in two out of 16 LMN patients (13%). [10] Our study thus confirms that GNA11Q209 
mutations are a rare event in LMNs (~10%). A similarly low GNA11Q209 mutational frequency 
has been reported in blue nevi (7%), but not in UMs (32%). [14] Furthermore, we detected 
GNAQQ209 mutations in 55% of LMNs, which is within the range of previous studies and 
similar to the GNAQQ209 mutational frequency in UMs (45%) and blue nevi (55%). [9, 10, 14] 
In UMs and blue nevi, mutations at codon 183 of both GNAQ and GNA11 are rare (1-3% in 
either gene, tested in >200 cases). [14] In contrast, little is known about the GNAQR183 and 
GNA11R183 mutational frequency in LMNs. Up to now, only one study searched for 
mutations in this codon and detected one GNAQR183 mutation in five LMN cases. [19] In 
our study, however, codon 183 mutations in GNAQ or GNA11 were absent, suggesting that 
these mutations are a rare event in LMNs. At the moment, it is unclear whether GNAQ or 
GNA11 mutations in LMNs have any association with histological characteristics or clinical 
behavior. In UM, no association has been found between GNAQ or GNA11 mutational 
status and histological characteristics or survival. [14, 25] Furthermore, although inhibition 
of the GNAQ/GNA11 dependent MAPK signaling pathway is now under investigation for 
UMs, it remains to be determined whether a similar approach would be effective in LMNs. 
[26-28]
In our present series of adult cases, we did not find any BRAF, NRAS or HRAS mutations. 
Similar results were obtained by Wang et al. [29] In contrast to the adult setting, we and 
others recently showed that mutations at Q61 of NRAS rather than GNAQ or GNA11 are 
involved in the development of LMNs in children. [10, 30, 31] 
Demonstration of a GNAQ or GNA11 mutation in a CNS melanocytic tumor in the adult 
setting may be very helpful in discriminating a primary LMN from a cutaneous melanoma 
(CM) metastasis in/around the CNS, as CMs only very rarely harbor GNAQ or GNA11 
mutations (0.5%, tested in >200 CM). [14] Conversely, the demonstration of a BRAF mutation 
favors a metastasis from a CM as these melanomas show a high frequency of BRAF 
mutations (50%). [32, 33] (Figure 4) This unequivocal discrimination is often difficult but 
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relevant because of different patient work-up and the substantially better prognosis of 
patients with a primary LMN (even when the tumor is malignant). [34] Importantly, in the 
presence of a GNAQ or GNA11 mutation in a CNS melanocytic lesion a metastasis from a 
UM or malignant blue nevus still needs to be excluded.
Based on the presence of GNAQ and GNA11 mutations in both LMNs and UMs, we 
postulated that UMs and the especially aggressive LMNs might share chromosomal copy 
number variations. The strong association of monosomy 3 and gain of 8q with poor UM 
patient prognosis is well documented. [21, 22, 39] Gain of 6p in UMs is often mutually 
exclusive with monosomy 3 and correlates with a better prognosis. [21, 22, 40] However, in 
our study, only two lesions carried the common gross chromosomal abnormalities seen in 
UM: one GNAQ-mutated LMM showed monosomy 3 and gain of 8q; and one 
GNA11-mutated LMM showed gain of 6p and loss of 6q. The former patient developed 
metastases in bone and lungs two years after initial diagnosis, but no liver metastases 
Figure 4 Frequency of GNAQ, GNA11 and BRAF “hotspot” mutations for LMNs, 
UMs and CMs. Demonstration of a GNAQ or GNA11 mutation in a CNS melanocytic tumor 
may be helpful in discriminating a primary LMN from a CM metastasis in/around the CNS, as 
CMs only very rarely harbor GNAQ or GNA11 mutations. Vice versa, the demonstration of a BRAF 
mutation favors a metastasis from a CM, as CMs show a high frequency of BRAF mutations. Note: 
the mutation frequencies include the hotspot mutations at codon 209 of GNAQ and GNA11, and 
codon 600 of BRAF, and were based on the following large series, including the present study: 
[9, 10, 13, 14, 29, 35-38].
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were demonstrated. The latter patient showed leptomeningeal seeding but no distant 
metastases. In addition, one GNAQ-mutated IMC, presenting with local recurrence and 
leptomeningeal seeding, also showed gain of chromosome 6. Due to the limited number 
of patients that could be tested, however, it is still unclear if the gross chromosomal 
changes in LMNs have any prognostic implications.                                                                                                              
In conclusion, primary LMNs in adult patients often harbour oncogenic mutations in 
GNAQ and GNA11 but lack mutations in BRAF, NRAS and HRAS. Copy number variations in 
some aggressive LMNs resemble those present in UMs but their significance is unclear. 
Testing for GNAQ, GNA11 and BRAF “hotspot” mutations may be of great help in the some-
times-difficult differential diagnosis between a primary LMN and a metastasis from a CM 
to the CNS.                   
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Supplementary methods
MLPA data analysis
Data analysis was performed in Microsoft Excel as follows: 1) the “average control probe 
fraction” of the control samples is calculated by dividing the peak value of each probe 
amplification product by the combined value of all the probes of the control samples 
(n=3), and subsequently to calculate the average of the obtained values, 2)  the “average 
patient probe fraction” is calculated by dividing the peak value of the patient probe 
amplification by the combined value of all patient probes, and, subsequently to divide this 
value by the “average control probe fraction”, 3) next, the obtained value is divided by the 
average of the reference probes of the patient sample, and 4) is corrected for tumor load. 
A normal or disomy copy number was determined from a signal of 0.8-1.2; above 1.2 was 
indicated an amplification and below 0.8 indicated a deletion.
Supplementary Table and Figures
Supplementary Table 1 Primers used for mutational analysis
Gene Exon Forward (Fw) 
Reverse (Rv)
Primer sequence 5’- 3’
GNA11 5 Fw GGTGGGAGCCGTCCTGGGATTGC
Rv CCCACCTCGTTGTCCGAC
GNA11 4 Fw GTGCTGTGTCCCTGTCCTG
Rv GGCAAATGAGCCTCTCAGTG
GNAQ 5 Fw TTCCCTAAGTTTGTAAGTAGTGC
Rv TCCATTTTCTTCTCTCTGACC
GNAQ 4 Fw TTCTCATTGTGTCTTCCCTCCT
Rv AAGGCATAAAAGCTGGGAAAT
BRAF 15 Fw CCTTTACTTACTACACCTCAG
Rv AAAAATAGCCTCAATTCTTAC
NRAS 2 Fw GGTTTCCAACAGGTTCTTGC
Rv CCACTGGGCCTCACCTCTATG
NRAS 3 Fw GATTCTTACAGAAAACAAGTGG
Rv TAATGCTCCTAGTACCTGTAGAG
HRAS 3 Fw CTGCAGGATTCCTACCGGA
Rv ACTTGGTGTTGTTGATGGCA
All primers except for the GNAQ reverse primer contained a M13 forward or reverse consensus sequence 
enabling standardized sequencing of different exons
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CHAPTER 4
Abstract
NRAS mutations are common in human melanoma. To produce a mouse model of 
NRAS-driven melanoma, we expressed oncogenic NRAS (NRASG12D) in mouse melanocytes. 
When NRASG12D was expressed in the melanocytes of developing embryos, it induced 
melanocyte proliferation and congenital melanocytic lesions reminiscent of human blue 
nevi but did not induce cutaneous melanoma. Unexpectedly, however, it did induce 
early-onset primary melanoma of the central nervous system (CNS). The tumors were 
rapidly proliferating and caused neurological symptoms, rapid health deterioration and 
death. NRAS is not a common driver oncogene of primary melanoma of the CNS in adults, 
but we report two cases of primary melanoma of the CNS in children, both of which 
carried oncogenic mutations in NRAS. We conclude that acquisition of somatic mutations 
in NRAS in CNS melanocytes is a predisposing risk factor for primary melanoma of the CNS 
in children, and we present a mouse model of this disease.
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Introduction
Malignant melanoma is a potentially fatal form of cancer that develops from specialized 
pigment cells called melanocytes. In humans, melanocytes are common in the epidermis 
(cutaneous melanocytes), but they also inhabit the dermis, eyes, ears, heart, the central 
nervous system (CNS), and mucosal surfaces of the mouth and genital areas. [1, 2] Thus, 
although the most common form of melanoma (~90% of cases) occurs on hair-bearing 
skin (cutaneous melanoma (CM)), primary melanomas also develop in other sites of the 
body. Melanoma of the non-hair-bearing skin (acral melanoma (AM)) and mucosal 
melanoma (MucM) accounts for approximately 5% [3], and 1% [4] of cases, respectively, 
whereas uveal melanoma (UM) accounts for approximately 3%. [5] In general, the rare 
forms have poorer prognosis, probably because they are diagnosed at a late stage.
Genetic analyses suggest that melanomas from different anatomic sites represent genetically 
distinct diseases. BRAF and NRAS are mutated in approximately 45% and 20% of CMs, 
respectively. In contrast, in AMs, BRAF mutations occur in only approximately 16% of cases, 
NRAS mutations are absent or very rare, and KIT mutations occur in approximately 20% of 
patients. [6, 7] Furthermore, in UMs,  BRAF, NRAS and KIT mutations seems to be extremely rare, 
and this disease instead is driven by mutations in GNAQ, GNA11 and BAP1. [8-10] Primary 
melanoma of the central nervous system (CNS) is another rare type of melanoma and is 
thought to arise from the melanocytes of the leptomeninges. Melanocytic lesions of the 
CNS range from benign (leptomeningeal melanocytosis and melanocytoma) to malignant 
tumors (leptomeningeal melanomatosis and melanoma). [11-13] In children, these neoplasms 
often but not always occur in the context of neurocutaneous melanosis, a rare non-hereditary 
neurocutaneous syndrome presenting with giant (>20cm) and/or multiple congenital 
melanocytic nevi (CMN) in association with leptomeningeal melanocytic neoplasms (LMNs). 
[14-16] Until recently, little was known about the genetic drivers of CNS melanoma, 
particularly in children. However, it was recently reported that the adult disease is associated 
with mutations in GNAQ and GNA11 [17-19], and in one case, NRAS. [19] Notably, approximately 
80% of human CMN harbor somatic mutations in NRAS [20, 21] and giant CMN are associated 
with increased risk of cutaneous and leptomeningeal melanoma. [22]
To study melanoma biology, mouse models of melanoma driven by oncogenic BRAF or 
oncogenic RAS have been developed [23-29], and we have used conditionally inducible 
alleles based on Cre-recombinase/LoxP technology to express oncogenes in mouse 
melanocytes. [24, 25, 30, 31] In adult mice, BRAFV600E induced skin darkening at 2 months, 
blue nevus-like lesions at 4 months, and melanoma in approximately 80% of the animals 
within 2 years. [24] In contrast, when BRAFV600E was expressed in the melanocytes of 
developing embryos (congenital expression), it induced developmental abnormalities 
and embryonic lethality. [31]
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Here, we investigated whether oncogenic NRAS could induce melanoma when it was 
expressed at physiological levels using the endogenous Nras gene. We found that 
expression of NRASG12D in the melanocytes of adult mice induced skin darkening and blue 
nevus-like lesions, but not CM. Expression of NRASG12D in the melanocytes of embryonic 
mice also induced skin darkening and congenital blue nevus-like lesions, but again, 
NRASG12D did not induce CM. However, when it was expressed in the congenital setting, 
NRASG12D induced melanoma of the CNS, and critically, the course of the disease in these 
mice closely resembled that in 2 children who developed melanoma of the CNS driven by 
oncogenic NRAS. We conclude that acquired somatic mutation in NRAS in the melanocytes 
of the leptomeninges is a predisposing risk factor for childhood melanoma of the CNS, 
and we have developed a mouse model of this disease.
Results
To develop NRAS-driven melanoma models, we expressed NRASG12D at physiological 
levels in mouse melanocytes. To achieve this, we used mice in which NRASG12D is expressed 
from the endogenous Nras gene under the control of a LoxP-STOP-LoxP (LSL) cassette 
(NrasLSL-G12D) [32], the removal of which by Cre-recombinase released NRASG12D expression 
in a conditional-inducible manner (Supplementary Figure 1A). We crossed the 
NrasLSL-G12D mice onto mice in which tamoxifen-activated Cre-recombinase (CreERT2) was 
expressed in melanocytes using a tyrosinase enhancer/promoter fragment (Tyr::CreERT2 
mice; see Supplementary Figure 1A). [32, 33] Although CreERT2 was expressed in the 
melanocytes of these mice from approximately embryonic day 10.5 (E10.5), it was only 
activated when the mice were treated with tamoxifen. We painted tamoxifen onto the 
shaven skin on the backs of the mice at approximately 2 months of age to induce NRASG12D 
expression. Within 4 to 8 months, we observed visible darkening of the skin 
(Supplementary Figure 1B) in the homozygous (NrasLSL-G12D/LSL-G12D;Tyr::CreERT2) mice and 
weak darkening of the skin in 50% of heterozygous (Nras+/LSL-G12D;Tyr::CreERT2) mice. The 
darkening was more apparent in the tamoxifen-treated areas, although systemic effects 
also occurred, with darkening of the tails of the homozygous mice (Supplementary Figure 
1B). Microscopic examination of the skin revealed small paucicellular nevi in the deep 
dermal and periadnexal regions of the skin of the heterozygous mice and larger 
multicellular nevi in the homozygous mice (Supplementary Figure 1C). However, 
despite this clear evidence that NRASG12D drives melanocyte proliferation, none of the 
mice developed tumors even after 24 months of expression (Supplementary Figure 1D).
Next, we crossed the NrasLSL-G12D mice onto mice expressing unmodified Cre-recombinase 
from the tyrosinase promoter/enhancer (Tyr::CreA; see Figure 1A) to induce NRASG12D 
expression in the developing melanocytes of embryonic mice. We previously reported 
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Figure 1 NRASG12D induces skin pigmentation and congenital nevi. (A) Schematic 
representation of the conditional-inducible approach used to express NRASG12D in embryonic 
mouse melanocytes. A tyrosinase gene enhancer/promoter construct (Tyr enh/prom) was 
used to express Cre-recombinase (Cre) in melanocytes from approximately E10.5 [38]. NRASG12D 
was expressed from the endogenous mouse Nras gene using a conditional-inducible targeted 
allele in which exon 2 is mutated to introduce the G12D mutation [32]. The LSL cassette blocks 
NRASG12D expression, but its removal by Cre-recombinase releases the block on expression. 
(B) Photographs showing skin pigmentation in control, Nras+/LSL-G12D;Tyr::CreA/° (+/G12D), and 
NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mice at 1 day, 3 weeks, and in adulthood. (C) Top: 
photomicrographs of hematoxylin and eosin (H&E)- stained skin in 1-day-old, 3-week-old, 
and adult control mouse skin. Scalebar = 200μm. Bottom: low-power photomicrographs of 
H&E-stained skin in 1-day-old, 3-week-old, and adult NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) 
mice. Hyperpigmented dendritic melanocytes are visible at low magnification in the 3-week-
old and adult mice. Scalebar = 200μm (n=6 mice per experimental group). (D) High-power 
photomicrographs of H&E-stained skin from boxed areas in the bottom panel from C in 1-day-old, 
3-week-old, and adult NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mice. Hyperpigmented dendritic 
melanocytes in the papillary and reticular dermis, and along the hair follicles and adnexal glands 
are indicated (black arrows) and are sparse in the skin of day 1-old-mice, but are prominent in 
3-week-old and adult mice. Scalebar = 20μm. (E) Photomicrographs of HMB45/MelanA-stained 
skin from a 1-day-old NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mouse, showing the presence of 
melanocytes (black arrows). The area boxed in the left photomicrograph is enlarged in the right. 
Scale bars = 200μm (left) and 20μm (right).
A
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that expression of BRAFV600E in embryonic melanocytes caused hydrocephaly, disruption 
in the development of the eyes and hearts, and embryonic lethality. [31] We were therefore 
intrigued that live-born Nras+/LSL-G12D;Tyr::CreA/° and NrasLSL-G12D/LSL-G12D;Tyr::CreA/° offspring 
were obtained at the expected ratio and did not present any signs of hydrocephaly 
(Figure 1B) or developmental abnormalities of the eyes or hearts (Supplementary 
Figure 2). Notably, all mice presented with darkening of the skin, tails, paws, and snouts 
that was evident from day 1, persisted throughout life, and was more pronounced in the 
homozygous than heterozygous mice (Figure 1B).
Figure 1 Continued
C
D
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These mice also developed benign paucicellular dermal melanocytic lesions reminiscent 
of human blue nevi (Figure 1C). Hyperpigmented dendritic melanocytes were visible in 
3-week-old and adult mice, particularly between the collagen bundles of the reticular 
dermis and along the adnexae of the deep dermal layers (Figure 1C). Notably, these 
hyperpigmented dendritic melanocytic lesions stained positive for HMB45/MelanA and 
were present in 1-day-old mice (Figure 1D and 1E), confirming that expression of 
NRASG12D in embryonic melanocytes induced congenital nevi.
Despite clearly driving melanocyte proliferation in the congenital setting, NRASG12D did 
not induce CM. However, at a median of 4 months for the homozygous animals, and 12.5 
months for the heterozygous animals (Figure 2A), the mice developed neurologic 
symptoms that presented as hyperreactivity to normal stimuli and motor dysfunction, 
including incoordination and tremor with impaired gait. Most animals developed 
increasing cranial perimeter or cranial deformity, and the symptoms progressed rapidly to 
akathisia and marked general malaise that necessitated sacrifice. 
The brains of the affected animals revealed marked darkening of the leptomeninges that 
followed the sulci and fissures, and was more prominent in the fronto-parietal region (Figure 
2B). We observed an increased number of pigmented melanocytes that followed the gyri 
and sulci and enveloped the ventricles (melanocytosis) (Figure 2C). The darkly pigmented 
areas were composed of large melanocytic lesions comprising pleomorphic cells that 
invaded the brain parenchyma (Figure 2D). The tumor cells were rapidly dividing (mitotic 
index >10/ mm2) and stained positive for Ki67 (Figure 2E), phosphorylated extracellular sig-
nal-regulated kinase (ppERK), and Cyclin D1 (Supplementary Figure 3A and 3B). They were 
melanin-laden (Figure 2F) and stained positive for HMB45/MelanA (Figure 2G and 
Supplementary Figure 3A and B) and S100 (Supplementary Figure 3C), but negative for 
the glial cell marker glial fibrillary acidic protein (GFAP) (Supplementary Figure 3D). 
To provide evidence that oncogenic NRAS was expressed, we reverse transcribed RNA 
from the tumors and PCR amplified an Nras fragment across the exon 2/exon 3 boundary. 
Sequencing of this fragment revealed that NrasG12D was expressed in the tumors, but not 
in the normal brains of the Tyr::CreA/° littermate controls (Supplementary Figure 4). 
Macroscopic and microscopic examination of the skin did not present evidence of CM 
(Figure 1B-D), and we did not observe primary tumors in the uvea, hearts (Supplementary 
Figure 2), or oral and genital mucosa (data not shown), the other tissues in which 
melanocytes reside. We therefore diagnosed primary melanoma of the CNS, and cells 
derived from these tumors displayed constitutive ERK activity that was sensitive to the 
MAP-ERK kinase (MEK) inhibitors PD184352, U0126, and AZD6244 (Figure 2H). Importantly, 
PD184352 also delayed the growth of tumor allografts formed by these cells in syngeneic 
immunocompetent mice (Figure 2I).
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Figure 2 NrasG12D induces CNS tumors in mice. (A) Kaplan Meier plot showing survival in 
months (m) of study mice. The experimental groups consisted of Nras+/LSL-G12D;Tyr::CreA/° (+/G12D; 
n=33) and NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D; n=23) mice. The control groups consisted of 
Tyr::CreA/° (n=22), Nras+/LSL-G12D (n=13) and NrasLSL-G12D /LSL-G12D (n=15) mice. (B) Photographs showing 
representative whole-brain and sagittal sections of the brains of control, Nras+/LSL-G12D;Tyr::CreA/° 
(+/G12D) and NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mice. (C) Photomicrograph of an H&E-
stained brain section from a NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse (boxed area in the bottom 
image of B), displaying proliferation of pigmented melanocytes in the leptomeninges along the 
external surface of the brain parenchyma (black arrow). Scalebar = 100μm. (D) Photomicrograph 
of an H&E-stained frontal lobe melanoma from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse, showing 
leptomeningeal spread of melanoma cells (black arrows). Scalebar = 1mm. (E) Photomicrograph 
showing nuclear Ki67 staining (white arrows) of a representative melanoma from a NrasLSL-G12D/LSL-
G12D;Tyr::CreA/° mouse. Note that some cells are melanin-laden (black arrowheads). L, leptomeninges; 
P, brain parenchyma. Scalebar = 20μm. (F) High-power photomicrograph of boxed area in D 
of an H&E-stained melanoma with atypical, epithelioid cells. Tumor cells frequently presented 
intracytoplasmic melanin (black arrowheads). Scalebar = 25μm. (G) Photomicrograph showing 
HMB45/MelanA staining in a representative melanoma from a NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. 
Note the predominant membranous staining and presence of intracytoplasmic deposits of 
melanin in the melanoma cells (black arrowheads). Scalebar = 50μm. (H) Western blot analysis of 
ppERK and total ERK levels of Nras-mutant melanoma cells following MEK inhibition for 3 hours 
using PD184352, U0126 and AZD6244. (I) In vivo allograft experiment, using Nras-mutant cells from 
a mouse brain melanoma showing the effect of the MEK inhibitor PD184352 on intradermal tumor 
growth in C57Bl/6 mice (n = 6 PD184352-treated mice and 9 vehicle-treated mice). 
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We observed hyperpigmentation of the leptomeninges in the brains of asymptomatic 
mice (melanocytosis). The pigmented cells followed the gyri and sulci and covered the 
parietal lobe in an arboriform pattern (Figure 3A). Even in the immediate postnatal period 
(1-day-old mice), the leptomeninges were thickened and hyperpigmented and presented 
HMB45/MelanA positive cells (Figure 3B and 3C). Thus, although NRASG12D induced hy-
perproliferation of melanocytes in both the skin and the CNS, those in the skin developed 
into CMN, whereas those in the leptomeninges progressed to become aggressive and 
invasive primary CNS melanoma.
Figure 2  Continued
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Figure 3 NRASG12D induces melanocytosis in embryonic mice. (A) Photograph 
showing a representative whole brain from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) and 
control mouse at 3 weeks of age. Note the hyperpigmentation of leptomeninges following 
the gyri (black arrow) and sulci (black arrowhead) and the arboriform pattern over the parietal 
lobe (white arrow). (B) Top, photomicrographs of H&E-stained mouse brains of control mice at 1 day 
and 3 weeks of age showing a single array of non-pigmented leptomeninges lining the cerebral 
parenchyma (black arrows). Scalebar = 50μm. Bottom, photomicrographs of H&E-stained mouse 
brains of NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mice at 1 day and 3 weeks of age, showing 
hyperpigmentation and thickening of the leptomeninges (black arrows). Scalebar = 50μm 
(n = 6 mice per experimental group). (C) Photomicrographs of an HMB45/MelanA-stained mouse 
brain (arrows indicate individual cells) from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° (G12D/G12D) mouse 
at 1 day of age. Scalebar = 50μm. The boxed area in the left photomicrograph is shown at higher 
magnification in the right.  Scalebar = 20μm.
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We were struck by the similarities between the disease in our mice and the disease we 
observed in 2 cases of primary melanoma of the CNS that occurred in young children. The 
first case involved a 4-year-old Caucasian boy who presented with somnolence and motor 
dysfunction. Initial clonic seizures of the right leg led to secondary generalized tonic-clonic 
seizures followed by paralysis of the right arm and leg that slowly recovered over 24 hours. 
Magnetic resonance imaging (MRI) revealed a hyperintense, contrast-enhancing lesion in 
the left parieto-occipital region, following the gyri and sulci. Cerebral spinal fluid (CSF) 
analysis with cytologic examination and computerized tomography (CT) scans of the thorax 
and abdomen yielded normal findings, and no pigmented lesions were found on the skin.
Despite treatment with valproic acid, carbamazepine and phenytoin, the seizures recurred 
and subsequent MRI revealed extension of the lesion to the right parietal cortex (Figure 4A). 
After 6 months, the child developed permanent right hemiparalysis and aphasia. The 
lesion was resected, and despite radiotherapy, the child passed away. Macroscopic 
examination of the cerebral tissue showed marked thickening and brownish discoloration 
of the leptomeninges and a zone of intense black discoloration of the underlying the 
cerebral cortex (Figure 4B). Microscopically, the lesion revealed a proliferation of atypical 
cells in the leptomeninges and Virchow-Robin spaces, with invasion of the adjacent 
cerebral cortex (Figure 4C). The tumor cells were highly mitotic (>10/mm2) and adopted 
an epithelioid morphology with nuclear pleomorphism (Figure 4D and 4E). Tumor cells 
stained positive for MelanA (Figure 4F), HMB45, and S100 (Supplementary Figure 5A 
and 5B), and the malignant cells in the Virchow Robin spaces and cerebral cortex 
contained copious amounts of melanin, whereas cells in the leptomeninges were sparsely 
pigmented (Figure 4C and 4D). These features are consistent with a diagnosis of 
leptomeningeal melanomatosis, and DNA sequencing did not uncover mutations in BRAF, 
HRAS, GNAQ, GNA11, CDKN2A or TP53 (data not shown), but did reveal a c.182A>G, p.(Q61R) 
mutation in NRAS (Figure 4G).
Figure 3  Continued
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Figure 4 Diagnosis of leptomeningal melanomatosis carrying an oncogenic 
mutation in NRAS in patient 1. (A) Axial T1-weighted MRI revealing a hyperintense, contrast-
enhancing lesion in the left parieto-occipital region following the gyri and sulci. (B) Photograph 
showing macroscopic appearance of the cerebral tissue from patient 1. Brownish discoloration 
of the thickened leptomeninges (L) and black discoloration of the underlying cerebral cortex 
(C) are evident. (C) Photomicrograph showing H&E staining of the melanoma revealing the 
proliferation of hypopigmented cells in the leptomeninges (L) and invasion of hyperpigmented 
cells (black arrowheads) into the CNS parenchyma (P). Scalebar = 100μm. (D) Photomicrograph 
showing H&E staining of the melanoma. Note the epithelioid morphology of the nonpigmented 
atypical cells in the leptomeningeal compartment (L) and pigmented tumor cells (white arrows) 
invading the CNS parenchyma (P). Scalebar = 25μm. (E) Photomicrograph showing details of 
epithelioid morphology of pleomorphic melanoma cells in the leptomeningeal compartment. 
Scalebar = 50μm. (F) Photomicrograph showing MelanA staining of the pigmented melanoma 
cells (black arrowheads) in the CNS parenchyma (black stars). Scalebar = 50μm. (G) Forward 
sequence of DNA from the primary CNS melanoma from patient 1 showing the presence of an 
NRAS c.182A>G, p.(Q61R) mutation (arrow). 
A B
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The second case involved a boy with a giant CMN over the lumbrosacral region, with 
multiple satellite congenital nevi over the trunk, face, arms and upper legs. Biopsies at 2 and 
5 years revealed a CMN with diffuse infiltration of nevomelanocytes into the dermis and 
subcutaneous tissue (Figure 5A-5C). Single cells in the dermis splayed the collagen bundles 
and extended around and within the periadnexal structures (Figure 5A and 5C). At age 7, 
the boy presented with motor dysfunction and paraesthesia of the left hand, progressive 
weakness of the left leg, and accompanying headache and vomiting. MRI revealed a large, 
heterogeneous, hyperintense tumor in the right frontotemporal area, causing midline shift 
and compression of the ventricles and mesencephalon (Figure 5D). The patient quickly 
deteriorated and passed away despite tumor debulking and supportive treatment with 
mannitol and dexamethasone. The tumor was composed of highly mitotic (>10/mm2) 
epithelioid cells with irregular nuclei, prominent nucleoli (Figure 5E and 5F), and positive 
staining for MelanA (Figure 5G), HMB45, and S100 (Supplementary Figure 5C and 5D). 
Dermatological examination did not reveal any clinical changes to suggest primary CM 
arising over CMN. In the absence of CM, we diagnosed primary melanoma of the CNS arising in 
the context of neurocutaneous melanosis. DNA sequencing did not reveal mutations in BRAF, 
HRAS, GNAQ, GNA11, CDKN2A or TP53 (data now shown), but did reveal a c.181C>A, p.(Q61K) 
mutation in NRAS in the tumor (Figure 5H) and the CMN (Supplementary Figure 5E).
Figure 4  Continued
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Figure 5 Diagnosis of NRAS-mutated leptomeningal melanoma in patient 2. 
(A) Photomicrograph showing H&E staining of full-thickness skin from the CMN. Scalebar = 
0.5mm. (B) Photomicrograph of the CMN showing detailed H&E staining of melanocytic nests 
(arrows) in the papillary dermis and single melanocytes in the reticular dermis (arrowhead). 
Scalebar = 300μm. (C) Photomicrograph of the CMN showing detailed H&E staining of the 
deep dermal melanocytes in the collagen and along the hair follicle (arrows). Scalebar = 300μm. 
(D) T1-weighted MRI with contrast, revealing a large tumor in the right frontotemporal region 
with meningeal attachment. (E) H&E staining of the CNS melanoma showing epithelioid tumor 
cells with low pigment content. Scalebar = 50μm. (F) H&E staining of the CNS melanoma. 
Note the atypical tumor cells with irregular nuclei and frequent nucleoli. Scalebar = 30μm. 
(G) Photomicrograph showing cytoplasmic brown chromogen MelanA staining in melanoma 
cells (black arrowhead) invading brain parenchyma (black star) of patient 2. Scalebar = 50μm. 
(H) Forward sequence of DNA from the primary CNS melanoma from patient 2 showing the 
presence of an NRAS c.181C>A, p.(Q61K) mutation (arrow). 
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Discussion
Here we show that oncogenic NRAS induced dose-dependent hyperpigmentation of the 
skin when expressed in the mature melanocytes of adult mice or the developing 
melanocytes of embryonic mice. This finding is consistent with previous data showing 
that NRASQ61K also increased skin pigmentation when expressed in embryonic mouse 
melanocytes using the tyrosinase promoter, and that oncogenic KRAS induced skin hy-
perpigmentation when expressed in mature melanocytes from the endogenous Kras 
gene [30] or from a Actb (β-Actin) promoter fragment. [25] We also show that like KRASG12V, 
when NRASG12D was expressed in mature melanocytes, it induced paucicellular nevi in the 
deep dermal layers of the skin that resembled human blue nevi. We also show that when 
NRASG12D was expressed in developing melanocytes, it induced congenital blue nevus-like 
lesions, complementing a recent report showing that NRASQ61K also induced congenital 
nevi when expressed using a tyrosinase promoter fragment. [34]
We previously reported that when BRAFV600E was expressed in embryonic melanocytes, it 
disrupted heart and eye development, and caused embryonic lethality [31], but here we 
show that NRASG12D did not induce these effects. The basis of this difference is unclear, but 
Figure 5  Continued
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a possible explanation is that BRAFV600E transforms developing melanocytes more readily 
than does NRASG12D, causing them to disrupt the development of the organs they 
colonize. Alternatively, perhaps oncogenic NRAS induces melanocyte senescence or 
apoptosis, so that unlike the BRAFV600E melanocytes, the NRASG12D melanocytes are 
unable to disrupt the development of their host organs. 
Of note, although none of the mice developed CM when NRASG12D was expressed in the 
melanocytes of embryonic or mature mice, when NRASG12D was expressed in the 
melanocytes of the embryos, the mice developed leptomeningeal melanoma that 
presented as neurological symptoms at a median of 4 months for homozygous animals 
and 12.5 months for heterozygous animals. The tumors generally affected the fronto- 
parietal region of the brain and presented as darkly pigmented lesions that followed the 
sulci and fissures and invaded the normal CNS parenchyma. The tumors were aggressive 
and had a high proliferative index, and showed evidence of RAS pathway activation, as 
well as expression of melanocytic, but not neuronal cell, markers. 
Cerebral metastases of CMs are usually multifocal, homogenous and well-circumscribed 
nodules, whereas the tumors in our mice arose from areas connected to leptomeningeal 
melanocytic hyperproliferation. They were firmly adhered to the surface of the dura and 
diploё, and invaded the CNS in a highly destructive infiltrative pattern. No macroscopic or 
histologic changes were observed in the skin of our mice, and at time of sacrifice, the nevi 
in the skin retained their paucicellularity, benign architecture and cytomorphology. We 
also ruled out primary tumors in the other organs colonized by melanocytes. Thus, the 
brain melanomas arose in the absence of any other primary tumors, and we diagnosed 
primary melanoma of the CNS. 
We were intrigued that although we observed melanoma of the CNS when we expressed 
NRASG12D off the endogenous Nras gene, when NRASQ61K was expressed using the 
tyrosinase promoter, it did not induce leptomeningeal melanoma. [26] However, as 
discussed below, the disease in our mice, which was driven by NRASG12D, mimicked the 
cardinal features of the disease in the children, which was drive by NRASQ61K/R. We 
therefore posit that the differences between our mouse model and the mice that were 
previously reported lies in differences in the pattern, levels, or timing of oncogenic NRAS 
expression, rather than differences in the biology of NRASG12D or NRASQ61K. 
This melanoma model is the first driven by oncogenic RAS expressed using the 
endogenous gene that did not require additional genetic engineering of the mice, or 
exposure to a carcinogen or tumor promoters. In most previously described mouse 
models of RAS-driven melanoma, tumor induction was inefficient unless the mice carried 
a second genetic lesion or were exposed to an environmental stress. For example, 
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HRASG12V-induced melanoma was inefficient unless the mice were exposed to ultraviolet 
light or the tumor promoter TPA. [23, 35, 36] Similarly, deletion of p16INK4A cooperated with 
HRASG12V and NRASQ61K to induce melanoma [26, 28], and KRAS-driven melanomagenesis 
was inefficient unless BRAFD594A was also expressed [30] or KRASG12V was strongly 
overexpressed using the Actb promoter. [25] Note, however, that we do not interpret this 
finding to mean that NRASG12D alone was sufficient to induce leptomeningeal melanom-
agenesis, and we are currently working to identify the cooperating events, using insertional 
mutagenesis and genomics. 
Importantly, our mice presented the same cardinal clinical features of the disease as those 
manifested in the 2 children. As in the mice, the children presented with neurologic 
symptoms, then experienced rapid health deterioration and death, and the cells in their 
tumors were highly proliferative, invaded the CNS parenchyma, and stained positive for 
melanoma markers. We did not observe primary melanoma of the skin in either child and 
therefore diagnosed primary melanomatosis and melanoma or primary malignant 
melanocytic tumors of the CNS in both cases. Sequencing revealed the presence of a 
NRAS mutation. Furthermore, one of the children presented with a giant CMN that shared 
the same NRAS mutation as his CNS melanoma. Because this child did not present CM 
arising in CMN, it seems that his leptomeningeal melanocytes were more susceptible than 
his cutaneous melanocytes to transformation by oncogenic NRAS. Mouse leptomeningeal 
melanocytes also seem to be more susceptible to transformation by oncogenic NRAS 
than cutaneous melanocytes. Thus, despite the evidence that NRASG12D induced 
proliferation of both cutaneous and leptomeningeal melanocytes, none of the mice 
developed CM, whereas 75% of the heterozygous mice and all of the homozygous mice 
developed melanoma of the CNS. It is unclear why developing leptomeningeal 
melanocytes are more susceptible to transformation by oncogenic NRAS than cutaneous 
melanocytes, but it seems unlikely that this is due to differences in the numbers of 
melanocytes in these 2 sites. More plausibly, it seems likely that, although oncogenic 
NRAS induced prenatal proliferation of the melanocytes in both the skin and brains, 
intrinsic (cell autonomous) or extrinsic (microenvironment) differences between the 
melanocytes in these 2 sites mean that those in the leptomeninges were more susceptible 
to transformation. This idea is supported by the observation that one of the children’s 
tumors had the same NRAS mutation as his giant CMN, suggesting a common ancestry, 
but nevertheless a more susceptible population in the leptomeninges. We anticipate that 
identifying the events that cooperate with NRAS to transform melanocytes will go some 
way toward explaining the underlying biology. 
Although we have reported 2 cases of childhood melanoma of the CNS that carry NRAS 
mutations, we note that in adults, melanoma of the CNS is associated with mutations in 
GNAQ and GNA11, whereas NRAS mutations are rare. [17-19] Previous studies have shown 
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that truly CMN harbor NRAS mutations and patients with these lesions may also have 
congenital deposits of leptomeningeal melanocytes. [20, 21] Furthermore, in humans, and 
in children in particular, CNS melanoma often arises in patients with giant CMN [12-16], 
approximately 80% of which carry somatic mutations in NRAS, but not in BRAF. [20, 21] Our 
data show that leptomeningeal melanocytes are more susceptible to transformation by 
oncogenic NRAS than are cutaneous melanocytes. We posit that a link exists between 
prenatal proliferation of melanocytes and early-onset melanoma of the CNS and that 
acquisition of somatic oncogenic mutations in NRAS in the melanocytes of the CNS is a 
predisposing risk factor to melanoma of the CNS. We present a mouse model that can be 
used to study this rare and devastating disease and note that the tumor cells from our 
mice are susceptible to MEK inhibitors, suggesting a potential therapeutic approach for 
these patients. 
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Methods
Animal procedures
All procedures involving animals were approved by the Animal Ethics Committees of the 
Institute of Cancer Research and the Cancer Research UK London Research Institute in 
accordance with National Home Office regulations under the Animals (Scientific 
Procedures) Act 1986 and according to the guidelines of the Committee of the National 
Cancer Research Institute. [37] Tamoxifen (Sigma-Aldrich T5648) was freshly prepared in 
100% ethanol. For genotyping, genomic DNA was prepared from tail biopsies and PCR 
was performed using the primers previously described [32, 38]. For allograft experiments, 
0.5 × 106 Nras-mutant cells in 0.1 ml PBS were inoculated intradermally into the flanks of 
female C57Bl/6 mice (Charles River). Mice were treated daily by oral gavage with vehicle 
(n=9 mice) or PD184352 (25 mg/kg; n=6 mice). Tumor volumes were determined using 
volume = length × width × depth (mm) × 0.5236.
RNA extraction and sequence analysis of mouse tissue
RNA was extracted from frozen tissues using RNAeasy kit (QIAGEN), and first-strand cDNA 
synthesized and DNAse treated as previously described. [24] Subsequentially, cDNA was 
amplified by PCR and the products were sequenced using dye-terminator chemistry with 
Nras primers:
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5’- ATGACTGAGTACAAACTGGTGGTGG-3’ and 
5’- CCATCAATCACCACTTGCTTTCGGTAAG-3’. Sequences were visualized using Sequencher 
software.
Tumor DNA extraction and sequence analysis of human cases
Three manually dissected sections of 10-mm formalin-fixed and paraffin-embedded tissue 
with an estimated tumor cell percentage of at least 80% were used for DNA extraction. 
DNA extraction and sequence analysis of BRAF, NRAS, HRAS, GNAQ, CDKN2A and TP53 was 
performed as previously described. [17] The GNAQ gene sequence amplified was 
gene-specific as GNAQ pseudogene-specific nucleotides were not detected. Sequence 
analysis for GNA11 was performed using M13-tailed GNA11 specific primers: 
5’- AAAACGACGGCCAGTGGTGGGAGCCGTCCTGGGATTGC-3’ and 
5’- CAGGAAACAGCTATGACCCCCACCTCGTTGTCCGAC- 3’. 
All PCR reactions were performed in duplicate using 2 independent PCR products for 
sequence analysis. 
Histology and immunohistochemistry 
Mouse tumors were formalin fixed and analyzed as previously described [24], and 
subsequently stained with H&E, Ki-67 (Dako M7249) and HMB45/MelanA (Abcam ab732). 
All procedures concerning the use of human tissue were in accordance with valid 
standards for this type of investigation in the Netherlands. [39] For tumor staining, the 
following antibodies were used: S100 (Dako Z0311), HMB45 (Novocastra NCL-HMB45) and 
MelanA (Mart clone M2-7C10, Neomarkers MS-716). Sample preparation for S100 staining 
was performed without retrieval, while sample preparation for HMB45 and MelanA 
staining was performed with retrieval (NAcitrate pH6.0 and pH9.0, respectively). 
Immunofluoresence labeling of FFPE samples
Three-millimeter sections of formalin-fixed paraffin-embedded (FFPE) material were used. 
Slides were dewaxed, and antigen retrieval was conducted using citrate buffer pH 6.0 
followed by blocking in PBS-Tween 0.1% + 1% BSA for 15 min and over-night incubation 
with primary antibody (1:100 in PBS + 1% BSA). The following primary antibodies were 
used: phospho-ERK1/2 (Cell Signaling Technology), GFAP (Dako), HMB45/MelanA and 
Cyclin D1 (Abcam), and S100 (MenaPath). Antibody detection was performed using Alexa 
Fluor-conjugated secondary antibodies (Invitrogen). Slides were counterstained with 
4’,6-diamidino-2-phenylindole (DAPI). Samples were analyzed, and pictures were taken 
using a Leica SP2 confocal scanning microscope (Leica Microsystems). 
Cell culture and Western Blotting 
The Nras-mutant tumor cell line was established by collecting murine brain melanoma in 
sterile PBS on ice and mechanically dissociating tumors in Dulbecco’s modified Eagle 
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Medium (DMEM). The cells were continuously cultured in DMEM supplemented with 10% 
fetal bovine serum (FBS) and 10 U/mL penicillin and 100mg/mL streptomycin. Cells were 
exposed to the MEK inhibitor PD184352, and cell lysates were prepared as previously 
described. [40] The following primary antibodies were used: anti-phospho-p42/p44 
MAPK, and total ERK1/2 (Cell Signaling Technology).
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Supplementary figures
Supplementary Figure 1  Expression of NRASG12D in mouse melanocytes does 
not induce melanoma in mice. (A) Schematic representation of the conditional-inducible 
approach used to express oncogenic NRAS in adult mouse melanocytes. (B) Photograph showing 
a tamoxifen-treated Nras+/LSL-G12D;Tyr::CreERT2 mouse (+/G12D), a tamoxifen-treated Nras+/+;Tyr::CreERT2 
(control), and a tamoxifen-treated NrasLSL-G12D/LSL-G12D;Tyr::CreERT2 mouse (G12D/G12D) showing 
increased pigmentation of the skin in experimental mice. The photograph was taken 16.5 months 
after treatment. (C) Upper panel: Low power photomicrographs showing H&E staining of the skin 
from a control mouse, a tamoxifen-treated Nras+/LSL-G12D;Tyr::CreERT2 (+/G12D), and a tamoxifen-treat-
ed NrasLSL-G12D/LSL-G12D;Tyr::CreERT2 (G12D/G12D) mouse. Note the presence of blue nevi-like dermal 
nevi in the heterozygous and homozygous mice. Scale bars= 300μm. Lower panel: 
Photomicrographs showing H&E magnifications of boxed areas in the upper panel. Note the 
presence of pigmented melanocytes in the deep dermis and periadnexal regions (black arrows). 
Scale bars= 50μm. (D) Kaplan-Meier plot showing survival time (months) of study mice. The 
experimental groups consisted of tamoxifen-treated Nras+/LSL-G12D;Tyr::CreERT2 (+/G12D;ERT2+Tam) 
mice (n=18) and tamoxifen-treated NrasLSL-G12D/LSL-G12D;Tyr::CreERT2 (G12D/G12D;ERT2+Tam) mice (n=9). 
The control groups consisted of EtOH-treated Nras+/LSL-G12D;Tyr::CreERT2 (+/G12D;ERT2+EtOH) mice 
(n=22) and EtOH-treated Nras LSL-G12D /LSL-G12D;Tyr:: CreERT2 (G12D/G12D;ERT2+EtOH) mice (n=11).
A B
C
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Supplementary Figure 1  Continued
Supplementary Figure 2  Expression of NRASG12D in mouse melanocytes does 
not affect the eyes or the heart. Upper panels: photomicrographs of H&E-stained eyes 
of a control (left), heterozygous (middle) and homozygous (right) mice. Scalebar= 0.5mm. 
Lower panels: photomicrographs of H&E-stained hearts of a control (left), heterozygous 
(middle) and homozygous (right) mice. Scalebar= 0.5mm. n=10 heterozygous experimental 
mice, 10 homozygous experimental mice and 8 control mice.
D
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Supplementary Figure 3 Tumors from mouse CNS are malignant melanoma. 
(A) Photomicrographs showing nuclear and cytoplasmic staining for ppERK (first panel), HMB45/
MelanA (second panel), DAPI (third panel) and a merged image (fourth panel) in tumors from 
an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. Scalebar = 10μm. (B) Photomicrograph showing nuclear 
cyclin D (first panel), HMB45/MelanA (second panel), DAPI (third panel) and a merged image 
(fourth panel) in a tumor from a NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. Scalebar = 10μm. (C) Photo-
micrographs showing S100 immunofluorescence staining of a representative melanoma from 
a NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. The cell nuclei were counterstained with DAPI and a 
merge image is provided. Scalebar = 10μm. (D) Left panel: photomicrograph of an H&E-stained 
CNS tumor from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse displaying leptomeningeal spread of 
melanoma cells (black star) overlying normal CNS parenchyma (black cross). Scalebar= 30μm. 
Remaining panels: photomicrographs showing HMB45/MelanA (second panel) and GFAP (third 
panel) staining in a tumor from an NrasLSL-G12D/LSL-G12D;Tyr::CreA/° mouse. The merged image (fourth 
panel) shows that the HMB45/MelanA and GFAP staining are mutually exclusive. Scalebar= 30μm. 
A
B
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Supplementary Figure 4  Mouse brain tumors express NRASG12D. Reverse sequence 
trace of cDNA from a mouse brain tumor (upper sequencing trace) showing the presence of 
an NRASG12D mutation (arrow) and from a brain of a control animal (lower sequencing trace) 
showing wild-type NRAS (p.G12).
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Supplementary Figure 5  Tumors from patients 1 and 2 are primary melanoma 
of the CNS. (A) Photomicrograph showing predominantly membranous red chromogen 
staining for HMB45 in CNS tumor cells from patient 1. Scalebar= 50μm. (B) Photomicrograph 
showing mixed cytoplasmic and nuclear staining for S100 in CNS tumor cells from patient 1. 
Scalebar= 50μm. (C) Photomicrograph showing membranous red chromogen staining for 
HMB45 in CNS tumor cells from patient 2. Scalebar= 50μm. (D) Photomicrograph showing brown 
cytoplasmic staining for S100 in CNS tumor cells from patient 2. Scalebar= 50μm. (E) Forward 
sequence of DNA from the CMN from patient 2 showing the presence of an NRAS c.181C>A, 
p.(Q61K) mutation (arrow).
A
B
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EXPERIMENTAL TREATMENT OF NRAS-MUTATED NCM WITH MEK162
Introduction
Neurocutaneous melanocytosis (NCM) is a rare congenital disorder, in which affected 
patients have an increased number of melanocytes in the leptomeninges of the central 
nervous system (CNS) and the skin. The skin is often affected in the form of a large 
congenital melanocytic nevus (CMN) usually associated with multiple smaller nevi, so 
called “satellites” in the vicinity. [1,,2, 3]
Leptomeningeal melanocytosis consists of a diffuse proliferation of histological benign 
appearing melanocytes in the leptomeninges without CNS invasion. Patients can develop 
neurological symptoms due to increased intracranial pressure, mass lesion, or compression 
of the spinal cord. Affected patients have an increased risk of developing melanoma in the 
skin, and neurological problems because of the melanocytic lesions in the CNS. The latter 
are often fatal. [2] Even in the absence of malignant progression, leptomeningeal 
melanocytosis carries a poor prognosis once neurological symptoms develop. [1, 4]
So far, surgical resection of the CNS tumor is the treatment of choice, but complete 
resection is often impossible. In addition, the value of chemotherapy and radiotherapy is 
not clear. Recently, different studies have demonstrated that early embryonic / postzygotic 
somatic mutations in the NRAS gene are implicated in the development of NCM and 
childhood melanoma of the CNS. [5-7]
In this case report, we present a 13-year-old boy with NRAS-mutated NCM who, despite 
repeated surgery, developed progressive neurological symptoms for which he was 
experimentally treated with MEK162, a MEK inhibitor. Although the patient died 5 days 
later and clinical benefit could not be established, we could demonstrate possible effect 
of MEK162 treatment on the protein level in the brain tumor tissue, suggesting a potential 
role for MEK inhibition in symptomatic NRAS-mutated NCM.
Case
A 13-year-old boy was admitted to the outpatient clinic of pediatric neurology with 
progressive neurological symptoms. Since birth, he had multiple large melanocytic nevi 
of the skin, for which multiple resections were performed in the past. As a child, his 
developmental milestones for speech and fine motor skills were slightly delayed. Now, he 
presented with vertigo, headache, nausea, vomiting and pain in his legs. Neurological 
examination revealed bilateral papilloedema, slurred speech, dysmetria and dysdiadocho-
kinesis of both arms, and an unsteady gait due to cerebellar ataxia plus mild pyramidal 
tract and sensory involvement. Knee and ankle jerk reflexes were clearly increased, but 
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plantar responses were normal. MRI of the brain showed enhanced signal intensity of the 
uncus, an enlarged fourth ventricle in contact with a retrocerebellar cyst extending 
through the foramen magnum, and an enlarged subarachnoid cistern anterior to the 
brainstem, extending from the medulla oblongata towards the floor of the third ventricle. 
The brain stem appeared to be compressed or atrophied due to the combined pressure 
from these cysts (Figure 1A). Spinal MRI showed a widened spinal canal and a distorted 
and atrophic spinal cord, due to the presence of multiple cysts with extensive 
leptomeningeal and dural contrast enhancement without the presence of solid masses 
(Figure 1B). Based on the history of large CMN and the neuroradiological findings, a 
diagnosis of NCM was made. 
To decompress the brainstem and cerebellum and obtain material for histology, a sub- 
occipital decompression was performed with drainage of the cerebellar cyst.  Intra-operatively, 
the floor of the fourth ventricle was covered with small cystic lesions, the arachnoid of the 
medulla spinalis was thickened and discolored, and the cyst wall covered all cranial nerves 
and arteries lateral to the brain stem, inhibiting cerebrospinal fluid flow. 
Histology indeed showed leptomeningeal melanocytosis and therefore confirmed the 
clinical diagnosis of NCM. Mutation analysis showed a mutation in exon 3 at codon 61 of 
NRAS (c.1818C>A (p.(Gln61Lys) alias “Q61K”). Revision of the previously removed congenital 
nevi from both legs, left arm, right shoulder and right eyebrow, showed melanocytic nevi 
without signs of malignancy. NRAS mutation analysis of one of them showed an identical 
NRAS mutation as in the leptomeningeal melanocytosis. Normal skin contained no such 
NRAS mutation, thereby excluding an NRAS germ-line mutation. After surgery, the patient 
initially improved. In the following months, however, neurological symptoms increased 
and repeated imaging showed progressive leptomeningeal lesions of the brain and spinal 
cord with (further) compression of these structures and hydrocephalus (Figure 1C-D). In 
an attempt to relieve some of the symptoms, a ventriculo-peritoneal shunt was placed in 
the right lateral ventricle. However, the fourth ventricle enlarged again due to aquaduct 
stenosis. Hence, aquaduct stenting was performed. Unfortunately, this could not prevent 
further deterioration. There were no neurosurgical options left. Also, we refrained from 
radiotherapy since no rapid clinical benefit was expected from this. 
In view of the previously described beneficial effect of MEK162 in NRAS-mutated metastatic 
melanoma [8], and knowing that our patient carried an activating NRAS mutation in his 
leptomeningeal melanocytosis lesion, we explored possibilities to treat our patient with 
MEK162. Novartis agreed to supply MEK162 on compassionate use base and after screening 
for eligibility and after parental consent, we started treatment with MEK162 45mg BID.
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In the following days however, the patient was readmitted to the hospital because of 
further deterioration with progressive general weakness and stridor. He had papules on 
the chest, consistent with mild skin toxicity due to MEK162. Cerebral MRI confirmed disease 
progression. Five days after starting treatment with MEK162, the boy died due to central 
neurogenic respiratory failure. The parents gave permission to perform autopsy.
Figure 1  A. MRI of the brain showed an enlarged fourth ventricle in contact with a retrocerebellar 
cyst extending through the foramen magnum, and an enlarged subarachnoid cistern anterior 
to the brainstem, extending from the medulla oblongata towards the floor of the third ventricle. 
The brain stem appeared to be compressed or atrophied due to the combined pressure from 
these cysts. T1- weighted image with contrast. B. Spinal MRI showed a widened spinal canal 
and a distorted and atrophic spinal cord, due to the presence of multiple cysts with extensive 
leptomeningeal and dural contrast enhancement without the presence of solid masses. T1 
weighted image with contrast. C and D. MRI of the brain and spinal cord, a few months after 
surgery, showed progressive leptomeningeal lesions of the brain and spinal cord with (further) 
compression of these structures and hydrocephalus. C with, D without contrast. 
A
C
B
D
102
CHAPTER 5
Results
Autopsy findings and histology
At autopsy, multiple large melanocytic nevi were seen on the skin, mainly on the trunk, 
some with scars because of previous surgical removal. At the base of the brain (Figure 2A), 
around the cerebellar hemispheres and the brainstem, the leptomeninges were greyish and 
thickened, embedding blood vessels and cranial nerves, and obstructing the cerebellar 
cisterna and foramina. This prominent leptomeningeal thickening extended along the 
entire spinal cord resulting in a thick plaque-like tumor compressing especially the cervical 
region of the spinal cord (Figure 2C). Some nodular thickening of leptomeninges around 
spinal nerve roots was present, while nerve roots from the cauda equina were completely 
Figure 2  A. The base of the brain was greyish and thickened, embedding blood vessels and 
cranial nerves. B. Microscopically, a leptomeningeal proliferation consisting of melanocytic cells 
was seen with extension of melanocytic cells in the perivascular Virchow Robins spaces of the 
brain, without frank invasion of the CNS parenchyma. C. The spinal cord was surrounded by 
a thickened brown-greyish tumorous proliferation. This prominent leptomeningeal thickening 
extended along the entire spinal cord resulting in a thick plaque-like tumor compressing 
especially the cervical region of the spinal cord. D. Microscopical picture of a transverse section 
through the spinal cord. E.  The melanocytic cells were ovoid and monotonous, with little 
cytonuclear atypia. Necrosis was absent and mitotic activity was low. 
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embedded in leptomeningeal tumor. At cut surface of the brain, black discoloration was 
seen of the amygdala and focally in the right basal cortex.
Microscopically a leptomeningeal proliferation consisting of melanocytic cells was seen 
(Figure 2B, D-E), confirmed by staining for S100, Melan-A and HMB-45. The melanocytic 
cells were ovoid and monotonous, with little cytonuclear atypia (Figure 2E) and 
occasionally some cytoplasmic melanin pigment. Necrosis was absent and mitotic activity 
was low. Extension of melanocytic cells in the perivascular Virchow Robins spaces of the 
brain (Figure 2B) and spinal cord was present, without frank invasion of the central 
nervous system parenchyma. Compression of the brain stem by the diffuse leptomeningeal 
melanocytosis, causing respiratory insufficiency by increased pressure, was considered 
the cause of death. Histological examination of the nevi at autopsy and revision of 
previously removed congenital nevi, demonstrated compound melanocytic nevi with 
congenital features, without signs of malignancy.
Immunohistochemistry
To study whether MEK162 had sorted an effect on the leptomeningeal melanocytosis 
after 5 days of treatment, tumor tissue removed at operation before treatment and tumor 
tissue at autopsy, was stained with the antibodies Ki-67 and pERK. The melanocytosis after 
MEK162 treatment showed lower MIB1 expression (1-2% versus 0%: compare figure 3A 
with figure 3B, before and after treatment, respectively, 400x) and lower pERK protein 
expression than before (compare Figure 3C, pretreatment, with Figure 3D pERK staining 
post-treatment, 200x; endothelial cells served as a positive internal control*).
Mutation analysis
An identical mutation in exon 3 at codon 61 of NRAS c.1818C>A (p.(Gln61Lys) alias “Q61K”) 
was present in the leptomeningeal melanocytosis removed at surgery and in one of the 
congenital nevi removed in the past, while normal skin did not reveal an NRAS mutation, 
thereby excluding an NRAS germ-line mutation.
Western blotting
Unfortunately, the brain specimen before MEK162 was insufficient for analysis. The Western 
blot showed presence of total ERK, but no presence of pERK in the brain sample after 
MEK162 treatment, which is in line with the immunohistochemical staining results. See 
Figure 3E and 3F.
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Figure 3  A. MIB-1 expression in the leptomeningeal melanocytosis before MEK162 treatment 
(magnification 400x, % of MIB-1 positive cells 1-2%). B. The melanocytosis after MEK162 treatment 
showed lower MIB-1 expression (0%: compare figure 3A). C. pERK protein expression in the 
leptomeningeal melanocytosis before MEK162 treatment (magnification 200x; endothelial cells 
serve as a positive internal control*). D. pERK protein expression after MEK162 treatment showing 
lower pERK expression than pre-treatment (magnification 200x, compare with 3C). E and 
F. Western blots showing expression of pErk (E) and total Erk (F) in the brain sample after MEK162 
treatment (lane 4), along with Rh-18 and Granta-519 as positive and negative controls in lanes 
2 and 3, respectively. In the brain sample, pERK cannot be detected after MEK162 treatment (E), 
whereas total ERK is present (F), as indicated by the long arrows.  Short arrows indicate GAPDH 
expression. 
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Discussion
Neurocutaneous melanocytosis (NCM) is a rare congenital disorder with an increased 
number of melanocytes in the leptomeninges of the central nervous system (CNS) and 
the skin. [1] Even in the absence of malignant progression, NCM carries a poor prognosis 
once neurological symptoms develop. [1, 4] At present, therapeutic options are limited. 
Surgery is the most important one, but this is often not complete and therefore not 
curative. 
Recently, different studies have demonstrated that early embryonic /postzygotic somatic 
mutations in the NRAS gene are implicated in the development of NCM and childhood 
melanoma of the CNS. [5-7] Thus far, all primary childhood melanomas of the CNS and 
leptomeningeal melanocytosis were found to harbor NRAS mutations: in the 6 cases 
reported in literature, including the present case, an exon 3 codon 61 mutation in NRAS (1 
case Q61L, 3 cases Q61R, 2 cases Q61K) was demonstrated. [5-7]
A recent non-randomized phase 2 study demonstrated that MEK162 showed activity in 
NRAS-mutated melanoma. [8] In addition, we previously reported on a mouse model in 
which embryonic induction of NRAS mutation led to a NCM-like disease in mice with 
development of primary CNS melanoma [5].  In that paper, we were already able to 
demonstrate that cells derived from the brain tumors in the mice displayed constitutive 
ERK activity that was sensitive to the MAP–ERK kinase (MEK) inhibitors PD184352, U0126, 
and AZD6244. [5] Thus, as an NRAS mutation was present in the melanocytosis and the 
patient showed clinical progression despite previous surgery, MEK162 treatment was 
started on compassionate use base. Unfortunately, therapy was probably started too late 
to be able to observe a clinical effect of MEK162 treatment. We observed immunohisto-
chemically that MEK162 led to a decrease in proliferation in the leptomeningeal 
melanocytosis as well as a decrease in pERK expression. The significance of this observation 
is questionable as we report a single case and the decrease in proliferation is limited. But 
our findings are in line with those of a recent case report, reporting effect of vemurafenib 
in diffuse leptomeningeal melanoma metastasis with a BRAF mutation. [9] Future studies 
are needed to determine whether symptomatic NRAS-mutated NCM can indeed 
effectively be treated by MEK inhibitors.
Materials and methods
Histology and immunohistochemistry
Material of the tumor at operation and autopsy was formalin-fixed and paraffin-embedded 
(FFPE) and partially snap frozen.
106
CHAPTER 5
The FFPE-tumor was stained with H&E, Ki-67 (DAKO-M7240, clone MIB-1; dil. 1:100; with 
antigen retrieval, citrate 10’), MART  (Immunologic, ILM022111-C1; dil.1: 100; with antigen 
retrieval, EDTA 10’), and HMB-45 (Leica-Menarini, NCL-L-HMB45; dil.1: 20; with antigen 
retrieval, citrate 10’). Frozen material of the leptomeningeal melanocytosis from the 
operation and at autopsy was stained with pERK (Cell Signalling, clone #4376; dil. 1:100). 
The latter detects endogenous levels of p44 and p42 ERK1 and ERK2 when dually 
phosphorylated at Thr202 and Tyr204 of Erk1 (and Thr185 and Tyr187 of Erk2), and singly 
phosphorylated at Thr202.
Tumor DNA extraction and sequence analysis
All procedures involving the use of human tissue were in accordance with valid standards 
for this type of investigation in the Netherlands. [10] Three manually dissected sections of 
10 μm formalin-fixed and paraffin-embedded tissue with an estimated tumor cell 
percentage of at least 50% were used for DNA extraction. DNA extraction and sequence 
analysis of NRAS were conducted as previously described. [11] All PCR reactions were 
conducted in duplicate using 2 independent PCR products for sequence analysis.
Protein lysates and Western blotting
Protein lysates of the brain sample after MEK-treatment and of the positive and negative 
cell line controls were prepared in RIPA Buffer (#9806s, Cell Signaling, Leiden Netherlands). 
Of the protein lysates 25 µg was loaded on a 10 % polyacrylamide gel. Gel electrophoresis 
and Western blotting onto a nitrocellulose Hybond-C extra membrane (RPN303E, GE 
Healthcare Europe GmbH, Diegem Belgium) was performed according to standard 
procedures.  After transfer of the proteins, the membrane was blocked using blocking 
buffer (927-40000, LICOR, Lincoln USA) for 1 hr. at room temperature (rt), and incubated 
with phospho-p44/42 MAPK (Erk1/2) mouse monoclonal antibody E10 as primary antibody 
(#9106; Cell Signalling, Danvers, MA, USA), overnight at 4 °C, washed with Tris-buffered 
saline (TBS), subsequently incubated with a Alexa Fluor goat-anti-mouse 680 antibody 
(A21057, Molecular Probes, Bleiswijk, the Netherlands) for 1 hr. at rt and washed with TBS 
again.  A similar blot was made using the total p44/42 MAPK (Erk1/2) rabbit polyclonal 
antibody (#9102; Cell Signalling, Danvers, MA, USA) as primary antibody. The blots were 
scanned using the Odyssey instrument (ODYSSEY CLx infrared imaging system, LICOR, 
Lincoln USA). After scanning, the blot was incubated with GAPDH mouse monoclonal 
antibody to assess protein loading (clone 6C5, # AB8245, Abcam, Cambridge, UK) for 1 hr. 
at rt, washed with TBS, and further incubated with goat anti-mouse 680 antibody (blot A) 
or goat-anti-mouse 800 antibody (#35521, Thermoscientific, Waltham, MA, USA; blot B), 
washed and scanned using the Odyssey. 
Financial support: This work was supported with a grant from the Koppie-Au foundation.
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Abstract
The histological differential diagnosis between melanotic schwannoma, primary 
leptomeningeal melanocytic lesions and cellular blue nevus can be challenging. Correct 
diagnosis of melanotic schwannoma is important to select patients who need clinical 
evaluation for possible association with Carney Complex. Recently, we described the 
presence of activating codon 209 mutations in the GNAQ gene in primary leptomeningeal 
melanocytic lesions. Identical codon 209 mutations have been described in blue nevi. The 
aim of the present study was to (1) perform a histological review of a series of lesions 
(initially) diagnosed as melanotic schwannoma and analyze them for GNAQ mutations, 
and (2) test the diagnostic value of GNAQ mutational analysis in the differential diagnosis 
with leptomeningeal melanocytic lesions. We retrieved 25 cases that were initially 
diagnosed as melanotic schwannoma. All cases were reviewed using established criteria 
and analyzed for GNAQ codon 209 mutations. After review, nine cases were classified as 
melanotic schwannoma. GNAQ mutations were absent in these nine cases. The remaining 
cases were reclassified as conventional schwannoma (n=9), melanocytoma (n=4), blue 
nevus (n=1) and lesions that could not be classified with certainty as melanotic 
schwannoma or melanocytoma (n=2). GNAQ codon 209 mutations were present in 3/4 
melanocytomas and the blue nevus. Including results from our previous study in 
leptomeningeal melanocytic lesions, GNAQ mutations were highly specific (100%) for 
leptomeningeal melanocytic lesions compared to melanotic schwannoma (sensitivity 
43%). We conclude that a detailed analysis of morphology combined with GNAQ 
mutational analysis can aid in the differential diagnosis of melanotic schwannoma with 
leptomeningeal melanocytic lesions.
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Introduction
Melanotic schwannoma is a rare variant of schwannoma composed of cells having the 
ultrastructure and immunophenotype of Schwann cells but containing melanosomes in 
varying stages of maturation. [24,25] They show a peak incidence in the fourth decade, 
and affect males and females equally. About half of these tumors arise in close proximity 
to the neural axis. These neoplasms are often associated with spinal nerve roots, cranial 
nerves or arising from the paraspinal sympathetic chain. [5,15] The other half arises in a 
wide variety of sites including the gastrointestinal tract, soft tissues, skin, heart and liver. 
[3,8,10,13,25] The biological behavior of melanotic schwannomas can be unpredictable 
with metastasis reported in up to 10% of cases, sometimes even in absence of histological 
features suggestive of aggressive behavior. [5,27]
A specific subgroup of melanotic schwannomas contain psammoma calcifications. About 
half of these so-called psammomatous melanotic schwannomas occur in the setting of 
the autosomal dominant Carney complex, a multiple neoplasia syndrome characterized 
by a markedly increased risk to develop myxomas, mucocutaneous lentigines and blue 
nevi, endocrine hyperactivity and/or psammomatous melanotic schwannomas. [5] 
Isolated cases of non-psammomatous melanotic schwannomas have been associated 
with Carney complex as well. [6] Nearly two thirds of patients with Carney complex have 
mutations spread over the PRKAR1A gene, which encodes the R1α regulatory subunit of 
cyclic-AMP-dependent protein kinase A. [14,29]          
                                       
The differential diagnosis between melanotic schwannomas and pigmented melanocytic 
lesions can be difficult, especially in small biopsy specimens. It includes primary or 
metastatic melanoma, a diagnosis with obvious prognostic and therapeutic relevance. In 
addition, melanotic schwannomas may histologically closely resemble leptomeningeal 
melanocytomas and cellular blue nevi. [20] Immunohistochemical stains are not always 
useful  in sorting out this differential diagnosis. All these lesions generally express S-100 
(which can be explained by their common neural crest origin) and one or more 
melanocytic markers. Although stains for components of the basement membrane can 
be useful in discriminating tumors with schwannian differentiation from tumors with 
melanocytic differentiation, overlap in staining patterns has been noted and can impair 
interpretation, especially in small biopsy specimens. [4,12,21,26]
Recently, we reported the presence of activating mutations in the GNAQ gene at codon 
209 in primary leptomeningeal melanocytomas (50%) and melanomas (25%). [16] The 
GNAQ gene maps on chromosome 9q21, and encodes the α-subunit of a heterotrimeric 
GTP-binding protein that couples G protein coupled receptor signalling to the MAP kinase 
pathway. [22] GNAQ codon 209 mutations form an alternative route to MAP kinase 
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activation. [28] Identical oncogenic mutations in the GNAQ gene have been reported in 
blue nevi (83%) and uveal melanomas (UMs) (46%). [17,28]                         
                                                                       
The aims of the present study were (1) to perform a thorough histological review of a 
series of lesions that were (initially) diagnosed as melanotic schwannoma and to analyze 
these cases for mutations in the GNAQ gene, and (2) to assess the diagnostic value of 
GNAQ mutational analysis in the differential diagnosis of melanotic schwannoma with 
primary leptomeningeal melanocytic lesions by including data from our previous study 
on GNAQ mutations in leptomeningeal melanocytic lesions. [16]
Materials and methods
Patients and histopathology
For this retrospective study, formalin-fixed and paraffin-embedded (FFPE) tissues of 
melanotic schwannomas were retrieved from archives of various Departments of 
Pathology in The Netherlands. The cases were obtained through the Dutch nationwide 
histopathology and cytopathology data network and archive (PALGA). [7] All cases (n=25) 
were initially diagnosed as melanotic schwannomas.
FFPE tissues were sectioned at 4 µm, deparaffinized, and subjected to antigen retrieval by 
limited protein digestion or citrate (CC1) and microwave treatment. Slides were then 
incubated at room temperature with antibodies to S-100 protein (polyclonal, 1:800, Dako 
Co. , Lot 00060051), Melan-A (Mart-1, 1:800, Neomarkers, Lot 799P807C), HMB-45 (1:50, 
Neomarkers, Lot 23068), MIB-1 (Ki-67, 1:200, Dako Co., Lot 00045312), EMA (E-29, 1:50, Dako 
Co., Lot 00051982), Collagen type IV (monoclonal, 1: 1250, Sigma, Lot 062K4819) and 
Laminin (polyclonal, 1:100, Thermo, Lot 82H907B). Amino-ethylcarbazole served as 
chromogen. Reticulin stains (Laguesse) were performed on each case. Schmorl and Perl´s 
(iron) stains were performed to confirm melanin pigmentation.           
                          
Histology was revised independently by two pathologists (HK, BK) without knowledge of 
molecular results. Revision of the slides included scoring of histological criteria and immuno-
histochemical stains.
The deposition of basement membrane material in the reticulin, Collagen type IV and 
Laminin stains was categorized into three staining patterns. The pericellular pattern was 
represented by an extensive network of basement membrane material around individual 
tumor cells, consistent with schwannian differentiation. [12,24] The nested/perilobular 
pattern consisted of deposition of  basement membrane material around nests of tumor 
cells (rather than around individual tumor cells), and is typically seen in melanocytic 
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lesions. [26] The biphasic staining pattern was characterized by areas with nested staining 
as well as areas with pericellular staining, and has been described in melanotic 
schwannomas. [12,24]
After revision, the cases were reclassified as: (1) melanotic schwannoma, with or without 
psammoma bodies and/or fat, (2) conventional schwannoma, (3) melanocytoma, (4) 
lesion not further classified with certainty as melanotic schwannoma or melanocytoma, 
or (5) blue nevus.
Criteria used for classification are presented in Table 1. The diagnosis of `melanotic 
schwannoma`  and ` conventional schwannoma`  was based on WHO criteria. [24] Additional 
detailed histological criteria of melanotic schwannoma were retrieved from Mooi [20], and 
included circumscribed, often encapsulated tumors consisting of spindle to epithelioid 
cells, with or without psammoma bodies and/or fat, variable melanin pigmentation, S-100 
positivity and expression of Melan-A and/or HMB-45. Schwannomas lacking positivity for 
both HMB-45 and Melan-A were classified as conventional schwannomas. A pericellular 
staining pattern in the basement membrane stains served as an additional criterion for 
conventional schwannoma, while in melanotic schwannomas also a biphasic staining 
pattern can be present. [12,24] The diagnosis of ` melanocytoma`  was based on histological 
criteria as described by Brat et al.. [1,2] This included circumscribed, non-encapsulated 
lesions consisting of nests or fascicles of spindle and/or epithelioid cells with little nuclear 
atypia and variable melanin pigmentation. Immunohistochemical criteria included S-100 
positivity, expression of Melan-A and/or HMB-45, and a nested staining pattern in the 
basement membrane stains. Lesions with increased mitotic activity or invasion of 
neuroglial tissue were classified as ´intermediate-grade´ melanocytomas.
The diagnosis of ‘cellular blue nevus’ was based on histological criteria described by Mooi. 
[19] This included a primary location of the lesion within the dermis with a biphasic 
architecture, especially at the base of the lesion, consisting of nodules and sheets of pale, 
oval melanocytes intermingled with pigmented dendritic melanocytes diffusely arranged 
in sclerotic stroma.
For statistical evaluation, 19 leptomeningeal melanocytic lesions from our previous study 
were included. [16]
DNA extraction
About five manually dissected sections of 10 mm FFPE tissue with an estimated tumor cell 
percentage of at least 60% were used for DNA extraction. After heating in ATL buffer, the 
tissue sections were incubated in proteinase K for one hour, followed by subsequent 
purification of the DNA according to the manufacturer (QIAamp DNA Mini Kit, QIAGEN 
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GmbH, Germany). DNA sample concentration was assessed spectrophotometrically (Varian 
Cary 50 spectrophotometer, Agilent Technologies).
Mutational analysis
Direct sequence analysis of GNAQ exon 5 was performed on DNA-specimens from 25 l 
pigmented lesions of schwannian or melanocytic origin. PCR amplification was performed 
Table 1   Morphological, esp. histopathological criteria used for classification 
Conventional 
schwannoma1
Melanotic schwannoma1,3 Leptomeningeal melanocytoma (MC) 2 Cellular blue nevus3
Localization Majority outside 
central nervous 
system, most often 
skin and subcutaneous 
tissue
Near the neural axis (esp. spinal nerve roots, cranial 
nerves) or  peripherally located in a wide variety of sites 
(soft tissue, skin etc.)
Mostly at the cervical and thoracic spinal level, posterior 
fossa and sometimes supratentorial compartment
Skin (mainly dermis);  frequently buttocks or 
sacrococcygeal region
Origin Nerve sheath  
(schwann cell)
Nerve sheath (schwann cell) Leptomeningeal melanocyte Dermal melanocyte
Growth pattern, 
margin
Circumscribed, 
encapsulated
Circumscribed, often encapsulated Circumscribed,  non-encapsulated; MC with invasion of 
CNS is classified as intermediate-grade MC
Non-encapsulated; both infiltrative and 
pushing border
Melanin 
pigmentation
Absent Variably, often heavily pigmented Variably, often heavily pigmented; can rarely be absent Variably, can rarely be absent
Psammoma 
bodies and/or fat
Absent Present in the psammomatous form Absent Absent
Schwannian 
features4
Present Often less pronounced than in conventional 
schwannoma
Absent Degenerative changes reminiscent of ancient 
schwannoma can be present
Cell phenotype Spindle Spindle, epithelioid Spindle, epithelioid Spindle, ovoid, dendritic (biphasic 
architecture)
Nuclear  atypia Generally absent;      
ancient changes 
(´degenerative atypia`) 
can be present 
Usually mild; prominent  nuclear atypia with increased 
mitotic activity and necrosis is indicative of aggressive 
behavior
Generally absent; MC with increased mitotic activity  
(2-5 per 10 HPF) is classified as intermediate-grade MC
Variable; absence of necrosis, mitotic activity 
< 2 per 2mm2
S-100 Positive Positive Positive Positive
HMB-45 and/ or 
Melan-A
Negative Positive Positive Positive
Basement 
membrane 
staining 
Pericellular pattern Pericellular or biphasic (pericellular and nested) pattern Nested pattern Predominantly nested pattern
1 Based on WHO criteria [24]
2 Based on criteria described by Brat et al. [1,2]
3 Based on criteria described by Mooi [19,20]
4 Esp. Antoni A and B pattern, Verocay bodies and lipid-laden macrophages
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in a total volume of 25 µL, containing 50 ng DNA, PCR-buffer IV (Integro),  37 mM MgCl2, 
250 µM of dNTPs, 37.5 µg bovine serum albumin (Sigma), 10 pmol of forward primer (p740, 
sequence: 5’ TGTAAAACGACGGCCAGTTTCCCTAAGTTTGTAAGTAGTGC 3’) and reverse 
primer (p 705, sequence: 
5’ CAGGAAACAGCTATGACCCTTACCTCATTGTCTGAC 3’, or p695, 
sequence: 5’ TCCATTTTCTTCTCTCTGACC 3’) and 0.05 units of thermostable DNA 
Table 1   Morphological, esp. histopathological criteria used for classification 
Conventional 
schwannoma1
Melanotic schwannoma1,3 Leptomeningeal melanocytoma (MC) 2 Cellular blue nevus3
Localization Majority outside 
central nervous 
system, most often 
skin and subcutaneous 
tissue
Near the neural axis (esp. spinal nerve roots, cranial 
nerves) or  peripherally located in a wide variety of sites 
(soft tissue, skin etc.)
Mostly at the cervical and thoracic spinal level, posterior 
fossa and sometimes supratentorial compartment
Skin (mainly dermis);  frequently buttocks or 
sacrococcygeal region
Origin Nerve sheath  
(schwann cell)
Nerve sheath (schwann cell) Leptomeningeal melanocyte Dermal melanocyte
Growth pattern, 
margin
Circumscribed, 
encapsulated
Circumscribed, often encapsulated Circumscribed,  non-encapsulated; MC with invasion of 
CNS is classified as intermediate-grade MC
Non-encapsulated; both infiltrative and 
pushing border
Melanin 
pigmentation
Absent Variably, often heavily pigmented Variably, often heavily pigmented; can rarely be absent Variably, can rarely be absent
Psammoma 
bodies and/or fat
Absent Present in the psammomatous form Absent Absent
Schwannian 
features4
Present Often less pronounced than in conventional 
schwannoma
Absent Degenerative changes reminiscent of ancient 
schwannoma can be present
Cell phenotype Spindle Spindle, epithelioid Spindle, epithelioid Spindle, ovoid, dendritic (biphasic 
architecture)
Nuclear  atypia Generally absent;      
ancient changes 
(´degenerative atypia`) 
can be present 
Usually mild; prominent  nuclear atypia with increased 
mitotic activity and necrosis is indicative of aggressive 
behavior
Generally absent; MC with increased mitotic activity  
(2-5 per 10 HPF) is classified as intermediate-grade MC
Variable; absence of necrosis, mitotic activity 
< 2 per 2mm2
S-100 Positive Positive Positive Positive
HMB-45 and/ or 
Melan-A
Negative Positive Positive Positive
Basement 
membrane 
staining 
Pericellular pattern Pericellular or biphasic (pericellular and nested) pattern Nested pattern Predominantly nested pattern
1 Based on WHO criteria [24]
2 Based on criteria described by Brat et al. [1,2]
3 Based on criteria described by Mooi [19,20]
4 Esp. Antoni A and B pattern, Verocay bodies and lipid-laden macrophages
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polymerase (Sigma). Primers p740 and p705 contained a M13 forward and a M13 reverse 
consensus sequence, respectively, enabling standardized sequencing of different exons.
DNA amplification was performed in duplicate in a PTC 200 Thermal Cycler (MJ Research). 
The PCR was started with 5 min at 92°C and followed with 35 cycles of denaturation 45 s 
at 94°C, annealing at 62°C for 45 s and extension at 72°C for 45 s, followed by a final 
extension at 72°C for 20 min and cooling down for 5 min at 20°C. PCR products were 
purified with MinElute plates (Qiagen). After analysis of the PCR products by agarose gel 
electrophoresis (2%; Invitrogen) , 1-4 µl of the PCR products were sent in for sequence 
analysis using an ABI PRISM 3700 DNA analyzer (Applied Biosystems).
Because the DNA-quality of some specimens was suboptimal, different primer combinations 
were used in the PCR. The DNA-samples of cases 1, 2, 3, 5, 6, 13, 14, 22 and 23 were of 
sufficient quality and the primer combination p740 and p705, yielding a PCR product of 
224 basepairs (bp), was used for DNA-amplification. Sequence analysis was performed 
using the M13 forward primer and reverse primer on duplicate DNA-amplifications of the 
same specimen. For the DNA-samples that were strongly degraded (cases 4, 7, 8, 9, 10, 11, 
12, 15, 16, 17, 18, 19, 20, 21, 24, 25) the primer combination p740 and p695, yielding a PCR 
product of 134 bp, was used. Sequence analysis (in duplicate) of these samples was 
performed using the forward primer only, since the reverse primer p695 is closely flanking 
the mutation hotspot. By sequence analysis of the entire PCR products, it was shown that 
the primers used specifically amplified the GNAQ gene (accession nr: NM_002072.2) and 
not its pseudogene (GNAQP1; accession nr: NG_000862.4v). The amplified gene sequence 
was specific for the GNAQ gene, and nucleotides that are present in the pseudogene were 
not detected. [9]
Statistical analysis
The diagnostic value of GNAQ mutational analysis in the differential diagnosis of melanotic 
schwannoma with primary leptomeningeal melanocytic lesions was tested using additional 
data from our previous study on GNAQ mutations in primary leptomeningeal melanocytic 
lesions. [16] Sensitivity and specificity of GNAQ mutational analysis was calculated. To assess 
whether the difference in GNAQ mutational status between melanotic schwannoma and 
leptomeningeal melanocytic lesions was statistically significant, we performed Fisher’s 
exact test (SPSS 16.0 for Windows).
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Results
Patient and histopathological characteristics
We retrieved 25 lesions initially diagnosed as melanotic schwannomas from the archives of 
various Departments of Pathology in The Netherlands. After revision, the lesions were 
reclassified using the above-mentioned criteria into nine melanotic schwannomas, nine 
conventional schwannomas, four melanocytomas, one blue nevus and finally two lesions that 
could not be further classified with certainty as melanotic schwannoma or melanocytoma.
Patient and histopathological characteristics are summarized in Table 2. As far as data 
were available, the melanotic schwannomas had an equal sex distribution and the mean 
age was 37.2 years. Most melanotic schwannomas were located around the spinal cord 
(7/9), while 2 lesions were located in the extremities (lower arm and lower leg).
As far as was assessable, melanotic schwannomas were circumscribed, encapsulated 
tumors (6/9) (Figure 1a) with variably but mostly intense melanin pigmentation (6/9) 
(Figure 1b). Eight of nine melanotic schwannomas contained psammoma bodies (Figure 
1a, b) and, in addition, one melanotic schwannoma contained large, empty vacuoles 
resembling fat (case 8) (Figure 1c). Tumor cells were arranged in sheets and fascicles and 
varied from spindle to epithelioid, often with  nuclear pseudoinclusions (Figure 1c) and 
conspicuous nucleoli. In some cases there was nuclear palissading and one case showed 
Antoni A and B areas together with Verocay bodies (case 4). Marked nuclear pleomorphism, 
necrosis, and invasion in surrounding structures was absent. These tumors were all 
negative in the EMA stains (excluding meningeoma). MIB-1 staining was less than 1 
percent. S-100 stains showed a diffuse and strong expression in all melanotic schwannomas 
(Figure 1d). In addition, all lesions showed positivity for Melan-A and HMB-45 (Figure 1e). 
Reticulin, Collagen type IV and Laminin stains showed in four of nine cases an extensive 
network of basement membrane material around individual tumor cells (pericellular pattern), 
consistent with schwannian differentiation (Figure 1f). In five melanotic schwannomas, a 
biphasic staining pattern was present consisting of areas with pericellular deposition of 
basement membrane material next to areas with deposition around nests of tumor cells 
(nested/perilobular pattern). One lesion initially diagnosed elsewhere as a `peripherally 
located melanotic schwannoma`  was reclassified as a cellular blue nevus (case 19). [19]
Nine lesions initially diagnosed elsewhere as melanotic schwannoma were reclassified as 
conventional schwannomas. These lesions showed the typical histological features of 
schwannomas with frequent Antoni A and B areas, nuclear palissading, blood vessel 
hyalinization and wavy nuclei. We did not classify them as melanotic schwannoma 
because positivity for both Melan-A and HMB-45 was lacking. They all contained focally 
some fine intracytoplasmic grayish pigment in tumor cells (Schmorl positive). Furthermore, 
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Table 2   Patient and histopathological characteristics and results of mutational analysis
Patient Sex Age Diagnosis Localization Origin  from 
nerve / 
ganglion
Circumscribed,  
capsule
Pigmentation Psammoma 
bodies
Cell  
type
Schwannian 
features
Nuclear 
pleomorphism
S-100 HMB-45 Melan- A Basement 
membrane 
staining
GNAQ exon 5 
mutation
1 F 75 MS L1-L2 na + 1+ + S Pa mi 2+ 1+ 1+ B -
2 F 35 MS L1-5 + + 3+ + E,S Pa mi 2+ 1+ 2+ B -
3 M 42 MS L2 na + 3+ - S - mi 2+ 2+ 1+ B -
4 na na MS C2 + + 3+ + E,S A, V mi 2+ 2+ 1+ P -
5 na na MS C1 na na 3+ + S - mi 2+ 1+ 2+ P -
6 na na MS C4 na na 3+ + E, S - mi 2+ 2+ 2+ B -
7 M 35 MS Lumbal + na 3+ + S Pa mi 2+ 1+ 2+ B -
8 F 23 MS Lower arm na + Focal 1+ +,  fat E - mi 2+ 1+ 1+ P -
9 M 13 MS Lower leg + + Focal 1+ + E, S - mi 2+ 1+ 1+ P -
10 M 72 Sw Vestibular nerve na na 2+ - S Pa mi 2+ neg neg P -
11 F 60 Sw Th11 na na Focal 1+ - S Pa, V mi 2+ neg neg P -
12 F 32 Sw Retroperitoneum na + Focal 1+ - S Pa, A mi 2+ neg neg P -
13 M 42 Sw Sacrum na + Focal 1+ - S Pa mi 2+ neg neg P -
14 na na Sw Intercostal nerve na + 1+ - S Pa, A mi 2+ neg neg P -
5 M 49 Sw S1 na na Focal 1+ - S Pa, A mi 2+ neg neg P -
16 F 74 Sw S2 + na Focal 1+ - S Pa mi 2+ neg neg P -
17 F 74 Sw Groin na na Focal 1+ - S Pa, A mi 2+ neg neg P -
18 M 44 Sw Sacral na + Focal 1+ - S Pa, A mi 2+ neg neg P -
19 na na blue nevus Foot na + 2+ - S,O - mi Focal 1+ 2+ Foc. 1+ N c.626A>T 
(p.(Gln209Leu))
20 na na IMC Cauda na No, invasion of CNS 1+ - S - mi Focal 1+ 2+ 2+ N c.626A>T 
(p.(Gln209Leu))
21 na na IMC IM na No, invasion of CNS 3+ - E,S - mi Focal 1+ 2+ 1+ N -
22 na na IMC IM na No, invasion of CNS 1+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
23 na na MC EM na na 3+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
24 F 41 NOS L5 + na 3+ - E,S - mo, sev 1 + 1+ 2+ B -
25 na na NOS CPA na na 3+ - S - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
na data not available, MS melanotic schwannoma, Sw conventional schwannoma with limited pigment 
(neuromelanin, lipofuscin), IMC intermediate-grade melanocytoma, MC melanocytoma, NOS lesion not further 
classified with certainty as melanotic schwannoma or melanocytoma, IM intramedullary, EM extramedullary, 
CPA cerebellopontine angle, S spindle cell phenotype, E epithelioid cell phenotype, O ovoid, Pa palissading of 
nuclei, V Verocay bodies, A Antoni A and B pattern, mi mild, mo
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Table 2   Patient and histopathological characteristics and results of mutational analysis
Patient Sex Age Diagnosis Localization Origin  from 
nerve / 
ganglion
Circumscribed,  
capsule
Pigmentation Psammoma 
bodies
Cell  
type
Schwannian 
features
Nuclear 
pleomorphism
S-100 HMB-45 Melan- A Basement 
membrane 
staining
GNAQ exon 5 
mutation
1 F 75 MS L1-L2 na + 1+ + S Pa mi 2+ 1+ 1+ B -
2 F 35 MS L1-5 + + 3+ + E,S Pa mi 2+ 1+ 2+ B -
3 M 42 MS L2 na + 3+ - S - mi 2+ 2+ 1+ B -
4 na na MS C2 + + 3+ + E,S A, V mi 2+ 2+ 1+ P -
5 na na MS C1 na na 3+ + S - mi 2+ 1+ 2+ P -
6 na na MS C4 na na 3+ + E, S - mi 2+ 2+ 2+ B -
7 M 35 MS Lumbal + na 3+ + S Pa mi 2+ 1+ 2+ B -
8 F 23 MS Lower arm na + Focal 1+ +,  fat E - mi 2+ 1+ 1+ P -
9 M 13 MS Lower leg + + Focal 1+ + E, S - mi 2+ 1+ 1+ P -
10 M 72 Sw Vestibular nerve na na 2+ - S Pa mi 2+ neg neg P -
11 F 60 Sw Th11 na na Focal 1+ - S Pa, V mi 2+ neg neg P -
12 F 32 Sw Retroperitoneum na + Focal 1+ - S Pa, A mi 2+ neg neg P -
13 M 42 Sw Sacrum na + Focal 1+ - S Pa mi 2+ neg neg P -
14 na na Sw Intercostal nerve na + 1+ - S Pa, A mi 2+ neg neg P -
5 M 49 Sw S1 na na Focal 1+ - S Pa, A mi 2+ neg neg P -
16 F 74 Sw S2 + na Focal 1+ - S Pa mi 2+ neg neg P -
17 F 74 Sw Groin na na Focal 1+ - S Pa, A mi 2+ neg neg P -
18 M 44 Sw Sacral na + Focal 1+ - S Pa, A mi 2+ neg neg P -
19 na na blue nevus Foot na + 2+ - S,O - mi Focal 1+ 2+ Foc. 1+ N c.626A>T 
(p.(Gln209Leu))
20 na na IMC Cauda na No, invasion of CNS 1+ - S - mi Focal 1+ 2+ 2+ N c.626A>T 
(p.(Gln209Leu))
21 na na IMC IM na No, invasion of CNS 3+ - E,S - mi Focal 1+ 2+ 1+ N -
22 na na IMC IM na No, invasion of CNS 1+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
23 na na MC EM na na 3+ - E - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
24 F 41 NOS L5 + na 3+ - E,S - mo, sev 1 + 1+ 2+ B -
25 na na NOS CPA na na 3+ - S - mi Focal 1+ 2+ 1+ N c.626A>T 
(p.(Gln209Leu))
na data not available, MS melanotic schwannoma, Sw conventional schwannoma with limited pigment 
(neuromelanin, lipofuscin), IMC intermediate-grade melanocytoma, MC melanocytoma, NOS lesion not further 
classified with certainty as melanotic schwannoma or melanocytoma, IM intramedullary, EM extramedullary, 
CPA cerebellopontine angle, S spindle cell phenotype, E epithelioid cell phenotype, O ovoid, Pa palissading of 
nuclei, V Verocay bodies, A Antoni A and B pattern, mi mild, mo
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extensive areas with deposition of basement membrane material around individual tumor 
cells in the basement membrane stains was present.
Based on the criteria described by Brat et al. [1,2], four lesions located around the spinal 
cord were reclassified as melanocytomas. Three of them showed an infiltrative growth 
pattern in the neuroglial tissues and were classified as intermediate-grade melanocytomas 
Figure 1  Melanotic schwannoma (case 4) showing a circumscribed tumor, covered by a 
fibrous capsule and containing several psammoma bodies (a) (x50). Detail of the same lesion 
showing spindle cell morphology, an ample amount of melanin pigment and a psammoma 
body (case 4) (b) (x200). Melanotic schwannoma (case 8) with more epithelioid cell morphology, 
nuclear pseudoinclusions (arrow) and large vacuoles resembling fat (c) (x400). Strong and diffuse 
positivity for respectively S-100 and HMB-45 in a melanotic schwanomma (case 4) (d, e) (x25, 
x100). Same lesion with pericellular deposition of basement membrane material (case 4) (f) 
(Laguesse stain, x400). 
A
C
E
B
D
F
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(Figure 2a). All lesions consisted of fascicles and nests of spindle and/or epithelioid cells 
with variable melanin pigment. Nuclei were round to oval and uniform in size, with mostly 
small nucleoli (Figure 2b). Prominent nuclear atypia was absent. In contrast to the 
melanotic and conventional schwannomas, S-100 was only focally positive (Figure 2c), 
while Melan-A and HMB-45 were more diffusely positive (Figure 2d, e). MIB-1 staining was 
less than 1 percent in all cases. Reticulin, Collagen type IV and Laminin stains showed 
deposition of basement membrane material around vascular structures and nests of 
tumor cells (nested/perilobular), but not around individual tumor cells (Figure 2f).
Figure 2  Intermediate-grade melanocytoma (case 20) with invasion of neuroglial tissue; note the 
Rosenthal fibers (arrow) in the surrounding neuropil (a) (x200). Epithelioid cell morphology with bland 
nuclei and small nucleoli in a melanocytoma (case 22) (b) (x400). Focal positivity for S-100 in the same 
lesion (case 22) (c) (x200). Diffuse positivity for HMB-45 and Melan-A, respectively, in the same lesion 
(d, e) and a nested staining pattern in the reticulin stain (f) (case 22) (Laguesse stain, x200). 
A
C
E
B
D
F
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Finally, two lesions could not be classified with certainty into melanotic schwannoma or 
melanocytoma (case 24 and 25). Case 24 was a variably, partly heavily pigmented lesion 
consisting of spindle to pleiomorphic cells (Figure 3a, c). The lesion showed infiltrative 
growth in or from a ganglion at the lumbar spinal region (Figure 3b). The nuclei showed 
moderate to strong atypia with conspicuous nucleoli (Figure 3c). MIB-1 staining was less 
than 10%. Psammoma bodies were absent. S-100, Melan-A and HMB-45 stains were 
diffusely positive. The reticulin, Collagen type IV and Laminin stains showed a biphasic 
pattern (Figure 3d,e). Based on these histological features we favored the diagnosis of 
melanotic schwannoma with atypical features suggestive of aggressive behavior. For case 
25, only limited biopsy material was available which impaired unequivocal histological 
assessment. It concerned a heavily pigmented lesion located at the cerebellopontine 
angle consisting of spindle cells with mild cytonuclear atypia and small nucleoli. S-100 was 
focally positive while the Melan-A and HMB-45 stains were diffusely positive. A nested/
perilobulated staining pattern was present in the reticulin, Collagen type IV and Laminin 
stains. In this case, we favored the diagnosis of melanocytoma.
Figure 3  Case 24 was a variably, partly heavily pigmented lesion consisting of spindle to 
pleomorphic cells (a, c) (x200), showing infiltrative growth in a ganglion at the lumbar spinal 
region with dispersed incorporated ganglion cells (arrow) (b) (x400). The nuclei showed marked 
atypia with conspicuous nucleoli (c) (x200). In the reticulin stain, both a pericellular (d) and 
nested staining pattern was seen (e) (Laguesse, x100). We, therefore, favored the diagnosis of 
a melanotic schwannoma with atypical features suggestive of aggressive behavior. Molecular 
analysis of this case did not reveal mutations in the GNAQ gene. 
A
C
B
D E
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Results of GNAQ mutational analysis
All lesions were tested for mutations in exon 5 of the GNAQ gene. The results are presented 
in Table 2. We detected mutations in exon 5 of GNAQ in 3 of 4 melanocytomas and the 
blue nevus (c.626A>T (p.(Gln209Leu))). No mutations were detected in melanotic or 
conventional schwannomas. In the two lesions which we could not classify with certainty 
as melanotic schwannoma or melanocytoma (case 24 and 25), only case 25 (the probable 
melanocytoma case) had a mutation in codon 209 of exon 5 (c.626A>T (p.(Gln209Leu))).
Diagnostic value of GNAQ mutational analysis
In our previous study on GNAQ mutations in primary leptomeningeal melanocytic lesions 
[16], codon 209 mutations of GNAQ were present in seven of 19 lesions. Taking these 
previous results into account, a total GNAQ mutation frequency of 43% (10/23) in primary 
leptomeningeal melanocytic lesions was detected. No GNAQ mutations were detected in 
the melanotic schwannomas. The mutational status between melanotic schwannoma 
and leptomeningeal melanocytic lesions was significantly different (P = 0.030). GNAQ 
mutations were highly specific for leptomeningeal melanocytic lesions compared to 
melanotic schwannoma (100%), however, sensitivity for leptomeningeal melanocytic 
lesions was low (43%).
Discussion
Especially on biopsy material, the differential diagnosis of melanotic schwannoma with 
primary leptomeningeal melanocytic lesions and, in case of peripherally located lesions, 
cellular blue nevi can pose a problem to pathologists since these lesions have overlapping 
histological features and immunohistochemical stains are not always useful. All these 
lesions are variably pigmented, spindle and/or epithelioid cell tumors, expressing S-100 
(owing to their common neural crest origin) and one or more melanocytic markers. 
However, some histological features favor the diagnosis of melanotic schwannoma, such 
as circumscribed, often encapsulated growth, and/or the presence of psammoma bodies. 
Psammoma bodies are generally absent in melanocytic tumors, although one case of a 
psammomatous melanoma arising in an intradermal nevus has been described. [18] 
Stains for components of the basement membrane can be useful in discriminating tumors 
with schwannian differentiation from tumors with melanocytic differentiation. [12] 
Deposition of basement membrane material around individual tumor cells (`pericellular`  
pattern) is a feature of tumors with schwannian differentiation, and is generally not 
pronounced in melanocytic tumors. [23,26] However, stains for basement membrane in 
melanin producing tumors should be interpreted with caution. First, in melanotic 
schwannomas a biphasic staining pattern has been described with deposition of 
basement membrane material around both individual tumor cells as well as around nests 
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of tumor cells [12], as was the case in five of nine melanotic schwannomas in our study. On 
biopsy material, with only limited tissue to evaluate, this might result in misinterpreting 
the lesion as a melanocytic tumor. Secondly, most melanomas show absence of basement 
membrane material around individual tumor cells [26], except for spindle cell melanomas 
and desmoplastic neurotropic melanomas in which also a biphasic staining pattern has 
been described. [4,21,26]                  
                                                                         
Recently, we reported the presence of activating mutations in codon 209 of the GNAQ 
gene in primary leptomeningeal melanocytic lesions. [16] This gene encodes the α-subunit 
of q class heterotrimeric GTP-binding proteins which couple G protein coupled receptors 
to the MAP kinase pathway. Identical codon 209 mutations have been reported in UMs 
(46%) and blue nevi (83%). [28] These codon 209 mutations occur in the ras-like domain 
turning GNAQ into a dominant acting oncogene. [28]                  
                                                                          
The aim of the present study was to perform a thorough histological review of a series of 
lesions that were initially diagnosed as melanotic schwannoma and analyze these cases 
for mutations in the GNAQ gene. In addition, we evaluated the diagnostic value of GNAQ 
mutational analysis in the sometimes difficult differential diagnosis with primary 
leptomeningeal melanocytic lesions. Twenty five cases initially diagnosed as melanotic 
schwannoma were reviewed and reclassified using established criteria into nine melanotic 
schwannomas, nine conventional schwannomas, four melanocytomas, one blue nevus 
and two lesions that could not be further classified with certainty as melanotic 
schwannoma or melanocytoma. The fact that in only nine of 25 cases the initial diagnosis 
melanotic schwannoma remained unchanged after review illustrates the difficult 
differential diagnosis with esp. conventional schwannoma and leptomeningeal 
melanocytic lesions. Including results from our previous study [16], a total GNAQ mutation 
frequency of 43% was present in leptomeningeal melanocytic lesions (10/23). No GNAQ 
mutations were detected in the melanotic schwannomas (0/9). These results show that 
GNAQ mutations are highly specific for leptomeningeal melanocytic lesions compared to 
melanotic schwannoma (100%). Thus, GNAQ mutational analysis can have diagnostic 
value: in case a GNAQ mutation is present this supports the diagnosis of a melanocytic 
lesion. It is important to note here that lack of a GNAQ mutation does not rule out the 
diagnosis of a melanocytic lesion. Correct diagnosis of melanotic schwannoma has clinical 
relevance as melanotic schwannoma can occur in the setting of the autosomal dominant 
Carney complex and may require additional clinical investigations.                                                                                      
                                 
GNAQ codon 209 mutations in blue nevi have been reported in up to 83%. [28] This high 
mutation frequency suggests that GNAQ mutational analysis can also be useful in the 
differential diagnosis of peripherally located melanotic schwannoma with blue nevus. 
Noteworthy, we reclassified a substantial number of lesions initially diagnosed as melanotic 
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schwannoma into conventional schwannoma (n=9), based on absence of staining for 
Melan-A and HMB-45. These lesions all contained some areas with fine intracytoplasmic 
grayish Schmorl positive pigment in tumor cells. However, the absence of staining for 
Melan-A and HMB-45 contradicts the presence of true melanosomes in these cells and 
suggests that the pigment is rather autophagosome-related (e.g. neuromelanin, 
lipofuscin). [11] Care should thus be taken not to over-diagnose melanotic schwannoma in 
order to prevent unnecessary clinical work-up for Carney Complex.
At the moment, it is unclear why mutations in the GNAQ gene are especially found in a 
subgroup of melanocytic lesions, including leptomeningeal melanocytic lesions, UMs 
and blue nevi but not in CM. [16,17,28] The fact that these GNAQ-mutated melanocytic 
lesions seem to be derived from non-epithelium related melanocytes may indicate that 
GNAQ mutations preferentially occur in melanocytes present in extra-epithelial structures 
such as leptomeninges, dermis and uvea. However, whether the site-specific occurrence 
of GNAQ mutations is a consequence of the mutations themselves or represents different 
target cell populations needs to be further determined. GNAQ codon 209 mutations seem 
to be an early event in the pathogenesis since they occur in benign as well as malignant 
melanocytic lesions. These activating codon 209 mutations form an alternative route for 
MAP kinase activation and probably represent an initial stimulus for melanocytes to 
proliferate [22,28]. Inhibition of GNAQ-dependent MAP kinase signalling may form a novel 
option for targeted therapy of these tumors.
In conclusion, this study illustrates the difficult differential diagnosis of melanotic 
schwannoma with leptomeningeal melanocytoma, and shows that a detailed analysis of 
morphology combined with molecular analysis of the GNAQ hotspot mutation can aid 
herein. Correct diagnosis of melanotic schwannoma is important to select those patients 
who need further clinical evaluation for possible association with Carney Complex.
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Abstract
The differential diagnosis between a primary uveal melanoma and a cutaneous melanoma 
metastasis in the eye may be difficult, both clinically and histologically. We report 
successful application of combined mutational analysis of the NRAS and the CDKN2A gene 
to discriminate between these two entities. The patient had a history of a superficial 
spreading cutaneous melanoma of the left shoulder. Nine years later, she developed a 
lymph node metastasis in the left axilla, and thirteen years later she presented with an 
atypical, pigmented tumor in the uvea. Histologically, the origin of the uveal melanoma 
could not be determined with certainty. We performed molecular analysis on the skin 
melanoma, the lymph node metastasis and the uveal melanoma. We detected an NRAS 
codon 61 mutation (c.182A>G (p.(Gln61Arg)) in all three tumor specimens. This mutation 
was absent in normal control tissue of the patient, thereby excluding a germ-line mutation. 
To confirm a clonal relationship between the tumors, we also performed CDKN2A 
mutational analysis. We detected a CDKN2A mutation ((p16) c.238C>T (p.(Arg80X)), (p14) 
c.404C>T (p.(Pro135Leu))) in the tumor samples, but not in normal control tissue of the 
patient. We concluded that the uveal melanoma is a metastasis from the cutaneous 
melanoma removed 13 years before.
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Introduction
Especially in case of two cutaneous melanomas (CMs) or a combination of an ocular and 
CM, the clinical and histological differential diagnosis between a second primary 
melanoma and a melanoma metastasis can be very difficult, since both organs show a 
relative high frequency of primary melanomas. The commonest primary intra-ocular 
malignancy of adults is uveal melanoma (UM). [10] Metastatic melanoma to the eye is rare 
and generally occurs in patients with widespread metastatic disease. [16] The most 
common site of metastatic CM involvement of the eye is the choroid (46%). Metastatic 
melanoma to the vitreous and anterior chamber is rare (11-18% of all intra-ocular CM 
metastases). [6] Differentiation between a primary UM and an intra-ocular metastasis is of 
prognostic and clinical importance, since intra-ocular metastases imply systemic spread 
and have a poor prognosis with a patient survival rarely exceeding more than 1 year. [16]
Mutations in BRAF and less frequently in NRAS are involved in CM development. [4,11] In 
contrast, in primary UMs, BRAF and NRAS do not appear to be involved in tumorigenesis. 
[3,8,14]
CDKN2A mutations have been detected in CM, both in sporadic melanoma and especially 
in familial melanoma, with frequencies ranging up to 30% for the latter. [15] Both in 
primary sporadic ocular melanoma and in familial cases of primary UM, CDKN2A mutations 
are very rarely detected (5%). [9,14]
We present a case of a rare and relatively late occurrence of an intra-ocular melanoma 
metastasis 13 years after development of a primary CM, and illustrate the diagnostic use of 
RAS and CDKN2A mutational analysis.
Clinical history
In November 2005, a 47-year-old caucasian female presented to her local ophthalmologist 
because of mouches volantes in her left eye. She had a history of a superficial spreading 
CM of the left shoulder (Clark level IV) removed in 1994, and a lymph node metastasis in 
the left axilla excised in 2003. Since then no systemic metastasis was detected at annual 
control. Visual acuity was 20/20 in both eyes and the vitreous of the left eye showed some 
opacities. These opacities increased gradually over a 2 month period, but resolved 
spontaneously thereafter. In July 2006, she again developed complaints of recurrent 
mouches volantes. The diagnosis uveitis was made, and the patient was treated with local 
steroids. However, local treatment was not effective and the patient was referred to our 
center. 
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Examination of the right eye revealed no abnormalities. The visual acuity in the left eye 
was 20/40, and non-pigmented cells were noticed in the anterior chamber, along with a 
vitreous haze. As an extensive uveitis screening revealed no abnormalities, intra-ocular 
metastasis of the CM removed 13 years earlier was suspected. A focal, white and preretinal 
condensation of vitreous cells developed within a few weeks and some pigmented cells 
became visible in the vitreous. Subsequently, the intra-ocular pressure increased to 25 
mmHg due to non-pigmented cells in the anterior chamber. A diagnostic vitrectomy was 
performed. Vitreous samples were positive for malignant melanoma cells. A total body 
examination excluded systemic metastasis outside the eye. Progressive worsening of the 
condition of the left eye turned into a visual acuity of 20/80 and a secondary glaucoma up 
to 50 mm Hg occurred, refractive to topical medication. On patient’s request, no eye 
salvaging treatment such as external beam radiation was performed, and the affected eye 
was enucleated. 
Histological examination of the eye ball revealed an atypical melanocytic lesion in the iris 
and ciliary body, with extension under the retina and invasion of the sclera. Although 
histologically the growth pattern was consistent with primary UM, an intra-ocular 
metastasis could not be excluded with certainty. Since discrimination between second 
primary and metastatic melanoma was of  prognostic importance, we decided to perform 
mutational analysis for the BRAF, NRAS, HRAS and CDKN2A genes on all tumor samples, as 
well as on normal control skin of this patient.
Materials and methods
BRAF, NRAS and HRAS mutational analysis
DNA isolation was performed as previously described. [1,2] In brief, of all tissue samples 
about three 10-mm unstained sections of formalin-fixed paraffin-embedded tissue were 
manually micro-dissected, using H&E stained sections as a reference. The tumor cell 
percentage in the microdissected specimens was estimated as 70% for the CM and UM 
and 90% for the lymph node metastasis.  DNA was purified using the DNeasy Blood & 
Tissue kit (Qiagen). Primer sequences are shown in Table 1. PCR amplification of BRAF 
exon 15, NRAS exons 2 and 3, and HRAS exon 3 was performed in a total volume of  50-μl 
PCR mix containing 50 ng template DNA, 5 μl PCR buffer IV (Integro), 10 μl dNTP 0.2 mM, 
6.0 μl MgCl2 3.0 mM,  0.125 μl Taq DNA polymerase (Integro, 5U/μl ) and 22.9 μl mQ. An 
initial denaturation at 92°C for 5 min was followed by 35 cycles of denaturation at 94°C for 
45 s, annealing at 60°C for 45 s, and extension at 72°C for 45 s with a final extension of 5 
min at 72°C. DNA amplification was performed in a MJ PTC 200 PCR cycler (Biozym). After 
purification of the PCR products using a Qiaquick PCR purification kit (Qiagen), sequence 
analysis was performed using BigDye terminator version 2 of Applied Biosystems on an 
ABI 3730 automatic sequencer (Applied Biosystems).
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CDKN2A mutational analysis
The CDKN2A mutation analysis was performed as previously described. [1,2] Briefly, PCR 
was performed with AmpliTaq Gold DNA Polymerase (Applied Biosystems) using an 
optimized MgCl2 concentration (varying from 1 to 2 mM) in a MJ PTC 200 PCR cycler 
(Biozym).  All primers used in the analysis contained either an M13 forward or M13 reverse 
consensus sequence. All primers and sizes of the PCR products are listed in Table 1. The 
entire open reading frames of CDKN2A were analyzed in DNA isolated from the tumor 
samples and normal skin.
Table 1   Primers used in the analysis of CDKN2A, BRAF, NRAS and HRAS, and the size of 
their PCR products  
Exon CDKN2A  
(INK4a-ARF)*
Forward Reverse Size PCR 
product (bp)
1B TCAGGGAAGGCGGGTGCGCG GCCGCGGGATGTGAACCAC 244
1B CGCCGCGAGTGAGGGTTTT CACCGCGGTTATCTCCTCC 263
1A GAGAGGGGGAGAGCAGGCAG GCACCTCCTCTACCCGACC 122
1A GGAGCAGCATGGAGCCTTC AGTCGCCCGCCATCCC CTG 177
2 AGCTTCCTTTCCGTCATGC GCAGCACCACCAGCGTGTC 202
2 AGCCCAACTGCGCCGACCC CCAGGTCCACGGGCAGACG 146
2 TGGACGTGCGCGATGCCTG GGAAGCTCTCAGGGTACAAATTC 188
3
   
CGGTAGGGACGGCAAGAGAG
                                        
GAGGGACCTTCGGTGACTGATG 162
BRAF* exon 15 CCTTTACTTACTACACCTCAG AAAAATAGCCTCAATTCTTAC 197
NRAS* exon 2 GGTTTCCAACAGGTTCTTGC      TGGGTAAAGATGATCCGACA 240
NRAS* exon 3 GATTCTTACAGAAAACAAGTGG TAATGCTCCTAGTACCTGTAGAG 230
HRAS* exon 3 CTGCAGGATTCCTACCGGA ACTTGGTGTTGTTGATGGCA 196
* All forward primers contained the M13 consensus sequence TGT AAA ACG ACG GCC AGT at the 5’ end.  
All reverse primers contained the M13 consensus sequence CAG GAA ACA GCT ATG ACC
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Results
Revision of the primary CM removed in 1994 revealed an asymmetric compound 
melanocytic lesion with focal ulceration and lack of maturation towards the base of the 
lesion. The melanocytes showed an epithelioid phenotype with anisokaryosis and 
prominent nucleoli. Deep mitotic figures were present (Figure 1). A satellite lesion was 
present at the junction of dermis towards subcutis. Tumor thickness measured 1.5 mm, 
Figure 1  A. The CM in 1994 was a superficial spreading melanoma, Breslow thickness 1.5mm, 
growing into the reticular dermis (H&E-staining, original magnification x50). The inset shows a 
detail of the deep portion of the tumor with epithelioid melanocytes, melanin pigment and 
mitotic figure (arrow, original magnification x400). B. The intra-ocular melanoma was located in 
the ciliary body and iris with invasion of the sclera, anterior angle (asterisk) and canal of Schlemm 
(arrow) (H&E-staining, original magnification x50). 
A
B
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not including the satellite. Focally, a pre-existent nevus was present. Resection margins 
were at least 2mm free of tumor. Revision of the lymph node metastasis in the left axilla 
that was excised in 2003 revealed a large tumor surrounded by limited preexistent 
lymphoid tissue. The tumor cells showed morphological resemblance to the CM cells with 
an epithelioid phenotype and frequent mitotic figures. Additionally, in the lymph node 
metastasis large areas of necrosis were present.
Histological examination of the eye ball revealed an atypical melanocytic lesion in the iris 
and ciliary body, with extension under the retina and invasion of the sclera. Tumor cells were 
also present at the surface of the ciliary body in the anterior angle, and showed invasion in 
the area containing the canal of Schlemm (Figure 1). The melanocytic cells showed an 
epithelioid morphology, with focally spindle cell pattern, marked pleiomorphism of tumor 
cell nuclei, and occasional mitotic figures. Tumor thickness measured 3mm.
Molecular analysis of the NRAS gene revealed a codon 61 mutation (c.182A>G (p.(Gln61Arg))) 
in all three tumor samples. This mutation was not present in the normal control skin of the 
patient (Figure 2). No mutations were detected in NRAS exon 2, BRAF exon 15 and HRAS exon 3. 
Figure 2  NRAS exon 3 mutation, c.182A>G (p.(Gln61Arg)), detected in the primary CM, the 
lymph node metastasis and the UM. Reverse sequence. 
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We also performed CDKN2A mutational analysis on all samples. A CDKN2A mutation ((p16) 
c.238C>T (p.(Arg80X)), (p14) c.404C>T (p.(Pro135Leu))) was present in all three tumor 
samples, but absent in normal control tissue of the patient, indicating that this is a somatic 
mutation (Figure 3). It was concluded that the ocular melanoma should be considered as 
a metastasis of the CM diagnosed 13 years before.
Discussion
This case report illustrates that molecular analysis can be very helpful in the differential 
diagnosis between a second primary melanoma and a melanoma metastasis. We chose 
for mutational analysis of the BRAF gene and the RAS proto-oncogenes NRAS and HRAS, 
Figure 3  CDKN2A exon 2 mutation, (p16) c.238C>T (p.(Arg80X)); (p14) c.404C>T (p.(Pro135Leu)), 
detected in the primary CM, the lymph node metastasis and the UM. Forward sequence. 
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because these genes are frequently involved in cutaneous melanocytic lesions, with a 
reported total mutation frequency for NRAS or BRAF of  82% in CM. [4] Furthermore, these 
mutations are described to occur early in tumorigenesis, before the development of 
metastasis. [4,11] We detected in all three tumor samples an NRAS codon 61 mutation 
(c.182A>G (p.(Gln61Arg))). NRAS mutations are known to occur in up to 30% of all CM cases, 
the most common being mutations in NRAS codon 61. [4,7,11] In contrast, NRAS mutations 
have been reported to be absent in primary UM. [3,14] The NRAS mutation thus strongly 
supports the metastatic nature of the intra-ocular melanoma in our patient. The finding of 
the same somatic mutation in CDKN2A in both CM and intra-ocular melanoma confirms 
the metastatic nature of the disease in this patient. In contrast to NRAS mutations that are 
limited to codon 61, codon 12 and 13 in CM, somatic CDKN2A mutations are much more 
tumor specific and thus are not expected to be identical in two different primary 
melanomas. [7] Furthermore, activating CDKN2A mutations are described to be very rare 
in primary ocular melanomas. [9,13]
Eskandarpour et al. reported specific activating mutations in NRAS codon 61 in 95% of 
primary hereditary CM (20/21), but in only 10% of sporadic CM (1/10). [5] Therefore, the 
presence of a somatic NRAS codon 61 mutation might indicate a familial predisposition to 
melanoma instead of a clonal relationship.
Discriminating between a second primary intra-ocular melanoma and metastatic disease 
is of prognostic importance. Intra-ocular metastases of melanoma are associated with a 
poor prognosis with a mean interval between diagnosis of the intra-ocular metastasis and 
death of 8.8 months. [16]  In contrast, survival in patients diagnosed with a primary 
intra-ocular melanoma is more variable, with a reported 5-year cumulative survival rate of 
up to 60%.  [12]
In conclusion, this case report illustrates that mutational analysis for the RAS proto-onco-
genes and CDKN2A can be useful in the clinically relevant, but sometimes difficult 
differential diagnosis between a primary intra-ocular melanoma and an intra-ocular 
metastasis of a CM.
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SUMMARIZING DISCUSSION AND FUTURE PERSPECTIVES
In this thesis, we demonstrated that primary LMNs in adults and children generally harbor 
distinct oncogenic mutations. This work provides new insight in the pathogenesis of 
these neoplasms and has diagnostic implications, as discussed in paragraphs 8.1 and 8.2, 
and 8.3. Potential targets for molecular therapy and future perspectives are discussed in 
paragraphs 8.4 and 8.5.
8.1 Oncogenic mutations in primary LMNs in adults
8.1.1 GNAQ and GNA11 mutations 
The Gq alpha subunit genes GNAQ and GNA11
GNAQ and its paralogue GNA11 map on chromosomes 9q21.2 and 19p13.3, respectively; 
and GNAQ and GNA11 mRNA and protein are expressed in a wide spectrum of tissues. [1] 
They belong to the family of genes that encode the α subunit of G proteins which couple 
cell surface receptors to various intracellular pathways. [2] G proteins are heterotrimeric 
GTP-binding proteins and consist of α and βγ subunits. [2] The α subunit genes are 
grouped into four classes; Gs, Gi, Gq, and G12/13. GNAQ and GNA11 belong to the Gq class 
of α subunit genes.[1, 3, 4]
G proteins function as a molecular switch: activation of the G protein coupled receptor 
(GPCR) catalyzes the exchange of GDP, bound to the inactive α subunit, for GTP, resulting 
in dissociation of the complex. [2] The Gα subunit then activates diverse effector proteins 
and intracellular signaling pathways by the release of second messengers, and this 
depends on the subclass of Gα: Gsα subunits signal through activation of adenylyl cyclase 
that activates protein kinase A (PKA) via cAMP, while Gqα activates phospholipase C (PLC) 
that leads to activation of protein kinase C (PKC) via diacyl glycerol (DAG). [1, 5]
GTP hydrolysis and re-association of the complex into its inactive, GDP-bound state is 
largely regulated by the intrinsic GTPase activity of the α subunit. [2] Mutations in this 
catalytic domain prevent hydrolysis of GTP and turn the protein in its active, GTP-bound 
state, resulting in constitutive activation of downstream signaling pathways. [2] For the 
GNAQ and GNA11 proteins, the glutamine (codon 209) or arginine (codon 183) is essential 
for GTP hydrolysis and mutations at these codons cause impaired GTPase activity. This 
leads to constitutive activation of the MAPK pathway via activation of protein kinase C by 
β-phospholipase C. [1, 6-9] 
As G proteins couple to a wide variety of GPCR, including receptors for hormones, they are 
involved in many physiological processes. [1] Defects in the activity of Gα subunits have 
been identified in several human disorders, including oncogenic point mutations in the 
gene GNAS that impair GTPase activity and lead to for instance formation of adenomas of 
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the thyroid and pituitary gland. [10-12] Until the identification of oncogenic mutations in 
the genes encoding Gq subunits GNAQ and GNA11 in UMs and blue nevi in 2009, it was 
unknown that genes encoding G protein alpha subunits q-class are implicated in 
melanocytic neoplasia as well, and that the previously observed MAPK activation in UMs 
can in fact largely be attributed to oncogenic mutations in these genes. [7, 13] 
GNAQ mutations are more frequent than GNA11 mutations
In chapter 2 and 3, we described the frequent presence of oncogenic mutations in codon 
209 of the GNAQ gene (up to 11/20, 55%) and, less frequently, in codon 209 of the GNA11 
gene (2/20, 10%) in LMNs in adults. [14, 15] As far as could be assessed, all mutations were 
somatically acquired. The GNAQ codon 209 mutations (or GNAQQ209, alternatively) were 
more or less equally distributed among melanocytomas (7/11), intermediate-grade 
melanocytic neoplasms (2/5) and melanomas (2/4), while the two GNA11 codon 209 
mutations (or GNA11Q209, alternatively) were present in an intermediate-grade melanocytic 
neoplasm (1 out of five) and a melanoma (1 out of four) but not in melanocytomas (0/11) 
(chapter 3). 
The study of Gessi et al. corroborates our findings: they reported a similar high mutational 
frequency for GNAQQ209 (6/14, 43%), and a low mutational frequency of GNA11Q209 (2/14, 
14%) in LMNs (fourteen adult cases). [16] The distribution of GNAQ and GNA11 gene 
mutations between the diagnostic groups was similar and the melanocytomas in their 
series (n=6) did not show GNA11Q209 mutations either. However, GNA11Q209 mutations in 
leptomeningeal melanocytomas have now been described in two case reports. [17, 18] 
Although our data thus suggest that GNA11 gene mutations are a rather infrequent event, 
larger series are needed to establish the true incidence of these mutations in LMNs.
As described in chapter 3, we did not find any mutations in codon 183 of the GNAQ and 
GNA11 genes in twenty LMNs. However, an activating mutation in codon 183 of the GNAQ 
gene, notably c.548G>A (p.(Arg183Gln)) has recently been reported in a leptomeningeal 
melanocytoma [18], and, we have unpublished data of a mutation c.547C>T (p.(Arg183Cys)) 
at codon 183 of the GNA11 gene detected in a melanocytoma located at the base of the 
brain. Taken together, mutations in codon 183 of the GNAQ and GNA11 genes do occur in 
LMNs but seem to be a rare event. 
In our studies, we could not ascertain an association between GNAQ and GNA11 gene 
mutations in LMNs and clinicopathological characteristics or survival, also because of the 
relatively limited number of patients that could be included and the fact that follow-up 
data were incomplete. To determine any prognostic value of GNAQ and GNA11 gene 
mutations in LMNs more extensive studies are needed. 
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GNAQ and GNA11 mutations in non-LMNs; implications for pathogenesis
UMs and blue nevi harbor oncogenic mutations in the GNAQ and GNA11 genes as well. [7, 
19, 20] The mutational frequency of GNAQQ209 in UMs and blue nevi is high (45% and 83%, 
respectively) [7], and in the range of that seen in LMNs (37-55%) (chapter 2 and 3). The 
GNAQQ209 mutations are identical among these entities and substitution of glutamine to 
leucine at codon 209 c.626 A>T (p.(Gln209Leu)) is most prevalent. [7, 19,14,15]
The most common GNA11Q209 mutation among LMNs, UMs and blue nevi is an adenine to 
thymine transversion c.626 A>T (p.(Gln209Leu)) resulting in substitution to leucine. [15-17, 
19] GNA11Q209 mutations are rare in blue nevi (6.5%; comparable to leptomeningeal 
melanocytoma) but more frequent in UMs (32%) and especially in metastases of UM 
(56.5%). [19] The high frequency of GNA11Q209 mutations in UM metastases compared to 
primary UMs and blue nevi has led others to hypothesize that GNA11Q209 mutations might 
have a more potent oncogenic effect on melanocytes than GNAQQ209 mutations, as 
proposed by Van Raamsdonk. [19] This seemed to be supported by their observation that 
mice injected with GNA11Q209L-expressing mouse melan-a cells developed distant 
metastases, while metastatic spread was absent in case of mice injected with GN-
AQQ209L-expressing melan-a cells. [7, 19] However, so far, no association has been found 
between GNAQ or GNA11 mutational status and survival in UM patients. [19, 21, 22] 
Mutations in codon 183 of the GNAQ and GNA11 genes are very rare in UMs and blue nevi 
(1-3%, in either gene, tested in > 250 cases) [19]. This is in line with our observation that 
mutations in codon 183 of the GNAQ and GNA11 genes are rare in LMNs as well (chapter 3). 
The GNAQ c.548G>A (p.(Arg183Gln) alias (R183Q) mutation is the only GNAQ codon 183 
mutation that has been detected in UMs and blue nevi [19], and is identical to the single 
GNAQR183 mutation that has been reported in LMNs up to now. [18] The most frequent 
GNA11R183 mutation reported in UMs and blue nevi is the c.547C>T (p.(Arg183Cys)) alias 
(R183C) mutation [19], and is the same as the GNA11R183 mutation we detected in a 
melanocytoma at the base of the brain (unpublished data). 
The group of Van Raamsdonk validated mutated-GNA11 at codon 209 and 183 as 
oncogenic variants by transduction experiments in mouse melan-a cells. [19] For the 
GNA11 c.547C>T (p.(Arg183Cys) alias R183C) variant, tumors developed with increased 
latency in only three of eight injection sites, compared to rapidly growing tumors that 
developed at each of the six injection sites for the Q209L variant, suggesting a reduced 
potency of the GNA11R183C variant compared with GNA11Q209L. [19]
Of note, GNAQ mutations alone are insufficient for malignant transformation of 
melanocytes, as illustrated by its occurrence in benign lesions such as blue nevi. This is 
comparable to mutated NRAS that is unable to induce malignant transformation alone 
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but needs additional events, for instance deletion of CDKN2A encoding p16INK4A. [23, 24] 
The pathways that synergize with GNAQ (or GNA11) mutations, however, are unknown.
Interestingly, oncogenic mutations in the GNAQ and GNA11 genes are absent or very rare 
in other types of melanocytic neoplasms, including (common) melanocytic nevi (0%), 
congenital melanocytic nevi (CMN) (0-4%), CMs (1.4%), AMs (0%), and MucMs (0%) (See 
Table 1 for an overview).  [19, 25, 26] 
Table 1   Frequency of oncogenic mutations in subtypes of melanocytic neoplasms 
GNAQ 
codon 209 
GNA11  
codon 209
BRAF 
codon 600 
NRAS  
codons 61, 
12, and 13
HRAS  
codons 61, 
12, and 13
Melanoma
Cutaneous 0-1.4%  
[19, 26]
0%  
[19]
50% 
[27] *
15-20% 
[28, 29]
2% 
[30]
Mucosal 0%   
[19, 26]
0%  
[19]
0-10%  
[27, 31, 32]
20% 
[33]
< 2% 
[34, 35]
Acral 0-1.2%   
[19, 26]
0%  
[19]
20% 
[31]
11% 
[33]
< 2% 
[35]
Uveal 45-49%  
[19, 20]
32% 
[19]
0% 
[13, 36]
0% 
[13, 36]
0% 
[13, 37]
Leptomeningeal 25-50%   
[14-16]
25% 
[15, 16]
0% 
[14-16] #
Present 
[16, 38-40] &
0% 
[14-16]
Benign melanocytic neoplasms
Common nevus 0% 
[19]
0%  
[19]
50-80% 
[41, 42]
15%  
[41]
0% 
[43]
Congenital nevus 0-4%  
[19, 25]
0% 
[19]
0% 
[44]
80% 
[44] 
0% 
[25, 43]
Blue nevus 83%  
[7]
6.5% 
[19]
0-12%  
[45, 46]
0%  
[45]
0% 
[47]
Spitz nevus 0% 
[19]
0% 
[19]
0% 
[48-50]
0% 
[51, 52]
15% 
[53]
Leptomeningeal 
melanocytoma ^
40-56% 
[14-16]
6-8% 
[15, 16]
0%  
[14, 16, 54]
0-7%  
[14, 16, 54]
0% 
[14-16]
* Especially in melanoma arising in intermittently sun-exposed skin;                                                       
#  The single BRAF mutation we detected in a leptomeningeal melanoma is not included in this table (chapter 
2), as we cannot rule out that this was a metastasis from a skin melanoma (see further discussion of this case 
in paragraph 8.3.1);                                                                                          
&  NRAS mutations are so far esp. found in pediatric cases of primary leptomeningeal melanoma, although its 
true incidence is unknown (small series) (paragraph 8.2). NRAS mutations are rare in primary leptomeningeal 
melanoma in adult patients (further discussed in paragraph 8.3.1);    
^ Including intermediate-grade neoplasms
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The preferential occurrence of GNAQ and GNA11 mutations in specific subgroups of 
melanocytic neoplasia (LMNs, UMs and blue nevi) suggests a common pathogenetic 
mechanism. In addition, these lesions rarely contain mutations in the BRAF gene (see also 
paragraph 8.1.3). [14-16, 36, 45, 46, 54] Interestingly, melanocytic neoplasms that carry 
GNAQ or GNA11 mutations originate from melanocytes that are not epithelium related. [55] 
Of note, blue nevi are thought to derive from a small pool of melanocytes located in the 
dermis that have not reached the epidermis during embryogenesis. [56] In contrast, 
(common) melanocytic nevi and CMs are derived from intra-epidermally located 
melanocytes and most frequently harbor BRAF mutations. [57] (Table 1) Apparently, 
epidermal and non-epidermal melanocytic cells are not only distinct but also targeted by 
different oncogenic mutations, e.g. GNAQ mutations in non-epidermal melanocytic 
tumors in humans; BRAF mutations in the epidermal counterparts. 
Studies in mice also provided evidence for distinct types of melanocytes in these animals. 
Van Raamsdonk et al. showed that GNAQ mutations result in hyperpigmentation in mice 
by an increased number of intradermal rather than epidermal melanocytes, implying that 
GNAQ is differentially implicated among melanocyte populations. [58] Another study 
reported that in mice differences exist in the requirement of growth and differentiation 
signals during development in epidermal versus non-epidermal melanocytes. [59] 
Non-epidermal melanocytes are highly dependent on endothelin 3 (ET3) and hepatocyte 
growth factor (HGF) signaling, and depend less on KIT signaling. In contrast, epidermal 
melanocytes mainly depend on KIT and less on ET3 and HGF signaling. [59] Interestingly, 
HGF is a much more effective stimulating growth factor for UM compared to CM [60], and 
in transgenic mice, HGF is able to promote survival, proliferation and differentiation of 
dermal melanocytes resulting in dermal melanocytosis. [61] 
8.1.2 Oncogenic role for GNAS in LMNs? 
Mutations in other G protein subunits were relatively recently detected in melanoma, for 
instance in GNAZ and GNG10, rendering the family of G protein subunit genes attractive in 
the search for novel oncogenes in melanoma. [62] We hypothesized that oncogenic 
mutations in the Gs alpha subunit gene GNAS might be involved in LMNs, as it is now 
known that activating GNAS mutations (at codon 201 and 227) play a role in some human 
endocrine neoplasms such as thyroid and pituitary tumors, as well as in the McCune 
Albright syndrome that is characterized by café-au-lait pigmentation, fibrous dysplasia 
and endocrine dysfunction. [11, 63, 64] Gsα is ubiquitously expressed and bound to the 
melanocortin-1 receptor (MC1R) in melanocytes. [65] Gsα acts via stimulation of adenylyl 
cyclase resulting in activation of protein kinase A (PKA). [65] Gsα signaling pathway in 
melanocytes results in the transcription of genes implicated in pigmentation, including 
tyrosinase, rather than proliferation. [64, 66]  Of the genes encoding Gsα, codon 227 and 
codon 201 correspond to the glutamine at codon 209 and the arginine at codon 183, 
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respectively. [19] We could not detect any GNAS codon 201 mutations in our series of LMNs 
(n=20) (data unpublished). Of note, the café-au-lait spots in the McCune Albright syndrome 
(that harbor GNAS codon 201 mutations) histologically show hyperpigmentation of the 
epidermis but only limited increase in numbers of melanocytes, suggesting that indeed 
the effect of activating GNAS mutations on melanocytes involves hyperpigmentation 
rather than proliferation. [64]
8.1.3 BRAF, NRAS and HRAS mutations
In chapter 2 and 3, we reported that oncogenic mutations in BRAF (0-5%), NRAS (0%) and 
HRAS (0%) are very rare or lacking in both benign as well as malignant LMNs in adults. 
These results were confirmed by others and are summarized in Table 1. Gessi et al. 
reported absence of BRAF and HRAS mutations in 15 adult cases of LMN and presence of 
only one NRASQ61-mutated case in their series (40-year-old female with an intermedi-
ate-grade melanocytic neoplasm in the spinal region) (1/15, 7%). [16] More recently, Wang 
et al. did not detect any BRAF c.1799T>A (p.(Val600Glu)) or NRAS (exon 2 and 3) mutation in 
twenty melanocytomas in adult patients. [54] Our results show that LMNs in adults are, in 
contrast to CMs, generally not driven by oncogenic mutations in the BRAF nor NRAS gene 
(nor HRAS). This observation can have diagnostic implications in routine pathology 
practice, as discussed in paragraph 8.3.
8.2 Oncogenic NRAS mutations in primary LMNs in children
8.2.1  Early embryonic somatic NRAS mutations cause neurocutaneous 
melanosis
Giant and/or multiple congenital melanocytic nevi (CMN) of the skin are associated with 
neurocutaneous melanosis (NCM), which is characterized by the presence of melanocytic 
neoplasms of both skin and leptomeninges. [67] NCM is thought to be a congenital error 
in morphogenesis of embryonic neuroectoderm, which in less pronounced form may 
also underlie the genesis of CMN of the skin. [68] Such CMN are known to frequently 
harbor oncogenic NRAS mutations. [44] The oncogenic mutational event that underlies 
LMNs in the context of NCM was up till now, however, not clear.
In chapter 4, we presented one child with NCM that developed primary leptomeningeal 
melanoma in the absence of cutaneous melanoma, and detected the oncogenic NRAS 
mutation c.1818C>A (p.(Gln61Lys) alias NRASQ61K) in the leptomeningeal melanoma as well 
as in one of the CMN we were able to investigate. A similar observation (identical NRASQ61K 
mutation in melanocytes of both skin and LMN) was made in the NCM patient described 
in chapter 5. Kinsler et al. confirmed this observation and reported two NCM patients each 
harboring identical NRASQ61R mutations in several CMN (up to 3) as well as in the LMNs of 
these patients. [39]
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The observation of identical NRAS mutations in melanocytic neoplasms from both skin 
and leptomeninges can be explained by the hypothesis that early during embryogenesis 
one of the melanocyte precursor cells (or melanoblasts) acquires a somatic NRAS mutation, 
which gives rise to a mosaic pattern of NRAS-mutated melanoblasts that further migrate 
to skin and/or leptomeninges and lead to congenital melanocytic neoplasms in these 
locations (Figure 1). Hypothetically, the exact timing of acquisition of the NRAS mutation 
during embryogenesis (and thus the position of the migrating melanoblasts) might 
determine whether melanocytic neoplasms develop in the skin, in the leptomeninges, or 
in both locations. 
8.2.2 Early acquisition predisposes to pediatric leptomeningeal melanoma
In chapter 4 and 5, we demonstrated that, in contrast to adults, LMNs in the pediatric 
setting are driven by oncogenic mutations in NRAS.
In chapter 4, a mouse model of NRAS-driven melanoma is presented: when NRASG12D was 
expressed in the melanocytes of developing mice embryos, it induced congenital 
melanocytic lesions of the skin, congenital melanocytosis of the leptomeninges and early 
onset primary leptomeningeal melanoma but not CM. The disease observed in the mice 
resembled that observed in two cases of primary leptomeningeal melanoma in children 
(also described in chapter 4), both of which carried oncogenic mutations in NRAS (Q61R 
and Q61K). We concluded that both our animal experiments and clinical cases suggest 
that early/embryonic acquisition of somatic NRAS mutations in melanocytes is a 
predisposing risk factor to primary leptomeningeal melanoma in children. 
In chapter 5, we presented another child with a primary leptomeningeal melanocytic 
tumor that harbored the oncogenic NRAS mutation c.1818C>A (p.(Gln61Lys) alias NRASQ61K). 
Emerging data from the literature seem to confirm that NRAS mutations are implicated in 
LMNs in children. Recently, Kinsler et al. reported an NRASQ61R mutation in both pediatric 
LMN cases included in their series (melanocytosis and primary cerebellar melanoma) [39], 
and, Gessi et al. have previously detected an oncogenic NRASQ61L mutation in the single 
pediatric leptomeningeal melanoma case in their series (posterior fossa melanoma). [16] 
Of note, mutations in codon 12 or 13 of NRAS have up to now not been reported in LMNs 
in humans, but more cases need to be investigated. In CMN of the skin, which frequently 
harbor NRAS mutations, codon 12 or 13 mutations are less frequent than codon 61 
mutations. [44]  
As discussed in chapter 4, the high frequency of NRAS mutations in benign lesions such as 
CMN also illustrates that these mutations are in itself insufficient for melanoma 
development. Furthermore, in most previously described mouse models of melanoma 
driven by oncogenic RAS, melanoma induction was inefficient unless the mice were 
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exposed to an environmental stress or carried a second genetic aberration. [24, 70] 
Identifying the events that synergize with oncogenic NRAS is needed in order to better 
understand the mechanisms involved in the development of primary leptomeningeal 
melanoma in humans. A possible contributing event could be deletion of CDKN2A 
(encoding p16INK4A), as it has been shown to cooperate with HRASG12V and NRASQ61K to 
induce melanoma in mouse models earlier. [23, 24] Also, recently, deletion of CDKN2A was 
shown to be present in a primary NRAS-mutated melanoma arising in the cerebellum of a 
10-year-old child. [39]
Figure 2  Anatomic distribution melanocytic neoplasms that frequently harbor 
oncogenic GNAQ, GNA11 or NRAS mutations. GNAQ and GNA11 mutations are frequent 
in LMNs in adults, including melanocytoma (MC) and melanoma (MM) (this thesis), and, in UMs 
and blue nevi (BN) (indicated in blue). [7, 19, 20] Oncogenic mutations in NRAS are frequent in 
LMNs in children, with or without associated neurocutaneous melanosis (NCM) (this thesis), and 
in congenital melanocytic nevi (CMN) (indicated in green). [39, 44] 
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Summarizing, the oncogenic event in LMNs in children often involves NRAS while GNAQ and 
GNA11 mutations are implicated in LMNs in adults (Figure 2). This knowledge may have 
diagnostic as well as therapeutic implications; these will be discussed in paragraphs 8.3 and 8.4. 
8.3  Diagnostic and prognostic implications of genetic 
alterations in primary LMNs
8.3.1  Differential diagnosis between primary LMN and melanoma metastatic 
to the CNS
Adults
The incidence of CNS metastasis in patients with melanoma ranges from 10% to 40% in 
clinical studies, and in autopsy series involvement of the CNS was present in up to two 
thirds of patients who died of this disease. [71,106,107] This high frequency of CNS 
metastasis in melanoma patients is in contrast to the very low incidence of primary 
melanoma of the CNS. [72] Consequently, it is much more likely that a melanoma in the 
CNS represents a metastatic lesion (esp. from CM as these are by far the most frequent 
malignant melanocytic neoplasms) than a primary CNS melanoma. Some features may be 
used as supporting evidence for the diagnosis of a primary LMN: 1. leptomeningeal rather 
than intraparenchymal location of the tumor; 2. localization in the posterior fossa or 
around the spinal cord; and 3. no (history of) melanoma elsewhere in the body. In this 
context, it is important to realize that primary CM may show ‘spontaneous regression’, a 
prior excision of a CM erroneously considered as nevus may not have been histologically 
examined, and primary melanomas may originate from less visible locations such as foot 
soles and genital areas. Still, the discrimination between primary versus metastatic 
melanocytic tumor in the CNS is relevant because of different patient work-up and the 
substantially better prognosis of patients with a primary neoplasm, even when the tumor 
is malignant. [73-77]
In chapter 2 and 3, we discussed that in the adult setting combined mutational analysis of 
the hotspots of GNAQ, GNA11 and BRAF can have diagnostic value in the differential 
diagnosis of a primary LMN versus a metastasis from a CM. Demonstration of a GNAQ or 
GNA11 mutation in a CNS melanocytic tumor favors a primary LMN. However, in case of a 
GNAQ or GNA11 mutation, a metastasis from an UM or malignant blue nevus to the CNS 
should be considered in the differential diagnosis. Conversely, knowing that about 50% of 
CMs carry a BRAF mutation [27] and that this mutation is exceedingly rare in primary LMNs 
(chapter 2 and 3) [16, 54] the demonstration of a BRAF mutation in LMNs strongly favors a 
metastasis from melanoma of the skin.
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The one BRAF mutation c.1799T>A (p.(V600E)) in a LMN case described in chapter 2 
concerned 49-year-old man who had a tumor in the frontal left lobe. Although no obvious 
melanoma localizations outside the CNS were present, the patient underwent an excision 
of an atypical skin lesion on the back one-month after diagnosis of the leptomeningeal 
melanoma. In retrospection, histology showed features that could fit the diagnosis of a 
melanoma in regression. After all, it is thus entirely possible that the leptomeningeal 
melanoma in this patient was in fact a metastasis from a CM in regression. 
Our data and that of others show that NRAS mutations are very rare in primary LMNs in 
adults (chapter 2 and 3). [14, 16, 54] To our knowledge, in adults, only one NRASQ61K-mu-
tated melanocytoma and one NRASQ61K-mutated primary brain melanoma have been 
reported to date. [16, 40] This suggests that NRAS mutational analysis could have some 
value too in the differential diagnosis between a primary LMN and a metastasis from an 
NRAS-mutated melanoma from elsewhere, for instance from the skin or mucosal 
surfaces as melanomas in these locations relatively commonly harbor NRAS mutations 
(approximately 20%). [28, 33] However, this should be interpreted with caution as 1) up 
to now, limited numbers of primary leptomeningeal melanoma in adults have been 
studied for the presence of NRAS mutations, and 2) adults can have a congenital 
background of their (primary) leptomeningeal melanoma. As described earlier, 
especially in the congenital setting, NRAS mutations are frequent in LMNs (chapter 4 
and 5). [16, 38, 39]  
Children
All types of primary melanoma in children are rare and to date, very little is known about 
their underlying oncogenic mutations. One study reported 50% BRAF mutations in 
primary CMs in children and absence of NRAS mutations (n=21). [78] However, as CMN 
frequently harbor NRAS mutations and a small percentage of these (especially large) CMN 
are known to undergo malignant transformation (life-time risk 2.5-5%), it can be expected 
that a subset of primary CM in children harbor NRAS mutations as well. [44, 68] We showed 
in chapter 4 and 5 that NRAS mutations are implicated in primary LMNs in children. 
Consequently, the detection of an NRAS mutation in a pediatric leptomeningeal melanoma 
alone is insufficient to make the distinction between primary and metastatic CNS 
melanoma. More cases of primary LMNs in children need to be tested to assess the 
implications of other mutated oncogenes in this setting. 
8.3.2 Differential diagnosis between primary LMN and melanotic schwannoma
In chapter 6, we showed that GNAQ mutational analysis can contribute in the differential 
diagnosis of LMN versus melanotic schwannoma. [79] This differential diagnosis can be 
difficult histologically, and correct diagnosis of (psammomatous) melanotic schwannoma 
is important to select patients who need further clinical work-up for Carney complex, a 
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potentially life-threatening disease especially due to the frequent occurrence of  multiple 
and recurrent cardiac myxomas in this disorder. [80, 81] 
Carney complex is caused by inactivating mutations in the regulatory subunit type 1 
alpha gene of protein kinase A (PKA) (PRKAR1A, located at chromosome region 17q22-24) 
[80] In contrast to GNAQ mutations, however, these are not hotspot mutations but the 
mutations are spread over eleven exons with more than 80 pathogenic sequence variants 
described. [82] Therefore, PRKAR1A mutational analysis is not practical for routine testing in 
daily pathology practice when a melanotic schwannoma is considered. In addition, early 
identification of characteristic manifestations such as (psammomatous) melanotic 
schwannoma is important and requires histological confirmation. [80, 81]
In none of the nine melanotic schwannomas we investigated, a GNAQQ209 mutation was 
present. Of note, all melanotic schwannomas were also tested for the presence of 
GNAQR183, GNA11Q209 and GNA11R183 mutations but none were detected (data unpublished). 
Including results from our previous study, [14] we concluded that GNAQQ209mutations are 
highly specific for leptomeningeal melanocytic lesions compared to melanotic 
schwannoma and that GNAQQ209 mutational analysis  has diagnostic value in this 
differential diagnosis: in case a GNAQQ209 mutation is present, this supports the diagnosis 
of a melanocytic lesion instead of melanotic schwannoma. However, in case GNAQQ209mu-
tation is absent, a melanocytic lesion cannot be excluded. Still, as melanotic schwannomas 
show some features indicating melanocytic differentiation ánd as both schwann cells and 
melanocytes are derived from the neural crest, one could speculate that (some) 
melanocytic tumors and melanotic schwannomas may carry similar genetic aberrations. 
[69] This topic is now under investigation in our institution.
8.3.3 Assessment of clonality in melanoma 
In chapter 7, we described how combined mutational analysis of the NRAS and the CDKN2A 
gene could be useful to confirm or exclude a clonal relationship between melanomas. In 
contrast to mutations in NRAS (or BRAF) that are hotspot mutations and thus are likely to 
be identical in different primary melanomas, mutations in CDKN2A are much more 
heterogeneous and thus much less likely identical in different primary melanomas. [83] 
We demonstrated the presence of an identical CDKN2A mutation in two NRASQ61R-mutat-
ed melanomas in one patient (UM and CM), and absence of the CDKN2A mutation in 
normal tissue of the patient, thereby excluding a germ-line mutation. Because of the 
clonal relationship between these two melanomas, we concluded that the UM was a 
metastasis from the CM removed 13 years before. 
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8.3.4 Copy number variations in primary LMNs 
Adults
The gross chromosomal alterations in LMNs are largely unrevealed. Based on the similarity 
of mutational profile of primary LMNs and UMs, we hypothesized that especially aggressive 
LMNs might share gross chromosomal alterations with UMs (chapter 3). In addition to 
similar oncogenic mutations, LMNs and UMs share some other features. For both, 
metastatic spread to remote organs is almost exclusively by the hematogenous route. 
However, in contrast to UM, in primary leptomeningeal melanoma distant metastases are 
rare and without clear predilection for metastatic spread to the liver (only a few cases of 
metastatic LMNs to the liver have been reported). [39, 84, 85] Furthermore, LMNs and UMs 
are both associated with the nevus of Ota (oculodermal melanocytosis) that also harbors 
mutations in the genes GNAQ and GNA11. [19, 86-88] Finally, as LMNs show histological 
similarities to UMs, the Callender classification system used for prognostication in UMs has 
been proposed for LMNs as well.  [89] However, prognostic relevance of using the 
Callender classification for LMNs has not yet been demonstrated.
In chapter 3, we showed that copy number variations (CNVs) in some aggressive LMNs 
resemble those present in UMs, including monosomy 3 and gain of 8q. The prognostic 
relevance of these CNVs needs to be investigated in larger studies with complete 
follow-up.  
Children
Currently, knowledge on CNVs in LMNs in children is largely lacking. In the single study 
that has been published on this subject, Kinsler et al. reported absence of large gains or 
losses in one case of NRAS-mutated melanocytosis in an 8-year-old boy with NCM (using 
array CGH). [39] In contrast, they detected multiple gains and losses in a primary 
NRAS-mutated melanoma in the cerebellum of a 10-year-old child with NCM that 
developed liver metastases. The aberrations that were present in this melanoma included, 
among others, loss of whole chromosome 3, gain of chromosome 8 and loss of 
9p24.3-p21.1, the latter including the CDKN2A locus. [39, 44] Based on our current 
knowledge in UMs, the occurrence of monosomy 3 and the presence of liver metastasis in 
this patient is intriguing and, although entirely speculative, might indicate a prognostic 
significance. Currently, we are investigating a series of primary NRAS-mutated LMNs in 
children for the presence of CNVs.
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8.4  Oncogenic mutations in LMNs reveal potential targets 
for targeted therapy
8.4.1 GNAQ and GNA11 
Signaling pathways downstream of GNAQ include activation of protein kinase C (PKC) 
family members through the release of diacylglycerol (DAG) by β-phospholipase C, which 
can activate the MAPK pathway leading to upregulation of MEK. [1, 6-8] Activation of the 
MAPK pathway is a common oncogenic mechanism in many types of cancers. [90] In vitro 
studies have shown that mutations in GNAQ result in MAPK pathway activation in human 
melanocytes and UM cell lines. [7] Van Raamsdonk et al. demonstrated that expression of 
GNAQQ209L in hTERT/CDK4R24C/p53DD melanocytes caused increased levels of phospho-ERK 
compared to wildtype GNAQ transfected control cells or an empty vector. [7] In addition, 
siRNA-mediated knockdown of GNAQ in UM cell lines harboring this GNAQ mutation 
resulted in decreased levels of phospho-ERK, and decreased anchorage-independent 
growth and reduction in cell number, similar to the effect of the MEK inhibitor U0126. [7] 
Moreover, by using a siRNA strategy, mutant GNAQ was shown to activate the PI3K/AKT/
mTOR pathway as well. [91]
Inhibition of the GNAQ/GNA11 signaling pathway is of interest in targeting melanomas 
carrying these mutations. To date, there are no direct inhibitors of mutant GNAQ (or 
GNA11) and current focus is on inhibition of downstream components of the MAPK 
pathway including upregulated MEK. [92] Currently, there are neither GNAQ- nor 
GNA11-mutated cell lines from primary human brain melanomas available. GNAQ-mutated 
melanoma cell lines used in in vitro studies are derived from UMs. Interestingly, such 
studies showed that GNAQ-mutated melanoma cell lines are sensitive to inhibition of MEK 
[7, 93-95], resulting in decreased levels of pERK and decreased proliferation. Of note, the 
PI3K/AKT/mTOR pathway is activated in UM as well, and dual pathway inhibition with a 
combination of MEK inhibitor and PI3K inhibitor or mTOR kinase inhibitor was described to 
be synergistic in inducing apoptosis and reducing cell viability in GNAQ-mutant UM cell 
lines, respectively. [91, 96, 97]
Some clinical data has shown isolated responses of MEK inhibition in subset analysis of 
patients with metastatic GNAQ-mutated UM treated with the MEK inhibitor AZD6244. [92] 
Recently, a randomized multicenter phase II study presented at the 2013 ASCO Annual 
Meeting showed that MEK inhibition with selumetinib resulted in a median progres-
sion-free survival that was double that achieved with chemotherapy in metastatic UM 
patients with GNAQ or GNA11 mutation. This is the first study to demonstrate an improved 
clinical outcome with any systemic therapy in patients with metastatic UM. [98] 
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While the above-mentioned results of MEK inhibition in GNAQ-mutated UM cell lines and 
in patients with advanced GNAQ-mutated UM might be of benefit for patients with 
GNAQ-mutated LMNs as well, sound (pre-) clinical evidence for therapeutic efficacy in this 
latter group is lacking. 
Other potential targets for treatment of GNAQ-mutated melanoma include Protein Kinase 
C (PKC), as activation of the MAPK pathway in GNAQ-mutated melanoma occurs through 
signaling from GNAQ to ERK1/2 by activation of PKC (see also Figure 2 in chapter 1). [1] The 
PKC inhibitor enzastaurin was shown to have antitumor activity against GNAQ-mutated 
UM cell lines via inhibition of the PKC/ERK 1/2 pathway. [99, 100] In addition, combination 
of PKC inhibition ánd MEK inhibition was demonstrated to be synergistic in suppressing 
MAPK signaling in GNAQ-mutated UM cell lines. [101]
8.4.2 NRAS 
As mutations in NRAS are relatively common in different subtypes of melanoma, it 
represents an interesting therapeutic target. The design of small molecules selectively 
inhibiting mutant NRAS in melanoma, however, remains up to date an unsolved challenge. 
[102] One of the strategies therefore is the use of inhibitors that target downstream-acti-
vated cascades such as, among others, the MAPK pathway and the PI3K/AKT/mTOR 
pathway. [29] Melanoma cell lines harboring NRAS mutations were shown to be sensitive 
to inhibition of MEK, and a recent clinical trial with MEK162, a potent MEK inhibitor, has 
revealed some activity in patients with NRAS-mutant melanoma. [94, 103, 104] As NRAS 
activates multiple downstream pathways, there is evidence that combination of inhibitors 
of molecules downstream of NRAS such as MEK and PI3K/mTOR effectors will be more 
effective, and clinical trials with such combinatorial approaches are currently underway. 
[29, 105]
To our knowledge, there are no NRAS-mutated cell lines from primary human CNS 
melanomas available for study. However, in chapter 4, we demonstrated that melanoma 
cells derived from primary NRAS-mutated brain melanomas of mice show constitutive ERK 
activity that is sensitive to MEK inhibitors, and that the MEK inhibitor PD184352 delayed 
tumor growth in in vivo allograft experiments using NRAS-mutant cells from a primary 
mouse brain melanoma. 
As mutations in NRAS are a frequent oncogenic event in primary LMNs in children (chapter 
4 and 5) [16, 39], these patients might benefit from MEK inhibition. In a recent phase 2 
study, the small-molecule MEK1/2 inhibitor, MEK162, was shown to have activity against 
some NRAS-mutated advanced melanomas (partial response in 20% of NRAS-mutated 
patients), including tumor shrinkage in two NRAS-mutated brain melanoma metastases. 
[103] In chapter 5, we described the history of a 13-year-old NCM patient with 
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leptomeningeal melanocytosis that carried a somatic NRASQ61K mutation. Despite surgery, 
the patient showed clinical progression and MEK162 treatment was started on 
compassionate use base five days before death. Although MEK162 treatment was probably 
started too late to be able to observe a clinical effect, we could demonstrate possible 
effect of MEK162 treatment on the protein level in the brain tumor tissue, suggesting a 
potential role for MEK inhibition in symptomatic NRAS-mutated NCM. However, further 
studies are needed to determine whether MEK inhibitors can effectively target 
symptomatic NRAS-mutated NCM. This is important considering the often-fatal course of 
symptomatic NCM and the limited treatment options.
8.4.3  Challenges in systemic treatment of primary and metastatic CNS 
melanoma
Up to now, the treatment of melanoma metastatic to the CNS has been challenging, 
including the use of systemic treatment with chemotherapeutic agents such as 
dacarbazine that have not significantly prolonged progression-free or overall survival in 
metastatic melanoma patients. [108] It is presumed that the inability or reduced ability of 
certain agents to cross the blood brain barrier (BBB) contributes to the lack of efficacy of 
chemotherapy in the CNS.  
With the recent availability of small molecule inhibitors such as BRAF for patients with 
BRAF-mutated metastatic melanoma, the outcome for metastatic melanoma patients has 
improved. [109-111] There is early evidence suggesting that the BRAF inhibitors 
vemurafenib and dabrafenib, and the MEK inhibitor MEK162 have activity against CNS 
melanoma metastases. [103, 112-116] For instance, results from a multicentre, open-label, 
Phase 2 trial have shown that dabrafenib led to an intracranial response in 39% of patients 
who had not received previous local treatments and in 31% of those who had received 
previous local treatment for brain metastasis. [114] In addition, MEK162 was demonstrated 
to result in tumor shrinkage of two NRAS-mutated brain melanoma metastases in a recent 
phase 2 study. [103] Obviously, more extensive clinical studies are needed on the clinical 
efficacy of small molecule inhibitors in metastatic melanoma in the CNS, in addition to 
more studies on the mechanisms that influence the ability of these inhibitors to cross the 
BBB. In this respect, the successful combination of whole-brain radiation therapy followed 
by vemurafenib in the treatment of a patient with melanoma metastases in the 
leptomeninges is interesting, as it is known that radiation therapy has the potential to 
disrupt the BBB and allow for greater drug penetration. [117] 
In this thesis, potential options for targeted therapy of primary LMNs were discussed. 
However, (pre-) clinical experience in the use of inhibitors targeting the oncogenic effect 
of gene mutations in LMNs is largely lacking. The above-described early observations 
regarding the use of small molecule inhibitors in the treatment of metastatic melanoma 
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in the CNS are, however, promising and may well indicate a similar potential benefit for 
patients with primary LMNs as well.  
8.5 Conclusions and future perspectives 
In the work presented in this thesis, we unraveled oncogenic mutations underlying 
primary LMNs and showed that these mutations are different in adults versus children. 
Mutations in the GNAQ and GNA11 genes are frequent in LMNs in adults, while LMNs in 
children often harbor mutations in the NRAS gene, especially in the congenital setting. 
This substantially contributes to our understanding of the pathogenesis of these 
neoplasms in both settings. The presence of mutations in GNAQ and GNA11 in LMNs in 
adults suggests a common pathogenetic mechanism with UMs and blue nevi and 
supports the idea of distinct subtypes of melanocytes that might be targeted by distinct 
oncogenic mutations. In the congenital setting, we showed that the acquisition of somatic 
mutations in NRAS early during embryonic development underlies the pathogenesis of 
NCM and that NRAS mutations are associated with the development of leptomeningeal 
melanoma in children. Of note, the distinction between adult and pediatric setting is 
somewhat arbitrary, as adult patients can still have a congenital background of their 
disease. Also, not all LMNs that occur in children are necessarily truly congenital in origin. 
The gene mutations described in this thesis have potential diagnostic implications in 
routine pathology practice as mutation analysis of these genes enables an improved 
discrimination between a primary LMN and a melanoma metastasis to the CNS, which has 
prognostic relevance. Furthermore, the mutations we described provide potential targets 
for treatment with specific molecular inhibitors. 
For the future, other issues remain to be addressed, for instance whether the exact 
mutations we describe have any prognostic or predictive value. In addition, as GNAQ/
GNA11 and NRAS mutations are early oncogenic events that in itself are insufficient for 
malignant transformation of melanocytes, the identification of additional oncogenic 
events associated with malignant progression will improve our understanding of the 
molecular pathogenesis of these neoplasms. Eventually, this might result in biomarkers 
that better predict the biologic behavior of these neoplasms and reveal novel targets for 
therapeutic intervention. However, as these neoplasms are rare, collection of sufficient 
numbers of patients and tumor tissues for systematic study is difficult. We therefore now 
joined forces in a collaborative international multicenter study with the goal to characterize 
in depth the genetic background of LMNs in a larger series with adequate follow-up. 
Finally, caution is still needed when extrapolating results of preclinical and clinical 
(targeted) therapeutic studies from the ‘non-primary CNS’ melanoma setting to patients 
with primary LMNs. Future studies need to clarify whether the mutations described in this 
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thesis indeed provide clinically relevant therapeutic targets for specific molecular 
inhibitors in patients with LMNs as well.
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SUMMARY
Summary
This thesis focuses on the genetic alterations in primary leptomeningeal melanocytic 
neoplasms (LMNs). These neoplasms are derived from melanin pigment producing cells 
or ‘melanocytes’. Melanocytes are normally located in diverse anatomic locations, 
including the skin, the uveal tract but also in the leptomeninges, i.e.  the soft membranes 
that cover the central nervous system (CNS). The physiological function of the melanocytes 
in the leptomeninges is not well understood, but they can give rise to both benign as well 
as malignant neoplasms. 
Primary LMNs are traditionally classified based on their growth pattern in circumscribed or 
diffuse neoplasms (chapter 1). The circumscribed neoplasms encompass melanocytomas 
and melanomas. Melanocytomas are benign tumors that mostly arise in adults, especially 
around the cervical spinal cord and in the posterior fossa. Leptomeningeal melanomas are 
the malignant counterpart and are difficult to discriminate from a CNS melanoma 
metastasis from elsewhere in the body. The diffuse neoplasms encompass a benign 
category called melanocytosis and a malignant counterpart known as melanomatosis. 
Both are characterized by diffuse proliferation of neoplastic cells along the leptomeninges. 
Melanocytosis is mostly present in children, and often in the context of neurocutaneous 
melanosis (NCM). NCM is a congenital disorder characterized by multiple and/ or large 
congenital melanocytic nevi of the skin in association with primary LMNs.
In the past decade, much has been learned about the genetic alterations in melanomas 
of the skin and of the uveal tract. A milestone was the discovery of oncogenic mutations 
in the BRAF gene in a substantial proportion of skin melanomas. This finding has led to 
successful molecular therapy with BRAF inhibitors for patients with metastatic BRAF- 
mutated melanoma. These recent advances in molecular therapy also resulted in increased 
interest in molecular sub-classification of melanoma. In this context, it is remarkable that, 
in contrast to melanoma of the skin and eye, until recently, the genetic background of 
primary LMNs was unknown.
This thesis describes the frequent presence of oncogenic mutations in the GNAQ and 
GNA11 genes in primary LMNs in adults, while primary LMNs in children often show 
oncogenic mutations in the NRAS gene. These findings not only provide new insight in 
the pathogenesis of these neoplasms but also lead to diagnostic applications and 
potential targets for molecular therapy in the future.
Chapter 2 and 3 report the frequent presence of oncogenic mutations in the GNAQ and 
GNA11 genes in melanocytomas and melanomas of the leptomeninges in adults. 
Mutations in GNAQ and GNA11 have previously been detected in melanomas of the uveal 
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tract and blue nevi of the skin. Our findings point toward a common pathogenetic 
mechanisms of primary LMNs, uveal melanoma and blue nevi, and support the hypothesis 
that subtypes of melanocytes (epithelial versus non-epithelial) are targeted by specific 
oncogenic mutations.
In chapter 3, we hypothesized that primary LMNs in adults have more genetic alterations 
in common with uveal melanomas. Copy number variations frequently present in uveal 
melanoma and that are of prognostic value in uveal melanoma patients were detected in 
some LMNs with aggressive clinical behavior. Further study is needed to determine 
whether these genetic alterations have biological and / or prognostic significance. 
The data presented in chapter 4 and 5 show that, in contrast to the adult setting, the 
oncogenic mutation in primary LMNs in children frequently involves the NRAS gene. In 
this chapter, we showed in a transgenic mouse model that the acquisition of a somatic 
NRAS mutation early during embryogenesis results in a phenotype strongly resembling 
that observed in NCM in humans. In addition, this mouse model showed that NRAS 
mutations are associated with the development of leptomeningeal melanomas in mice. 
The observations in this mouse model were correlated with the observations made in two 
humans patients with NRAS-mutated primary leptomeningeal melanomas. 
The diagnostic applicability of the mutations described in this thesis are illustrated in 
chapter 3 and 6. In chapter 3, we show that the identification of a GNAQ or GNA11 mutation 
in a melanocytic neoplasm in or around the CNS can help in the differential diagnosis 
between a primary LMN versus a melanoma metastasis to the CNS from elsewhere in the 
body. This differential diagnosis can be difficult, both for the clinician and for the 
pathologist, while the correct diagnosis is important both for prognosis and further 
therapeutic strategy. Chapter 6 describes how GNAQ mutation analysis can aid in the 
differential diagnosis with other pigmented tumors in or around the CNS, for instance 
melanotic schwannoma. Correct histological diagnosis of melanotic schwannoma is 
important as patient with these neoplasms require follow-up for possible association with 
Carney Complex. In chapter 7, we show how the combined mutation analysis of NRAS 
and CDKN2A can help in the differential diagnosis between a primary uveal melanoma 
and cutaneous melanoma metastatic to the eye.
With the recent availability of molecular therapy for patients with metastatic skin 
melanoma, the mutations described in this thesis reveal potential targets for future 
molecular therapy in patients with primary LMNs as well. These strategies are discussed in 
chapter 8 and an example is presented in chapter 5. In this chapter, we report a child with 
NCM and symptomatic NRAS-mutated melanocytosis that was experimentally treated 
with a MEK inhibitor.
171
9
SUMMARY
Summarizing, this thesis reveals oncogenic mutations in primary LMNs in both in adults 
and children. These results obtained provide new insights in the pathogenesis of these 
neoplasms, have diagnostic implications and reveal potential targets for molecular 
therapy in the future.  

173
9
SUMMARY IN DUTCH | NEDERLANDSE SAMENVATTING
Nederlandse samenvatting
In dit proefschrift wordt onderzoek naar de genetische achtergrond van zogenaamde 
‘primaire leptomeningeale melanocytaire neoplasieën’ beschreven. Dit zijn tumoren 
ofwel neoplasieën die ontstaan uit cellen die melanine pigment produceren, ook 
genoemd ‘melanocyten’. Melanocyten komen voor in diverse anatomische lokaties. Het 
best bekend hiervan is de huid alwaar de melanocyten een rol spelen in de bescherming 
van het genetisch materiaal van de huidcellen tegen de schadelijke effecten van zonlicht. 
Melanocyten zijn echter ook aanwezig in de slijmvliezen, het oog, én de leptomeningen 
(de zachte hersenvliezen die de hersenen en het ruggemerg omgeven). Melanocyten 
komen dus bij iedereen voor in de hersenvliezen, maar de rol van deze cellen is tot nu toe 
onbekend. Wel kunnen ook de melanocyten in de leptomeningen aanleiding geven tot 
zowel goed- als kwaadaardige tumoren.
Melanocytaire tumoren van de leptomeningen worden traditioneel onderverdeeld op 
basis van hun groeiwijze in ofwel circumscripte of diffuse vormen (hoofdstuk 1). De groep van 
de circumscripte (dwz goed afgrensbare) tumoren omvat het melanocytoom en het 
melanoom. Melanocytomen zijn goedaardige tumoren die meestal voorkomen bij 
volwassenen, met name rondom het cervicale ruggemerg en in de achterste schedel-
groeve. Het melanoom is de kwaadaardige tegenhanger en is lastig te onderscheiden van 
een uitzaaiing van een melanoom elders in het lichaam naar het centraal zenuwstelsel 
(CZS). Onder de diffuse vormen vallen de zogenaamde melanocytosis en melanomatosis. 
Beide kenmerken zich door een diffuse uitbreiding van melanocytaire cellen in de 
hersenvliezen, goedaardig (melanocytosis) danwel kwaadaardig (melanomatosis). 
Melanocytosis komt met name voor bij kinderen, en dan meestal in de context van 
neurocutane melanosis. Dit is een aangeboren afwijking waarbij zowel moedervlekken 
van de huid voorkomen als melanocytaire afwijkingen van de hersenvliezen.
In de afgelopen decade is veel kennis vergaard op het gebied van genetische afwijkingen 
in het melanoom van de huid en het oog. Hierbij staat met name de ontdekking van het 
frequent voorkomen van zogenaamde ‘oncogene’ mutaties in het BRAF gen in het 
huidmelanoom centraal. Dit heeft recent geleid tot nieuwe, succesvolle behandelopties 
met BRAF inhibitoren voor patienten met BRAF-gemuteerd, uitgezaaid huidmelanoom. 
Deze ontwikkelingen op het gebied van moleculaire, ‘targeted’ therapie gericht op de 
gevolgen van specifieke oncogene mutaties in melanomen heeft geleid tot een 
toegenomen interesse in de genetische subclassificatie van melanomen. Hierbij is het 
opvallend dat, in tegenstelling tot het melanoom van de huid en het oog, er tot voor kort 
niets bekend was over de oncogene mutaties in primaire melanocytaire tumoren van de 
leptomeningen. 
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Dit proefschrift beschrijft het frequent voorkomen van oncogene mutaties in het GNAQ 
en GNA11 gen in primaire melanocytaire tumoren van de leptomeningen bij volwassenen 
terwijl we in dergelijke tumoren bij kinderen mutaties in het NRAS gen konden aantonen. 
Deze bevindingen leveren niet alleen nieuwe inzichten op in het ontstaan van deze 
tumoren maar bieden ook diagnostische toepassingen en potentiële aanknopingspunten 
voor (gen) gerichte moleculaire therapie in de toekomst. 
Hoofdstuk 2 en 3 beschrijven het frequent voorkomen van oncogene mutaties in het 
GNAQ en GNA11 gen in het melanocytoom en melanoom van de leptomeningen bij 
volwassenen. Mutaties in GNAQ en GNA11 werden eerder aangetoond in het melanoom 
van het oog en de blauwe nevus van de huid maar vrijwel niet in het huidmelanoom. 
Onze bevindingen wijzen in de richting van een gemeenschappelijk ontstaansmecha-
nisme van leptomeningeale melanocytaire tumoren, het oogmelanoom en de blauwe 
nevus, en ondersteunen de hypothese dat subtypes van melanocyten (epitheliaal versus 
niet-epitheliaal) getroffen worden door specifieke oncogene mutaties. 
In hoofdstuk 3 werd getest of het melanocytoom en melanoom van de leptomeningen 
bij volwassenen nog meer genetische afwijkingen gemeen hebben met het oog- 
melanoom. Copy nummer variaties die vaak voorkomen in oogmelanomen en die hier 
prognostische waarde hebben werden inderdaad aangetroffen in enkele leptomeningeale 
melanocytaire tumoren met aggressief klinisch beloop. Verder onderzoek moet uitmaken 
of deze genetische afwijkingen biologische en / of prognostische betekenis hebben.
Hoofdstuk 4 en 5 laten zien dat, in tegenstelling tot bij volwassenen, primaire melanocytaire 
tumoren van de leptomeningen bij kinderen gekenmerkt worden door een oncogene 
mutatie in het NRAS gen. In hoofdstuk 4 konden we met behulp van een muismodel 
aantonen dat het verwerven van een oncogene, somatische NRAS mutatie vroeg tijdens 
de embryonale ontwikkeling, aanleiding geeft tot een aangeboren fenotype sterk 
vergelijkbaar met dat van neurocutane melanosis bij de mens. Bovendien liet dit 
muismodel zien dat deze NRAS mutaties geassocieerd zijn met het ontwikkelen van 
primaire melanomen van de leptomeningen bij muizen. Deze bevindingen in het 
muismodel worden in hoofdstuk 4 gecorreleerd aan de bevindingen bij twee humane 
patientjes met NRAS-gemuteerde primaire leptomeningeale melanomen. 
De diagnostische consequenties van de mutaties beschreven in dit proefschrift worden 
geïllustreerd in hoofdstuk 3 en 6.  In hoofdstuk 3 laten we zien dat de identificatie van een 
GNAQ of GNA11 mutatie in een melanocytaire tumor in of rond het CZS diagnostische 
informatie kan opleveren met betrekking tot de differentiaal diagnose tussen een primaire 
tumor dan wel een metastase van een melanoom elders in het lichaam. Deze differentiaal 
diagnose is lastig, zowel voor de clinicus als voor de patholoog, en is belangrijk voor met 
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name het inschatten van de prognose en het bepalen van het verder therapeutisch 
beleid.  Hoofdstuk 6 beschrijft hoe GNAQ mutatie analyse kan helpen in de differentiaal 
diagnose met andere gepigmenteerde tumoren in en rond het CZS, zoals het melanotisch 
schwannoom. Correcte histologische diagnose van een melanotisch schwannoom is 
belangrijk, onder andere omdat patiënten met zo’n schwannoom klinisch moeten 
worden gevolgd in verband met mogelijke associatie met Carney Complex, een 
aandoening met potentieel levensbedreigende complicaties. In hoofdstuk 7 wordt een 
andere diagnostische toepassing van mutatie analyse geïllustreerd: hoe gecombineerde 
NRAS en CDKN2A mutatie analyse kan helpen in de differentiaal diagnose tussen een 
primair oogmelanoom en een metastase van een huidmelanoom naar het oog. 
Tegen de achtergrond van de recente succesvolle moleculaire therapieën voor het 
huidmelanoom leveren de mutaties beschreven in dit proefschrift interessante opties om 
ook patienten met primaire melanocytaire tumoren van de leptomeningen een specifieke, 
doelgerichte moleculaire therapie aan te kunnen bieden. Deze strategieën worden 
besproken in hoofdstuk 8. Een voorbeeld uit de praktijk wordt gegeven in hoofdstuk 5. 
Hier wordt een patientje beschreven met neurocutane melanosis en NRAS-gemuteerde 
melanocytosis die kort voor overlijden experimenteel behandeld werd met een MEK 
inhibitor, gericht tegen het oncogeen effect van de NRAS mutatie. 
Samenvattend beschrijft dit proefschrift oncogene mutaties in primaire melanocytaire 
tumoren van de leptomeningen bij zowel volwassenen als kinderen. Dit levert nieuwe 
inzichten in het ontstaan van deze tumoren, biedt diagnostische toepassingen in de 
differentiaal diagnose met andere melanocytaire tumoren en levert inzicht in beloftevolle 
aangrijpingspunten voor moleculaire / gen-gerichte therapie.
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Duitse samenvatting | Zusammenfassung 
In dieser Dissertation werden genetische Veränderungen in den primären leptomeninge-
alen melanozytären Tumoren beschrieben. Diese Tumoren entstehen aus Melaninpig-
ment-produzierenden Zellen  (Melanozyten). Melanozyten finden sich in verschiedenen 
Geweben. In der Haut schützen sie mit Melanin das genetische Material (DNA) gegen 
Sonnenlichtschäden. Melanozyten finden sich aber auch in Schleimhäuten, im Auge und 
in den weichen Hirnhäuten (Leptomeningen), die Hirn und Rückenmark bedecken. Ihre 
Funktion in den Leptomeningen ist bislang unbekannt, sie können jedoch Ausgangspunkt 
von gut- oder bösartigen Tumoren sein.
Leptomeningeale melanozytäre Tumoren werden anhand ihres Wachstumsmusters unterteilt 
in zirkumskripte und diffuse Formen (Kapitel 1). Die zirkumskripten (gut abgrenzbaren) 
Tumoren umfassen das Melanozytom und das Melanom. Melanozytome sind gutartige 
Tumoren, die oft bei Erwachsenen im Bereich der zervikalen Wirbelsäule und hinteren 
Schädelgrube auftreten. Das leptomeningeale Melanom ist die bösartige Variante und 
lässt sich nur schwierig von einer Melanommetastase aus anderen Organen unterscheiden. 
Unter den diffusen Formen versteht man die sogenannte Melanozytose (gutartig) und als 
bösartige Ausprägung die Melanomatose. Die Melanozytose kommt meistens bei Kindern vor, 
häufig im Rahmen einer neurokutanen Melanose. Bei dieser angeborenen Veränderung findet 
man sowohl Muttermale der Haut als auch melanozytäre Läsionen in den Hirnhäuten.
Im letzten Jahrzehnt sind viele genetische Veränderungen bei Melanomen der Haut und 
des Auges beschrieben worden. So führte die Beschreibung der onkogenen Mutationen 
des BRAF-Gens in Hautmelanomen zur Entwicklung von BRAF-Inhibitoren für die 
Behandlung von metastasierten Hautmelanomen. Aus weiteren genetischen Sub-
klassifikationen von Melanomen können sich auch zukünftig Angriffspunkte einer 
molekularen Therapie ergeben. Im Gegensatz zum Hautmelanom und dem Melanom des 
Auges sind genetische Veränderungen in melanozytären Tumoren der Hirnhäute noch 
nicht näher untersucht.
In Kapitel 2 und 3 dieser Arbeit wird das häufige Auftreten onkogener Mutationen in den 
Genen GNAQ und GNA11 in primären leptomeningealen melanozytären Tumoren bei 
Erwachsenen beschrieben. Diese Mutationen wurden zuerst in Augenmelanomen und 
sogenannten blauen Nävi der Haut nachgewiesen. Dies kann auf eine gemeinsame 
 Entstehungsweise von leptomeningealen melanozytären Tumoren, Melanomen des 
Auges und blauen Nävi der Haut hinweisen. In Kapitel 3 wird gezeigt, dass weitere 
genetische Übereinstimmungen zwischen leptomeningealen melanozytären Tumoren 
und Augen-melanomen bestehen. Weitere Untersuchungen müssen zeigen, welche 
 tumorbiologische und prognostische Bedeutung diese genetischen Veränderungen haben.
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In Kapitel 4 und 5 zeigt sich die Bedeutung von Mutationen im NRAS-Gen für die 
Onkogenese primär leptomeningealer melanozytärer Tumoren des Kindesalters. Im 
Tiermodell der Maus führt ein frühes embryologisches Auftreten einer NRAS-Mutation zu 
einem spezifischen Phänotyp, der vergleichbar ist mit der sogenannten neurokutanen 
Melanose des Menschen. Diese NRAS-Mutation konnte auch in primär leptomeningealen 
melanozytären Tumoren bei 2 jungen Patienten nachgewiesen werden.
Welche diagnostischen Möglichkeiten sich aus den beschriebenen Mutationen ergeben, 
beschreiben die Kapitel 3 und 6. Der Nachweis einer GNAQ- oder GNA11-Mutation in 
Melanomen des zentralen Nervensystems kann diese als primäre Tumoren identifizieren 
und abgrenzen von einer Melanometastase aus der Haut;  dies ist sehr hilfreich, da sich 
histologisch und immunhistochemisch eine Unterscheidung schwierig gestaltet. Eine 
Unterscheidung, die hinsichtlich Therapie und Prognose wichtig ist.  
In Kapitel 6 wird gezeigt, dass eine GNAQ-Mutationsanalyse primär leptomeningeale 
melanozytäre Tumoren von anderen pigmentierten Tumoren, z.B. dem pigmentierten 
Schwannom, unterscheiden kann. Dadurch können unterschiedliche Komplikationen 
beider Erkrankungen frühzeitig verfolgt werden.
Kapitel 7 beschreibt exemplarisch, wie eine Kombination von NRAS- und CDKN2A- 
 Genmutationsanalyse differentialdiagnostisch zwischen primärem Augenmelanom und 
Melanommetastase im Auge unterscheiden kann.
In Kapitel 8 werden mögliche neue molekulare Therapiemöglichkeiten erörtert, die in 
den Signalwegen der in den vorherig beschriebenen Genmutationen eingreifen könnten. 
Eine Kasuistik hierzu wird in Kapitel 5 beschrieben.
Zusammenfassend beschreibt diese Dissertation onkogene Mutationen in primär lepto-
meningealen melanozytären Tumoren bei Erwachsenen und Kindern. Dies liefert nicht 
nur neue tumorbiologische Erkenntnisse über diese Tumoren, sondern zeigt auch neue 
diagnostische und potentiell therapeutische Möglichkeiten bei diesen Erkrankungen.
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täglichen Ablauf in unsere Familie!
Tenslotte, mijn lieve echtgenoot Benno. Beste Benno, jou wil ik danken op tweeërlei vlak. 
Niet alleen voor je inhoudelijke bijdrage als neuropatholoog aan meerdere publicaties in 
dit proefschrift maar vooral voor je steun op het thuisfront bij het tot stand komen van dit 
alles! Ik ben je daarvoor zeer dankbaar.
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DANKWOORD
Tenslotte, als rode draad doorheen dit alles, mijn twee lieve schatten Caroline en Anton, 
die dit alles doen relativeren…
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